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Summary
Malaria is the most important parasitic disease of man: almost two billion people live
in areas in which the most pathogenic human Plasmodium species is transmitted. The parasite
P. falciparum accounts for more than 90% of world-wide malaria morbidity and mortality:
every year it is responsible for about 500 million clinical malaria cases and for up to 2.7
million deaths world-wide.
A characteristic feature of infections with P. falciparum is the ability of infected red blood
cells (iRBC) to adhere to venular endothelial cells. This adhesive behaviour is manifested by
the iRBC some 16-20 hours into the intraerythrocytic cycle, when the parasite matures to the
early trophozoite stage. At this stage, it expresses and transports molecular adhesins to the
red cell surface, leaving ring-infected erythrocytes to be the predominant form of parasites
found in the peripheral blood. This phenomenon, called sequestration, is proposed to be the
key event in vital organ failure, and by adhesion to the microvasculature of the brain, leads to
the major life-threatening manifestation of falciparum malaria: cerebral malaria.
The major parasite-derived adhesin, incorporated in the iRBC membrane, was detected 1984
and termed Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1). PfEMP-1
was originally described as a strain specific, high molecular weight (250-350 kDa), highly
polymorphic protein on the surface of P. falciparum-infected RBCs and it was thought to be
involved in adhesion to the already identified receptors on the surface of the endothelial cells,
such as CD36, thrombospondin (TSP), inter-cellular adhesion molecule-1 (ICAM-1), and
others. Later on (1991), it was shown, that PfEMP-1 undergoes antigenic variation in cloned
isolates and that changes in antigenic type are accompanied by changes in the binding
specificity for host receptors. Further progress was made 1995 when the genes encoding
PfEMP-1 were identified and sequenced: It was shown that each variant antigen type was
encoded by a single gene. These genes, termed var genes, were shown to be present at 50-100
copies per haploid genome, to be highly polymorphic, both within a single parasite and
between isolates, but to have a similar basic structure. Briefly: this structure includes a
cysteine-rich interdomain region (CIDR), 2-5 Duffy binding like domains (DBL) and a acidic
terminal sequence (ATS). Nevertheless, the causal proof, that va genes re indeed involved
in sequestration n vivo has to be shown.
It was the aim of the presented thesis, to undertake new and innovative approaches, in
order to identify and analyze possible parasite-derived ligands, involved in sequestration: a
schizont-specific P. falciparum cDNA expression library was constructed and introduced in
simian COS 7 cells by transient transfection. In a first approach, these transfected COS 7
cells were used in a newly developed in vitro assay. Screening cells, expressing ICAM-1 or
CD36 on their surface were used to identify parasite-derived genes, whose gene products
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confer adherence to these host cell receptors. In a second approach, the transfected COS 7
cells were screened with antibodies against surface molecules of iRBCs to identify the genes
involved. A more direct, third approach was applied by transfecting COS 7 cells with
fragments ofvar genes, identified by PCR amplification using primers binding to conserved
var gene domains, such as DBL1 or ATS, in order to analyze the role of var gen s in
cytoadherence. And finally, in the fourth approach, var gene domains, expressed as 6xhis-
tagged proteins in Escherichia coli, were used to analyze binding of these selected domains
(CIDR- and DBL1 domain) to different host receptor molecules, expressed on the surface of
Chinese hamster ovary (CHO) cells.
With the fourth approach, we were able to show, that the CIDR domain of var genes
binds to chondroitin sulphate A (CSA) in a dose dependent manner. This binding could be
inhibited by 50 µg of soluble CSA (62.4%) and by chondroitinase ABC treatment (up to
94.4%) of the CHO cells.
Unfortunately, all approaches using transfected COS 7 cells, did not lead to the identification
of new or known adhesive molecules. In the course of this thesis it became evident, that the
AT-richness of the P. falciparum genome (69% in coding and 86% in non coding-regions)
might be responsible for this lack of expression of P. falciparum genes in COS 7 cells, since
the existence of AUUUA-motifs can mediate mRNA decay in mammalian cells, a motif
which is abundant in P. falciparum RNA.
Nevertheless, it was possible during this thesis, to establish the techniques of transient and
stable transfection of mammalian cells, to improve screening techniques by the use of green
fluorescent protein (GFP) as a reporter system and to pick and isolate single cDNA clones
from transfected COS 7 cells.
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Abbreviations
AA amino acid
ABI Applied Biosystems Incorporation
AEC 3-amino-9-ethyl-carbazole
amp ampicillin
AP alkaline phosphatase
ATP adenosine triphosphate
ATS acidic terminal sequence
BCRR basic case reproduction rate
BII Basel Institute of Immunology
BLAST basic local alignment search tool
bp base pair
BSA bovine serum albumin
CAPS 3-cyclohexylaminopropan-1-sulphuric acid
CD cluster of differentiation
cDNA complementary deoxyribonucleic acid
CHO cells Chinese hamster ovary cells
CIDR cysteine-rich interdomain region
clag gene family cytoadherence-linked asexual gene gene family
CSP circumsporozoite protein
CSA chondroitin sulphate A
CSase chondroitinase (Chondroitin lysase)
DBL domain Duffy binding like domain
DEAE-dextran diethylaminoethyl-dextran
DEPC diethylpyrocarbonate
DMEM Dulbecco's modified Eagle's medium
DMF N,N-Dimethylformamide
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
dNTP deoxy nucleotide triphosphate
DPBS Dulbecco's phosphate buffered saline
DTT dithiothreitol
EB ethidium bromide
E. coli Escherichia coli
EDTA ethylene diamine tetraacetate
EIR yearly entomological inoculation rate
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ELAM-1 Endothelial Leukocyte Adhesion Molecule-1
EtOH ethanol
FACScan fluorescence-activated cell scan
FCS foetal calf serum
FITC fluorescein isothiocyanate
GAG(s) glycosaminoglycan(s)
gDNA genomic deoxyribonucleic acid
GFP green fluorescent protein
HBD HEPES-buffered Dulbecco's modified Eagle's medium
HEPES N-2-Hydroxyethylpiperazine-N-2-ethanesulphoric acid
his histidine
HPS heparan sulphate
HRP horseradish peroxidase
HSVgD Herpes simplex virus glycoprotein D
hu human
ICAM-1 intercellular cell adhesion molecule-1
IFA indirect immunofluorescence assay
IgG immuno globulin type G
IMDM Iscove's modified Dulbecco's modified Eagle's medium
IPTG isopropyl-b D-galactoside
iRBC(s) infected red blood cell(s)
kan kanamycin
kb kilobase
kDa kilodalton
LB Luria Bertani
mAb monoclonal antibody
MeOH methanol
MHC major histocompatibility complex
MSP merozoite surface protein
mRNA messenger ribonucleic acid
NTA nitrilotriacetic acid
OD optical density
PBS phosphate buffered saline
PCR polymerase chain reaction
PE polyethylene
PECAM-1 platelet / endothelial cell adhesion molecule-1
P. falciparum Plasmodium falciparum
PfEMP-1 Plasmodium falciparum erythrocyte membrane protein-1
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Pfu DNA polymerase Pyrococcus furiosus DNA polymerase
PNG Papua New Guinea
PP polypropylene
PS polystyrene
RBC(s) red blood cell(s)
rif gene family repeated-interspersed family gene family
RNA ribonucleic acid
RNAse ribonuclease
RPMI Rosewell Park Memorial Institute
RT room temperature
SA-AP streptavidine connected to alkaline phosphatase
SDS sodium dodecyl sulphate
SOC solution C
SSC saline sodium citrate
STET sodium-Tris-EDTA-triton buffer
STI Swiss Tropical Institute
Taq DNA polymerase Thermus aquaticus DNA polymerase
TBE Tris-boric-EDTA
TE Tris-EDTA
tet tetracycline
TM thrombomodulin
TNFa tumor necrosis factor alpha
TRAP thrombospondin related adhesive protein
Tris tris[hydroxymethyl]aminomethane
TSP thrombospondin
u unit(s)
UTR untranslated region
UV ultraviolet
VCAM-1 vascular cell adhesion molecule-1
WHO World Health Organisation
X-gal 5-bromo-4-chloro-3-indolyl-b-D-galactosylpyranoside
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1. Introduction
Malaria is the most important p rasitic disease of man: about 40% of mankind lives at
risk to become infected with one of the four human-pathogenic Plasm dium species (WHO,
1997). Whereas three species give rise to considerable malaria morbidity (P. vivax, P.
malariae and P. ovale) only P. falciparum results in high mortality: every year it is
responsible for about 500 million clinical malaria cases and for up to 2.7 million deaths
world-wide (WHO, 1997).
One of the major questions in malaria research is why infections with P. falciparum alaria
are often lethal, if untreated, as compared to the other species. A pos ible xplanation lies in
the additional mechanism, that has been developed by this parasite, to evade the human
immune response and to avoid clearance by its host: while all four human-pathogenic
Plasmodium species have an almost completely intracellular life cycle in the human host and
show genomic plasticity, only P. falciparum uses complex cellular interactions between
parasite and human host, which lead to the sequestration of infected red blood cells (iRBCs).
The present study is within this context and focuses on a central event of immune
evasion, the sequestration of iRBCs. The opening chapters will provide an introduction to P.
falciparum malaria and to the immune evasion strategies used by this parasite.
1.1. Plasmodium falciparum malaria
1.1.1. Life cycle, transmission and exposure
Life cycle
The life cycle of the protozoan parasite P. falciparum involves two hosts: female mosquitoes,
exclusively of the genus Anopheles and humans. No animal reservoir or free living stages are
known. Infection with Plasmodium falciparum occurs by injection of few sporozoites,
perhaps between five and twenty (Coppel et al., 1998), into the bloodstream of the human
host during the blood meal of an infected female mosquito. Within minutes after entering the
blood circulation, sporozoites are arrested in the liver and enter hepatocytes, where they
multiply and develop into liver schizonts. After 5-14 days of parasite multiplication, the
hepatocytes rupture and release thousands of merozoites into the bloodstream, where they
exclusively invade red blood cells. The intracellular parasites undergo maturation from ring
stages to trophozoites to schizonts within 48 hours. Each schizont gives rise to 8-32
merozoites until the iRBC finally disrupts, thereby releasing the merozoites, which find their
way into another erythrocyte within a few seconds, starting a new cycle of intraerythrocytic
asexual replication. Often an adhesive behaviour is manifested by the iRBC some 16-20
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hours into the intraerythrocytic cycle, when the parasite matures to the early trophozoite
stage. At this stage, it expresses and transports molecular adhesins to the red cell surface,
which are responsible for the sequestration of iRBCs to the deep vascular bed of organs or for
the rosetting with uninfected red blood cells. This phenomena of sequestration will be dealt
with in chapter 1.2.2.
While propagation of intraerythrocytic parasites may persist for months, occasional
ring stages develop into sexual forms of the parasite, termed micro- and macro gametocytes,
which are infective for the female Anopheles mosquitoes. In the mosquito midgut, the
gametocytes differentiate into gametes (1 macro- or 8 i  gametes, respectively) and, after
fertilisation and zygote formation, transform into ookinetes. Each ookinete penetrates the
midgut wall, develops into an oocyste and begins with sporogony: upon maturation, one
oocyste contains thousands of sporozoites, which are released into the hemolymph. The
sporozoites invade the salivary glands of the mosquito from where they are injected into a
human host during the next blood meal.
Transmission
The transmission of P. alciparum alaria in a certain region depends on many factors, such
as the natural environment, vector and parasite population and behavioural and social
situation of man.
Natural factors limit the area of transmission of malaria: it is restricted to the habitat
of the Anopheles pecies that is located at altitudes below 2200-2500 metres over sea-level
and at places where open water pools provide breeding sites. At temperatures below 17°C,
the life cycle of P. falciparum will not be completed in the mosquito and will therefore
terminate the transmission cycle (Macdonald 1952). These factors limit the area of
transmission to 91 countries where 2460 million people, or about 40 % of the total world
population live (Figure 1.1, WHO 1997).
Man-made factors include environmental, social, economic and demographic factors.
Their influence aims in two directions: they influence the density of the vector (e.g.
additional, man-made breeding sites) as well as the availability of the host (e.g. migration
behaviour, urban settings or the amount of money, which can be spend for preventive
measures like bednets).
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Figure 1.1      Areas with malaria transmission
Areas with malaria transmission
Exposure
The level of exposure is regarded as the key factor shaping the presentation of malaria in the
human host. The degree of exposure shapes the pattern of host morbidity and host immunity.
This pattern can be used to describe a defined area as holoendemic or hypoendemic (see:
Table 1-I). Exposure can be characterized by the yearly entomological inoculation rate (EIR)
and the basic case reproduction rate (BCRR). Whereas the EIR is determined also by the
host's availability, the BCRR is determined by the mosquito only (population density, feeding
behaviours, longevity, duration of sporogony). The BCRR gives a good estimate for
transmission stability in malaria areas, and subsequently for endemicity, describing the
average number of secondary cases to which a single malaria case would give rise after one
passage through one mosquito. Unstable malaria occurs in areas where the BCRR lies just
above 1, the minimal level for malaria to sustain itself. In rural sub-Saharan Africa, the
BCRR may reach values of up to 1000 (Bradley, 1995)
A moderate EIR often results in parasite prevalences and densities which undergo
significant changes throughout a year. These changes are often due to the availability of
surface water and humidity, resulting in the lowest vector density at the end of the dry
season. Under these circumstances, malaria transmission is seasonal but table. A high EIR is
often correlated with a ye r-round stable malaria transmission. Under such conditions, the
prevalence of falciparum malaria infection and the respective parasite densities peak during
early infancy at the individual level (Bradley, 1991, Table 1-I).
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Table 1-I        Endemicity levels c assified by parasite prevalence*
Level Prevalence
Holoendemic Parasite rate in the one-year age group constantly over 75%, spleen rate
in adults high (New Guinea type) or low (African type), parasite density
declining rapidly between 2-5 years of live and then slowly.
Hyperendemic Parasite rate in children of 2-9 years constantly over 50%.
Mesoendemic Parasite rate in children of 2-9 years as a rule 11-50% (may be higher
during part of the year).
Hypoendemic Parasite rate in children of 2-9 years as a rule less than 10% (may be
higher during part of the year).
*adapted from (Molineaux, 1988)
1.1.2. Infection, disease and immunity
Infection
The symptoms of all human malaria infections are manifold and may include distinct attacks
of fever, often associated with headache, myalgia, chills, sweating and/or anaemia. If present,
the attacks of fever are correlated with the asexual intraerythrocytic life cycle of the parasite:
Fever occurs at the time of rupture of iRBCs (approx. every 48 hours in P. falciparum
malaria) leading to the classical sequence: cold stage, then hot stage, then sweating. Rigors
are common and splenomegaly is often a consequence.
In areas where infection with P. falciparum constantly occurs (holoendemic), it appears that
only a small proportion of all infected people fall ill. Therefore, it will be useful to
distinguish between malaria as an infection and malaria as a disease: the proportion of P.
falciparum infections developing from asymptomatic, to uncomplicated symptomatic, to
severe, and finally fatal disease for children under 5 years is illustrated in Figure 1.2 (adapted
from: Marsh, 1992). In semi-immune adults, the ratio of asymptomatically : symptomatically
infected would rather be 10-20 than 2. WHO (1997) estimates P. falciparum to be
responsible for about 400-500 million clinical cases each year, resulting in the death of 1.5 to
2.7 million individuals world-wide, with the worst situation in children under 5 years old,
living in sub-Saharan Africa (app. 1 million deaths per year).
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Figure 1.2       The spectrum of malaria, from infection to mortality
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The clinical outcome of an infection (i.e. a first infection, without considering the influence
of the history of previous P. falciparum infections) in an individual person may depend on a
wide range of factors, arising from the parasite, the host and the environment:
Factors arising from the parasite could include virulence factors like growth and
multiplication rates, expression of a cytoadherent phenotype, toxin production, immune
evasion ability and, more and more important, drug resistance.
Factors arising from the host can be dependent on the 'genotype' which codes for a red
cell polymorphism (Stirnadel et al., 1999), glucose-6-phosphate dehydrogenase deficiency
(Cappadoro et al., 1998), polymorphism in immune response genes such as T-cell receptors
(Murillo et al., 1992), and polymorphism in endothelial receptors like the Kilifi-mutant of
ICAM-1 (Fernandez-Reyes et al., 1997), or can be dependent on the actual 'phenotype', as
defined by the acute hormonal disposition (pregnancy), by the nutritional status (e.g. iron
supplementation, Menendez et al., 1997 and Beck et al., 1999), by concomitant diseases
(Ravindran et al., 1998), and finally by the presence of another simultaneous P. falcipar m
infection, since a high multiplicity of P. falciparum infections appears to be protective
against clinical malaria in young children (Al Yaman et al., 1997).
Factors arising from the environment could be related to the level of knowledge about
malaria and its prevention (bednets) or the availability of health care in the community.
All these factors might influence the outcome of malaria but no clear correlation
between any of these factors and the severity of disease could be established up to now.
Nevertheless, it was proposed, that the overall incidence of uncomplicated or severe malaria
morbidity in a population depends largely on its exposure history, since immunity to malaria
might develop slowly upon repeated infection and can be short-lived (Molyneux, 1995).
1. Introduction                                                                                                                       11
___________________________________________________________________________
Disease and immunity
The first 3-6 months after birth, infants born from immune mothers are protected from the
disease, and after this period, clinical manifestations depend on transmission intensity:
In areas of very high endemicity (holoendemic), the most frequent manifestation of severe
malaria is severe anaemia, characteristically occurring in the first year of life (Snow et al.,
1994 and Kitua et al., 1996). Disease susceptibility rapidly declines after the first year of life,
as antimalarial semi-immunity is acquired.
The relationship between multiple infections and the development of immunity, and its
relation to morbidity has only recently been brought under extensive examination (Al Yaman
et al., and Beck et al., both 1997) and led to the hypothesis, that in the first months of life,
defence against infection relies mainly on fever and related cytokine activities, and individual
infections are of short duration. However, older children develop a chronic, low-level
parasitaemia with multiple infections of many different genotypes. These chronic infections
seem to confer cross-protection against newly inoculated parasites - a phenomenon that has
been called 'premunition', in contrast to 'semi-immunity' (Smith et al., 1999).
Therefore adults are mostly asymptomatic but with the exception of primigravidae mothers,
which become highly susceptible to malaria infections, probably by providing a CSA-rich
placental substrate, which selects for CSA-binding parasites, a phenotype, primigravidae
mothers might not have had encountered before, thereby leading to maternal malaria (Fried &
Duffy, 1996 and Maubert et al., 1997).
In areas of lower endemicity and seasonal transmission (EIR 10-20), exposure can be
insufficient to induce significant immunity. As a result, all age groups are susceptible to
severe disease, but complications are most prominent in children below 1 to 4 years of age,
with severe anaemia being a problem in children less than 1 year. In contrast, cerebral
malaria is typically seen in older children (Greenwood et al., 1991, Snow et al., 1994).
People lacking continuous exposure like during epidemics or travellers and migrating
populations therefore have to be considered as non-immune and all age groups are at equal
risk to develop severe and fatal disease.
The overall exposure and its temporal distribution in an area determines the immune
status of the residing individuals. The observation, that prevalence of P. falciparum infections
is not always 100% and that parasitic densities remain relatively stable over time (despite the
theoretical 8 to 32-fold multiplication every 48 hours), both illustrate the effective, but not
complete, immunity in highly exposed individuals. Kwiatkowski (1992) proposed three
effector mechanisms to control asexual erythrocytic infection:
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(-1.) an immediate monocyte/macrophage-derived tumor necrosis factor alpha (TNFa)-
response to parasite toxins, possibly released during iRBC disruption, causing fever and other
non-specific mechanisms to constrain parasite growth.
(-2.) an early T cell-derived interferon-g response, which in combination with TNFa
stimulates macrophages and neutrophils to attack parasites.
(-3.) a slowly evolving B-cell response that is eventually capable of eradicating the infection.
The fact, that the acquisition of individual immunity occurs over several years
supports the view, that immunity is strain-specific, or variant-specific respectively. The
finding, that high multiplicity of P. falciparum infections appears to be protective against
clinical malaria in young children in Tanzania or in PNG (Al Yaman et al. nd Beck et al.,
both 1997 and FŠrnert et al. 1999) additionally supports this hypothesis. The enormous
diversity of P. falciparum antigens allows the parasite to avoid complete clearance by the
host's immune system, since the immuno-dominance of repeat regions might lead to poor
defence reactions, especially in individuals frequently confronted with new infections
('smoke screen': Day and Marsh, 1991) Antigenic variation supports the immune evasion
since a new variant can lead to a weak defence reaction, when a slightly different variant was
encountered before by the immune system: In presence of the new, slightly different variant,
old memory B cells may be triggered, whose antibodies fail to recognize the new variant
('antigenic sin': Good et al., 1993).
Therefore, the interaction between the parasite and the host's immune system is mostly
determined by the parasite's ability to actively evade the immune response. The main
strategies involved in immune evasion are given in the next chapter:
1.2. Immune evasion
Two main strategies are involved in immune evasion of Pl modium falciparum
parasites: the first strategy involves the phenomenon of adherence, and the second strategy
deals with the phenomenon of antigenic variation. Both strategies are coupled with each
other: since adhesive determinants on the surface of the parasite or on the surface of the
iRBCs are likely to be antigenic, it would be useful for the parasite to be able to switch from
one adhesin to another. On the other hand, antigenic variation has to be limited, since any
given adhesin should still be able to mediate adherence to a given receptor.
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1.2.1. The role of adherence
The need of adherence for P. falciparum is two-fold: first, infection of the host cells
(to evade the immune system) requires host-parasite recognition events, which are mediated
by adhesion- and signalling molecules, and secondly, iRBCs express on their surface
parasite-derived adhesins, which mediate adherence to endothelial cells in the deep vascular
bed of different organs (sequestration), and allows the parasite to avoid spleen-dependent
killing of iRBCs. (Langreth and Peterson, 1985).
In its vertebrate host, the malaria parasite spends most of its life cycle intracellulary,
shielded from an attack by antibodies. Only the sporozoites injected by the mosquito and the
merozoites emerging from disrupted iRBCs are extracellular stages, and even then for a very
short time. For both, sporozoites and merozoites, accurate targeting is facilitated by the
abundance of the appropriate host cells (hepatocytes and erythrocytes). Invasion in o the host
cells requires the specific recognition of the host cell's surface molecules by molecules from
the parasite's plasma membrane, often followed by additional adhesion and signalling events
mediated by the secretion of proteins by micronemes and rhoptries, specialized organelles in
the anterior pole of both extracellular stages, sporozoites and merozoites.
Two sporozoite surface proteins were described to participate in hepatocyte invasion:
the circumsporozoite protein (CSP, Nussenzweig & Nussenzweig, 1989) and the
thrombospondin related adhesive protein (TRAP, Robson et al., 1988). CSP covers the entire
surface of sporozoites uniformly, but is not expressed in blood stages nor in the initial stages
of parasite development in mosquitoes. By disrupting the CSP gene, it has been shown, that
CSP is essential for sporozoite development in the mosquito (Menard et al., 1997). In the
vertebrate host, a conserved region (region 2) of CSP mediates initial attachment to the
glycosaminoglycans (GAGs), which are expressed on the surface of the liver cells. About one
third of the CSP molecule consists of tandemly repeated motifs, which vary widely in
sequence within each plasmodium species, and might therefore be responsible for the
'camouflage' of the protein.
The second protein, TRAP, is found in small clusters on the plasma membrane of
sporozoites and in micronemes, and contains a sequence of amino acids homologous to the
region 2 of CSP. As excepted, TRAP also binds to liver GAGs (Muller et a ., 1993), but its
most important role seems to be to provide the mechanical support necessary for gliding and
invasion, since the protein is connected, via a transmembrane and cytoplasmic domain, to the
cytoskeleton of the parasite (Sultan et al., 1997).
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Red cell invasion on the other hand is a complex, poorly understood multistep
process, during which different proteins of the merozoite adhere to the red cell. Two prot ins
fit into the context of this thesis and will be mentioned here: EBA175 (Erythrocyte binding
antigen 175), since it was one of the first P. falciparum proteins, which was successfully
expressed in COS cells (Sim et al., 1994) and p235 (in P. yoelli), since it is encoded by a
large multigene family (approximately 50 copies per haploid genome) with each nucleus in a
single developing schizont transcribing and expressing a different variant (Preiser et al.,
1999).
After the penetration of the red cell by the merozoite, the parasite matures and starts to
express and transport molecular adhesins to the surface of the iRBC. The functions of these
adhesins will be presented in the next chapter:
1.2.2. Sequestration, rosetting and auto-agglutination
A characteristic feature of infections with P. falciparum is the ability of iRBCs to
adhere to venular endothelial cells (MacPherson et al., 1985). Adhesive behaviour is
manifested by the iRBC some 16-20 hours into the intraerythrocytic cycle, when the parasite
matures to the early trophozoite stage, at which time it expresses and transports molecular
adhesins to the red cell surface, leaving ring-infected erythrocytes to be the predominant form
of parasites found in the peripheral blood. These adhesins have been shown to be associated
with protrusions on the surface of the iRBC, called 'knobs'. For many years knobs were said
to be necessary but insufficient for adhesion, but it is now recognized, that parasite lines
exist, which are able to adhere to endothelial cells in vitro, despite the lack of knobs (Biggs et
al., and Udomsangpetch et al., both 1989), but that knobs might be necessary under
physiological shear stress (Crabb et al., 1997). Additionally, knobs have been shown to be
the site at which ligands for some host receptors are expressed (Nakamura et al., 1992).
These adhesins on the surface of iRBCs mediate adherence to endothelial cells
(sequestration), to uninfected RBCs (rosetting, David et al., 1988) and to other iRBCs (auto-
agglutination, Roberts t al., 1992).
Sequestration:
The peripheral withdrawal of iRBCs was recognized over one hundred years ago, as
was the accumulation of these cells in small blood vessels of vital organs (Bignami &
Bastianelli, 1889). For the parasite it may offer a possibility of avoiding passage through the
spleen and its non-specific clearance mechanisms. Although this advantage has not been
formally proved, the advantage which sequestration confers to P. falciparum, is sufficient to
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be maintained in natural populations, whereas it is rapidly lost in vitro in the absence of a
selective pressure or in vivo in splenectomized animals (David et al., 1983). For the host,
sequestration is a pathological event, tolerated to varying degrees with respect to the site of
sequestration and the amount of sequestered iRBCs. Nevertheless, sequestration has been
proposed to be the key event of vital organ failure in the pathogenesis of cerebral malaria,
and cytoadherence in the brain plays a major role, as indicated by studies which quantified
the amount of sequestered iRBCs in the brain vessels from fatal cerebral malaria cases
(MacPherson et al., 1985 and Aikawa et al., 1992). However, the discussion, whether these
findings indicate post-mortem artefacts and the fact, that cerebral malaria also occurs,
although rarely, in P. vivax malaria, a species which shows no sequestration, indicates, how
many questions are still unanswered (This argumentation is reviewed in P. today (1994), Vol.
10, Nr. 10: Grau and de Kossodo / Clark and Rockett / Berendt et al.).
Undisputed is the theory, that in each venule where sequestration occurs, a certain
degree of obstruction to flow will occur. This might be sufficient to decrease the efficiency of
metabolite exchange in these segments of the microvasculature. Additionally, the lower flow
rates may favour further sequestration, since binding to CD36 seems to be more sensitive to
shear stress than ICAM-1 (see below, Cooke et al., 1994, and reviewed by: Cooke & Coppel,
1995). Furthermore, sequestered iRBCs themselves are metabolically highly active and
release large amounts of lactic acid, which may worsen the biochemical imbalance in the
tissue (White et al., 1985). In addition to adherence to endothelial cells, iRBCs can also
adhere in vivo to platelets, monocytes, lymphocytes (Barnwell et al., 1985), uninfected RBCs
(rosetting, David et al., 1988) and other iRBCs (auto-agglutination, Roberts et al., 1992).
Rosetting and auto-agglutination:
An additional complexity has come up with the recognition, that iRBCs can adhere to
uninfected RBCs to form 'rosettes' (David et l., 1988) or to auto-agglutinate with other
iRBCs (Roberts et al., 1992). Unlike sequestration, rosetting is a property of only some
strains, varying quite dramatically in the extent to which they form rosettes (Wahlgren et al.,
1994) but was found in all 4 species of human malaria parasites (Lowe et al., 1998). Most
(e.g. Carlson et al., 1990 and Rowe et al., 1995) but not all (Al Yaman et al., 1995) studies,
which have examined the relationship between rosetting and disease, suggest that parasites of
the rosetting phenotype are more likely to occur in patients with severe disease. It has also
been shown in some (e.g. Carlson et al., 1990) but not all (Reeder t al., 1997) studies, that
antibodies, which disrupt rosettes are less common in patients with disease. Nevertheless, it
seems likely that the ability to form rosettes might be a virulence factor, since it had been
suggested that the parasite, cocooned within a group of uninfected red blood cells may
rapidly reach and invade these cells, thereby diminishing its extracellular, vulnerable stage.
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On the other hand, no difference could be found in the growth rates of strains capable to form
rosettes, compared to those that cannot (Clough e al., 1998).
The molecular basis for adhesion of P. falciparum-infected RBCs was started to be
investigated by the advent of electron microscopy (Miller, 1969), and, as it became possible
to cultivate intraerythrocytic forms (Trager and Jensen, 1976), by the development of in vitro
cell adhesion models (Udeiyna t al., 1981), which were subsequently improved by flow
chambers (Cooke et al., 1994) or by appropriate in vivo models (e.g. Willimann et al., 1995).
The host's receptors for iRBCs and the ligands on the surface of iRBCs, responsible for
sequestration and/or rosetting, which are characterized up to now, will be introduced in the
next two chapters.
1.2.2.1. Host receptors involved in sequestration
Over the past ten years, a number of molecules express d on the surface of endothelial
cells have been shown to bind erythrocytes infected with P. falciparum, varying from
members of the immunglobulin superfamily to substituted sugars.
In chronological order, these are: thrombospondin (TSP) (Roberts et al., 1985), CD36
(Barnwell et al., 1985), ICAM-1 (CD54) (Berendt et al., 1989), VCAM-1 (CD 106), E-
selectin or ELAM-1 (CD62E) (both Ockenhouse et al., 1992a), chondroitin sulfate A (CSA)
(Rogerson et al., and Robert e al., both 1995), PECAM-1 (CD31) (Treutiger et al., 1997)
and P-selectin (CD62P) (Udomsangpetch et al., 1997). Indirect evidence also suggests a role
for the avb3 integrin (CD51 / CD61) (Siano et al., 1998).
As possible receptors on the surface of uninfected red blood cells, i.e. receptors mediating
rosetting, CD36 (Handunnetti et al., 1992), complement receptor 1 (CR1, CD35) (Rowe et
al., 1997) and heparan sulfate (HPS) (Chen et al., 1998a), were described. Additionally, the
AB0 blood group antigens have been identified as receptors, but they influence the size of the
rosettes, rather than the frequency of rosetting (Carlson and Wahlgren, 1992).
The molecular structure of these molecules, th ir expression and the evidence for their role in
malaria will be presented in the following (see also: Table 1-II).
Thrombospondin (TSP)
TSP is a secreted glycoprotein consisting of 3 identical 150 kDa subunits, linked to
each other by disulphide bonds. It is stored within platelets and is synthesized as well by
endothelial cells, macrophages and melanoma cells like C32 cells. It is a multifunctional,
multidomain protein that binds many different ligands such as heparin, fibrinogen or
collagen.
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Nearly all isolates collected from malaria patients and analyzed after a brief in vitro cultu e
bound to TSP in static assays (Sherwood t al., 1987). With electron microscopy, it was
shown, that soluble TSP binds the surface of iRBCs specifically at knobs (Nakamura et al.,
1992). Lately, the importance of TSP as a receptor in vivo was diminished by the finding, that
the strength of binding of iRBCs to TSP is possibly too low to allow interaction in a post
capillary venule under flow conditions (Cooke et al., 1994). More recently, it was argued,
that soluble TSP might be capable of bridging parasite-induced membrane alterations on
iRBCs and endothelial CD36 to increase binding (Siano et al., 1997).
PfEMP-1 (Baruch et al., 1996) and Pfalhesin (Lucas and Sherman, 1998) were identified as
possible ligands in binding of TSP.
CD36
CD36 (also called glycoprotein (GP) IIIb, GPIV and GP88) is an integral membrane
glycoprotein existing as a monomer of about 88 kDa, consisting of two extracellular loops,
interspaced by a membrane-associated region, and two membrane-spanning regions at both
termini (Greenwalt et al., 1992). CD36 was originally isolated from platelets, but it is also
present on the surface of monocytes, microvascular endothelial cells , some epidermal cells,
on erythroid precursors and weakly on erythrocytes (Handunnetti et al., 1992), and a wide
variety of cultured cell lines. CD36 is a receptor for the extracellular matrix proteins collagen
and TSP. The binding site to TSP (which might be important in cytoadherence of iRBCs, see:
Siano et al., 1997) is located on AA 87-99, whereas two malaria binding sites were mapped
to AA 8-21 and 97-110 (Asch et al., 1993). Furthermore, a site-directed, single mutagenesis
of the histidine at position 242 of human CD36 to tyrosine (rodent CD36) showed the
importance of that residue in the conformation of the iRBC-binding domain(s) of CD36
(Serghides et al., 1998). Mature iRBCs bound to purified CD36 immobilized to plastic, and
purified soluble CD36 inhibited the adherence to HUVEC and C32 melanoma cells
(Barnwell et al., 1989). In contrast to huICAM-1-mediated adhesion, iRBCs bound to CD36
under physiological flow conditions by firm, static attachment (Cooke et al., 1994) whereas
co-expression of CD36 and huICAM-1 had a synergistic effect on iRBC binding
(McCormick et al., 1997), indicating that cytoadherence in vivo will most likely result from
the sum of several interactions between iRBCs and endothelial receptors (Newbold et al.,
1997).
Like TSP, CD36 bound specifically to the knobs of iRBCs (Nakamura et al., 1992). Most
wild isolates investigated in vitro, bound to CD36 (Hasler et al., 1990), and the most common
interactions appeared to be between PfEMP-1 and CD36 (Baruch et al., 1996) but also
between Pfalhesin and CD36 (Crandall et al., 1994 and 1996) and between Sequestrin and
CD36 (Ockenhouse, 1991).
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Intercellular Adhesion Molecule-1 (ICAM-1, CD54 )
ICAM-1 belongs to the immunoglobuline (Ig) gene superfamily molecules (Imhof &
Dunon, 1995), and is a glycoprotein of approximately 100 kDa. ICAM-1 is expressed on the
surface of lymphocytes, monocytes, macrophages, the vascular endothelium, and on
transfected cell lines like L-huICAM-1- (Van Kooyk et al., 1993) and CHO-huICAM-1 cells
(Hasler et al., 1993). Under physiological conditions, ICAM-1 is the ligand for lymphocyte
function-associated antigen-1 (LFA-1, CD11a/CD18, Lb2, Staunton et al., 1990), and for
complement receptor 3 (CR3, MAC-1, CD11b/CD18, aMb2, Diamond et al., 1990). In
addition to the binding of iRBCs, ICAM-1 had also been found to act as an endothelial
receptor for human rhi o-virus (Marlin et al., 1990). Two studies (Ockenhouse et al., 1992b
and Berendt et al., 1992) have assigned two distinctly different sites in ICAM-1 to be
responsible for binding to LFA-1 and iRBCs respectively.
Furthermore, ICAM-1 can be present in a biologically active, soluble form in human
serum (Gearing and Newman, 1993) and increased plasma levels of soluble ICAM-1 were
detected during acute phase of P. falciparum induced malaria. This indicates a high level of
surface expression of ICAM-1 at this stage of infection (Wenisch et al., 1994b). In general,
the expression of ICAM-1 is upregulated by stimulation with interleukin-1 (IL-1), TNFa or
interferon-g. In an in vivo model, it was shown that the endothelium of the mid brain showed
the highest responsiveness to such an inflammatory stimulus (Willimann et al., 1995),
indicating a correlation between the expression of ICAM-1 and cerebral malaria. This
association is supported by results from a large case-control study in Kilifi, Kenya, in which
the adhesion of iRBCs to ICAM-1 was highest in the cerebral malaria category, compared to
asymptomatic control (Newbold et al., 1997). Also in Kilifi, a coding polymorphism in the
N-terminal domain of ICAM-1 (K29/M; i.e. in the mutant, the lysine at position 29 is
replaced by a methionine) was found with a high frequency. Carriers of this mutant were
shown to have increased susceptibility to cerebral malaria (Fernandez-Reyes et l., 1997).1
Under physiological flow conditions, iRBCs tether and roll along ICAM-1, even at
high wall shear stress (Cooke et al., 1994). This is in contrast to an immobilizing effect of
ICAM-1 on leukocytes.
In contrast to CD36 and TSP, many parasite strains fail to bind to ICAM-1 in vitro, but those
which do, presumably bind via PfEMP-1 (Baruch et al., 1996).
                                         
1 The binding site of the rhinovirus is in a area that overlaps the K29 residue (Craig et al., 1991) and therefore,
protection from rhinovirus is a possibility for the high frequence of the ICAM-Kilifi-mutant.
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Vascular Cell Adhesion Molecule-1 (VCAM-1, CD106), Endothelial Leukocyte
Adhesion Molecule-1 (ELAM-1, E-Selectin, CD62E), and P-Selectin (CD62P)
VCAM-1 can be present in two alternatively spliced isoforms of a single gene, but its
predominant form is that of a glycoprotein of approximately 100 kDa. Like ICAM-1 it
belongs to the Ig gene superfamily and is expressed by vascular cells involved in leukocyte
activation and migration, and on bone marrow stromal cells. Again, a soluble form has been
detected in the serum of patients suffering from cancer or inflammatory diseases (Wenisch et
al., 1994a and Imhof & Dunon, 1995). Under physiological conditions, VCAM-1 is the
receptor for the very late antigen 4 (VLA-4, CD49d/CD29, a4b1), expressed on leukocytes,
and binds weakly to the a4b7 integrin on the surface of gut homing lymphocytes and
activated platelets (Vonderheide & Springer, 1992). It is also upregulated during
inflammation in response to TNFa, IL-1 and IL-4 (Masinovsky et al., 1990). Together with
ICAM-1, it regulates tight adhesion of leukocytes to endothelium, and recruitment of
leukocytes to sites of inflammation (Imhof & Dunon, 1995).
ELAM-1, now designated E-Selectin (Bevilacqua et al., 1989), is a glycoprotein of
110 kDa, exclusively expressed by inflamed endothelial cells. Like P-Selectin (140 kDa,
expressed by activated platelets and endothelium), it belongs to the selectin family. Both
proteins show a typical mosaic structure, consisting of a sugar binding domain (N-terminus),
a epidermal growth factor (EGF)-like domain, several short consensus sequences, a
transmembrane domain and an intercellular C-terminus. A variety of glycoproteins have been
reported to bind to these selectins. Elevated levels of circulating, soluble E-Selectin, are
specific for diseases that provoke marked endothelial activation, including malaria (Gearing
and Newman, 1993)
In the context of malaria, both VCAM-1 and ELAM-1 were found to bind weakly to
iRBCs from a particular patient's isolate called CY36. CY36-infected RBCs also bound
weakly to ICAM-1, but adhered well to CD36. Infected RBCs from this isolate were
subsequently selected in vitro by sequential panning over purified immobilized CD36,
ICAM-1, VCAM-1 and ELAM-1. A parasite clone, that bound strongly to all of these
receptor proteins, was isolated, which demonstrates the potential of natural parasite isolates
to bind to a variety of endothelial cell surface proteins (Ockenhouse et al., 1992a). However,
VCAM-1, as well as ELAM-1 and P-Selectin, seem to be uncommon binding targets for
iRBCs and the parasite-derived ligand remained unidentified.
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Platelet / Endothelial Cell Adhesion Molecule-1 (PECAM-1, CD31)
PECAM-1, a glycoprotein of 130 kDa, also belongs to the Ig gene superfamily as
well, and its expression is restricted to endothelial and intravascular cells including
granulocytes, monocytes and platelets (Newman et al., 1990). Its physiological function is to
mediate transendothelial migration of leukocytes, its main ligand is avb3.
In the context of malaria, RBCs infected by a particular strain (FCR3S1.HUV), were selected
by panning over PECAM-1. After multiple rounds of selection, iRBCs bound to PECAM-1,
expressed on transfected L-cells, or directly to recombinant PECAM-1 absorbed onto plastic
(Treutiger et al., 1997). Binding was blocked by both, mAbs to domains 1-4 of PECAM-1,
and soluble PECAM-1. The significance of this interaction is hard to gauge, since PECAM-1
appears to be confined to areas of cell-cell contact between endothelial cells and to be absent
from the luminal face, to which iRBCs adhere, although interferon-g may r distribute the
receptor expression to the surface of the endothelium (Romer et al., 1995). The ligand on the
surface of iRBCs is unknown.
Interestingly enough, in the large case-control study in Kilifi, Kenya (Newbold et al., 1997),
CD31 was used as a negative control.
The integrin avb3 (CD51 / CD61)
The integrins comprise of a large family of molecules that mediate adhesion in
immune and inflammatory responses between cells, and between cells and the extracellular
matrix. Integrins consist of a large a chain, with multiple cation-binding sites, non-covalently
paired with a smaller b chain. The b3 chain (CD61) associates with the aIIb chain on platelets
(CD41/CD61) or the av chain (CD51) on a variety of cultured cells, including endothelium.
The avb3 integrin (254 kDa) recognizes multiple matrix proteins such as fibrinogen and
thrombospondin and is constitutively expressed on microvascular endothelium. Its expression
is rapidly increased at sites of vascular inflammation and damage (Swerlick et al., 1991).
In the context of malaria, it was shown (Siano et al., 1998) that binding of iRBCs to
endothelial cells under flow conditions could be inhibited by a mean of 45% by using anti-av
antibodies. Furthermore, this adherence was independent of the addition of thrombospondin
or other adhesion mediators. The ligand(s) on the surface of iRBCs is unknown.
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Chondroitin sulfate A (CSA)
The glycosaminoglycan (GAG) CSA was the first receptor for iRBCs showing, that
sequestration not only depends on protein-protein interaction, although GAGs were already
known to be involved in adherence of sporozoites to hepatocytes (Pancake et al., 1992). 
GAGs, the polysaccharide chains in proteoglycans, are made up of disaccharide
repeating units, containing a derivative of an amino sugar, either glucosamine or
galactosamine.
At least one of the sugars in the disaccharideFigure 1.3        Disaccharide unit of CSA
has a negatively charged carboxylate or
sulfate group. Hyaluronate, chondroitin
sulfate, keratan sulfate, heparan sulfate
(HPS) and heparin are the major GAGs. The
classical structure of CSA is one of repeating
units of alternating glucuronic acid [1->3]
and N-acetylgalactosamine-4-sulfate [1->4]
(see: Figure 1.3), although it is now clear,
that GAGs are more heterogeneous than pre-
viously suspected (Karamanos et al., 1994).
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In CSB, glucuronic acid is replaced by iduronic acid and in CSC, the N-acetylgalactosamine
is predominately 6-sulphated. However, these GAGs do not mediate adherence (Gysin et al.,
1997). In the vascular system, the only abundant CSA containing proteoglycan is
thrombomodulin (TM), a transmembrane protein, which often has a CSA chain attached at
one of two sites (Gerlitz et al., 1993). CSA contributes to the role of TM, principally binding
and inactivating the circulating coagulant thrombin. TM is found widely on vascular
endothelium (~100'000 molecules per cell), and interestingly, in the context of malaria, it is
expressed at high levels on the syncytiotrophoblasts, lining the maternal blood sinusoids
(Maruyama et al., 1985 and Maubert et al., 1997), a site to which iRBCs have recently been
shown to bind in the placenta (Fried and Duffy, 1996). CSA is also found on the vascular
endothelium of the lung and the brain, indicating a possible role in the development of
cerebral malaria (Prudhomme et al., 1996). Binding of iRBCs to CSA was almost completely
inhibited in vitro by competition with soluble CSA oligosaccharides, with the minimum
length being 7 disaccharide repeats (Beeson et al., 1998) or by chondroitinase ABC treatment
of the cells. CSA is also present on many cultured cell lines, including C32- and Chinese
hamster ovary (CHO) cells. Very recently, it had been shown, that PfEMP-1 mediated
binding of iRBCs to CSA (Reeder t al., 1999).
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Table 1-II       Adhesion molecules implicated in malaria sequestration
CD
Number
Other
names
Main functionMain
distributio
n
Size
kDa
Main
ligands
Parasite
ligands
Comments
CD31 PECAM-1 Transendothe-
lial migration
of leukocytes
EC., M., P. 130 avb3 ? uncommon binding target.
CD36 GPIIIb Flag for phago-
cytosis of cells
undergoing
apoptosis
EC., M., P. 88 TSP,
collagen
PfEMP-1
Pfalhesin
Sequestrin
most common binding phe-
notype of parasites confers
tight binding.
CD51 /
CD61
avb3 Distribution ofcells via extra-
cellular matrix
molecules
EC., M., P. 254 CD31,
laminin
TSP
? uncommon binding target.
CD54 ICAM-1 Leukocyte ad-
hesion to endo-
thelium in in-
flammation
EC., M.,
DC
90
to
115
LFA-1
(aLb2)
MAC-1
(aMb2)
PfEMP-1
Pfalhesin
Rolling receptor for iRBCs,
the binding site has been
mapped.
CD62E E-SelectinRolling of lym-
phocytes on
activated endo-
thelium
EC. 110 ESL-1 ? uncommon binding target.
CD62P P-SelectinPlatelet-Adhes-
ion to neutro-
phils & mono-
cytes
act-EC., P. 140 PSGL-1 ? uncommon binding target.
CD106 VCAM-1 Recruitment of
leukocytes to
inflammation-
sites
EC. 90
to
110
VLA-4
a4b7
? uncommon binding target.
- TSP various EC, also
soluble
450 CD36 PfEMP-1 Physiological role in
question due to the weakness
of bin-ding under flow
conditions.
- CSA binding and in-
activating sol.
thrombin
on EC and
syncytiotro-
phoblasts
- thrombinPfEMP-1 Appears to be important in
malaria during pregnancy.
Legend to Table 1-II
9 host molecules, described to be involved in iRBC sequestration, are listed and compared
relative to their size, function, distribution and role in P. falciparum alaria.
Abbreviations used:
DC: dendritic cell, EC: endothelial cell, act-EC: activated EC, ESL-1: E-selectin ligand-1,
LFA-1: Lymphocyte function-associated antigen-1, M: Monocytes, P: Platelets, PSGL: P-
Selectin glycoprotein ligand-1 and VLA-4: very late antigen-4.
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1.2.2.2. Parasite-derived or -modified ligands involved in sequestration
A number of parasite-derived or -modified candidates, involved in sequestration, have
been identified, including Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-
1, Leech et al., 1994), sequestrin (Ockenhouse et al., 1991), modified erythrocyte band 3
anion transporter, also termed Pfalhesin (Sherman et al., 1992 and Crandall et al., 1994). Of
all these above mentioned ligands, PfEMP-1 is the only parasite derived protein for which
full sequence information is available and it is the only adhesion mediating molecule, which
has been shown by several laboratories to be parasite encoded and to be located on the iRBC
surface. For two recently described proteins, the rif gene family encoded molecules on the
surface of iRBCs (rifins, Cheng et al., 1998) and the proteins, encoded by the clag gene
family (Bowman et al., 1999), no involvement in cytoadherence has been shown. On the
other hand, direct (Baruch et al., 1996 and 1997) and indirect (Gardner et al., 1996 and
Chaiyaroj et al., 1994) experiments by a number of investigators showed PfEMP-1 to be
involved in binding to diverse receptors (TSP, CD36, ICAM-1 and CSA, see above).
Furthermore, PfEMP-1 is also involved in rosetting via binding to CD36 (Handunnetti et al.,
1992), complement receptor 1 (CD35) (Rowe et al., 1997) and heparan sulfate (HPS) (Chen
et al., 1998a).
Role of Sequestrin and Pfalhesin in sequestration
Evidence for an involvement of sequestrin in cytoadherence of iRBCs was attained from
indirect experiments: Ockenouse et al., (1991) were able to demonstrate binding of CD36 to
an antigen from knobless parasites, today considered to be most likely PfEMP-1 (Deitsch and
Wellems, 1996), which they named sequestrin.
On the other hand, the modified erythrocyte band 3 anion transporter (Pfalhesin) is a clearly
defined host receptor, but modified by the intraerythrocytic parasite (Crandall and Sherman,
1991). They showed that iRBCs bind via a 65 kDa protein, present in the membrane of
iRBCs. This protein was recognized by mAbs, specific for the cytoplasmic domain and the
N-terminal side of the membrane-spanning region of human band 3, but was not recognized
by an antibody specific for the C-terminal part of the membrane spanning region. Later on, a
CD36-like binding domain was found in this protein (Crandall and Sherman, 1996) and
finally it was hown, that TSP mediates parasitized erythrocyte band 3-related adhesin
binding (Lucas and Sherman, 1998).
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Role of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) in adhesion
PfEMP-1 was originally described as a strain specific, high molecular weight (250-
350 kDa), highly polymorphic protein on the surface of P. falciparum-infected RBCs (Leech
et al., 1994). Its biochemical characteristics of insolubility in non-ionic detergents and
extreme sensitivity to proteases, together with its location and degree of antigenic diversity in
field isolates suggested, that it was the P. falciparum-equivalent of the phenotypically
variable antigen (SICA antigen, Brown and Brown, 1965) of P. knowlesi. Indeed, in the early
nineties, in vitro data from two laboratories (Biggs et al., 1991 and Roberts e  al., 1992)
showed, that PfEMP-1 did undergo antigenic variation in cloned isolates and that changes in
antigenic type were accompanied by changes in the receptor binding specificity. More
recently, it was suggested that the presence of antibody to specific PfEMP-1 variants protects
against subsequent clinical infection with isolates expressing that variant (Bull et al., 1998).
Further progress was made 1995, when the genes encoding PfEMP-1 were identified and
sequenced. It was shown that each variant antigen type was encoded by a single gene (Baruch
et al., Smith et al., and Su et al., all 1995). These genes, termed var genes (Su et al., 1995),
were shown to be present at 50-100 copies per haploid genome, to be highly polymorphic,
both within and between isolates, but to have a similar basic structure (see also 1.2.3.1.).
Briefly: this structure includes a cysteine-rich interdomain region (CIDR), 2-5 Duffy binding
like domains (DBL), a transmembrane domain, and an acidic terminal sequence (ATS).
The ATS represents the C-terminal, intracellular part of PfEMP-1 and is possibly
involved in interactions with other parasite derived proteins and with sub membranous
proteins of the RBC cytoskeleton, which might be responsible for the correct presentation
and anchoring of PfEMP-1. Furthermore, the ATS domain is the most conserved domain of
the var genes.
Different DBL domains identified as candidates for binding: Very recently it was
shown, that antibodies to the DBL3 domain and to the CIDR domain of a CSA-binding
PfEMP-1 also inhibited binding of iRBCs to CSA (Reeder et al., 1999). Specific DBL1
domains were shown to mediate rosetting via binding to CR1 (Rowe et al. 1997) or to HPS
(Chen et al., 1998a).
The CIDR domain was the first domain, which has been found to mediate binding:
using an expressed var gene from the Malayan Camp (MC) parasite, Baruch and co-workers
(1997) expressed the CIDR domain as a glutathione-S-transferase fusion protein and showed
that this domain mediated binding to CD36.
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For huICAM-1, which is also a receptor for PfEMP-1 (Baruch et l., 1996) no binding
domain of PfEMP-1 could yet be characterized, but most ICAM-1 binding PfEMP-1 variants,
identified so far, were encoded by var genes, which encode for a larger than average
molecule, containing five DBL domains (Gardner et al., 1996 and Smith e  al., 1998).
TSP-binding to PfEMP-1 was shown to be insensitive to immune serum, binding
showed no variant-specific characteristics, and it was not pH-dependent, in contrast to the
binding of CD36 or ICAM-1 to PfEMP-1. These data suggested that TSP-binding occurred at
another molecule, possibly at the modified erythrocyte band 3 anion transporter (Gardner et
al., 1996).
Little data exists for the involvement of PfEMP-1 in binding to other receptors, such
as VCAM-1, E-selectin, P-Selectin and PECAM-1.
A possible role of PfEMP-1 in rosetting was first proposed, when CD36 was found to
be present on iRBCs (Handunnetti et al., 1992). Recent data support the role of PfEMP-1 in
rosetting: by growing rosetting and non-rosetting lines from the rosetting clone R29 (Rowe et
al., 1997), it was shown that a single dominant var gene is expressed in rosetting but not in
non-rosetting parasites. This gene was sequenced and fragments were expressed on the
surface of COS 7 cells. Only the construct containing the first DBL domain (DBL1), but none
of the other constructs permitted binding of RBCs. Similar results were obtained by another
group (Chen et al., 1998a) using a different parasite genotype, expressing a distinct rosetting-
associated var gene. Thus, it seems likely that the DBL1 domain of the expressed PfEMP-1
variant mediates rosetting. The binding of the DBL1 domain to the surface of RBCs was
proposed to be mediated either via complement receptor 1 (CR1, CD35, Rowe et al., 1997) or
via heparan sulfate (HPS, Chen et al., 1998a).
1.2.3. Antigenic diversity and antigenic variation
Antigenic diversity as a consequence of variation is considered to be a second crucial
strategy in immune evasion, coupled with the expression of adhesins on the surface of
iRBCs. The difficulty lies in the trade-off between variation (to evade the immune system)
and conformity (to bind the receptors) of the parasite-derived ligands involved (Reviewed in
Borst et al., 1995).
Antigenic diversity is defined as the expression of antigenically diff rent alleles of a
gene at a single genetic locus in different clones of the parasite (Reeder and Brown, 1996).
Several plasmodial antigens, such as the merozoite proteins 1 and 2 (MSP-1 and MSP-2)
highlight the phenomenon of antigenic diversity, since many different alleles of these genes
exist in a Plasmodium falciparum population and therefore, an immune response directed
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against one antigen encoded by a certain allele may not be effective against an infection with
parasites expressing a different allele (Prescott et al., 1994).
Antigenic variation, on the other hand, is defined as the ability of a clonal population
to switch its antigenic phenotype. In the context of P. falciparum-derived adhesins, antigenic
variation is the mechanism of immune evasion, which has to deal mainly with the trade-off
mentioned above and was attributed to P. falciparum in 1991 (Biggs et al., 1991). The
phenomenon was already well known from African trypanosomes (the causative agent of
sleeping sickness), which express variant surface glycoproteins (VSGs) on their surface
during the course of infection (Reviewed in Borst and Rudenko, 1994).
Biggs et al., (1991) could demonstrate that parasite clones, isolated from a parental clonal
culture, were serologically distinct from the parental clone, despite the absence of any
selective pressure. Furthermore, it was found in the same experiment, that this antigenic
switch was accompanied by changes of the molecular weight of PfEMP-1. Further studies
(Roberts et al., 1992) revealed that antigenic variation of PfEMP-1 is due to the differential
expression of var genes, leading to the exposure of phenotypically different PfEMP-1
variants on the surface of iRBCs. These differences are manifested in distinct antigenic and
adhesive properties of these variants (Scherf et al., 1998).
1.2.3.1. Role ofvar genes and expression of Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP-1) in antigenic variation
Structure
All var genes have a two-exon structure. The large 5' exon (exon 1) codes for the
extracellular part of the protein and is highly diverse, containing 2-5 cysteine-rich Duffy
binding like (DBL) domains and a cysteine-rich interdomain region (CIDR) of 300-400
amino acids, located between DBL1- and DBL2 domain. Exon 1 terminates with a sequence
of variable length (SVL) and a short hydrophobic egion which shows characteristic features
of a transmembrane segment (Engelman et al., 1986). The DBL domains, which show broad
homologies to domains previously identified in other malarial proteins such as the Duffy
binding protein of P. vivax and the erythrocyte binding antigen (EBA 175) of P. falciparum
(Chitnis and Miller, 1994) are highly diverse and can only be identified by a few conserved
residues; however, the DBL1- and the subsequent CIDR domain are the most conserved
regions of exon 1, and were found in all var genes so far, leading to the suggestion, that the
DBL1- and CIDR domain together comprise a conserved head structure (Su et al., 1995). The
number of DBL domains may be indicative for the binding phenotype of the corresponding
PfEMP-1 molecule, since most ICAM-1 binding PfEMP-1 molecules are encoded by var
genes, which encode for a larger than average molecule, containing five DBL domains
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(Gardner et al., 1996 and Smith et al., 1998). Additionally, the CSA binding PfEMP-1,
termed varCSA (Scherf et al., 1998) contains only two DBL domains.
The smaller 3' exon (exon 2) is well conserved and codes for a segment, that is rich in acidic
amino acids, therefore termed acidic terminal sequence (ATS), representing the intracellular
portion of PfEMP-1, which is probably involved in anchoring the protein to the cytoskeleton
of the iRBC. The two exons are separated by an intron sequence of approximately 1 kb. A
schematic diagram of a vargene containing 4 DBL domains is given in Figure 1.4
DBL1 DBL4DBL2 DBL3CIDR SVL
intron
ATSexon 1 exon 2
Semi-conserved variable conserved
Figure 1.4    Schematic of the general structure of a var gene
Rosetting domain
Putative CD36 and CSA binding domain
Transmembrane region
Putative Cytoskeletal 
binding domain
DBL1
CIDR
SVL
ATS
Duffy-binding like domain 1
Cysteine-rich interdomain region
Sequence of variable length
Acidic terminal sequence
Distribution
The var gene family shows extensive diversity and consists of 50-150 var genes per
haploid genome, distributed throughout all 14 chromosomes (Rubio et al., 1996), and located
at chromosome-internal sites (chromosome 4, 7, 8, and 12; Thompson et al., and Fischer t
al., both 1997), as well as within nearly all subtelomeric regions, next to the non-coding
repetitive element Rep20 (Hernandez-Rivas t al., and Fischer t al., both 1997). It has been
shown that subtelomeric var genes are more closely related to each other than to sequences
found in central regions, indicating, that recombination might more frequently occur among
subtelomeric var genes (Rubio et al., 1996). Furthermore, a sequence termed pf60, which has
been shown to correspond also to a large gene family (Carcy et al., 1994), shows strong
homology to the conserved ATS domain of var genes and hybridized primarily to
chromosomes 4, 7, and 12, where they are located next to the chromosome-internal var genes
(Thompson et al., 1997). On the other hand, the recently described rif and clag gene families
were found next to the subtelomeric var genes (Bowman et al., 1999).
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Expression
From studies correlating var gene expression with antigenic and adhesive properties
of iRBCs, it appears that only a limited number, probably only one, var gene variant is
expressed at any given time (Rowe et al., 1997, Chen et al., 1998b, and Scherf et al., 1998),
with var gene switching occurring at a rate of ~2% per generation in vitro (R berts et al.,
1992 and Smith et al., 1995). Scherf and colleagues (1998) showed, that only one distinct var
gene was expressed after selection of parasites on endothelial receptors (CD36, CSA, and
ICAM-1), termed varCSA, varCD36 and varICAM-1 respectively. varCSA, and varCD36 were
located in subtelomeric regions whereas varICAM-1 was present within a central domain of
chromosome 12. Taken together, these data suggest, that expression from individual va
genes is controlled by a mechanism that allows activation in situ (Scherf et al. 1998) ,
without need for gene conversion or telomeric exchange events, such as these described in
trypanosome VSG switching (Borst and Greaves, 1987). While there is thought to be
transcription from the entire var pertoire during the first few hours after red cell invasion
(Chen et al. 1998b), only a single var gene appears to be active during the time in parasite
development, when PfEMP-1 is actively translated and transported to the surface of iRBCs
(Scherf et al., 1998). Very recently Deitsch et al. (1999) found evidence, that var gene
expression is under epigenic control, possibly through changes in the chromatin structure.
1.2.3.2. PfEMP-1 and immune selection
Given that each particular 'brood' or 'strain' of P. f lciparum has a limited repertoire of
distinct PfEMP-1 variants, among which switching can occur, it was proposed (Gupta and
Day, 1994) that the selective pressure excerted by human immune responses, directed against
PfEMP-1, is sufficient to structure the parasite population, such that an overlap in the
repertoire is minimized between 'strains' of P. falciparum.
According to that 'distinct strain theory', the specific anti-PfEMP-1 response, elicited
by a particular parasite strain after one or a few exposures, will reduce multiplication of that
particular type in the human host and render transmission of that strain less likely with each
subsequent exposure (Gupta et al., 1996). This model is supported by a field study (Contamin
et al., 1996), showing that clinical episodes in Senegalese children were associated with
recently inoculated 'new' strains of P. falciparum. More recently, Bull et al. (1999) found in
21 children from Kenya an inverse relationship between each child's repertoire of
agglutinating antibodies and the agglutination frequency of the isolated parasites, indicating
an immune selection of rare surface variants.
On the other hand, a phylogenetic analysis of 103 DBL1 domains could not support the
theory of distinctly segregating repertoires of var g nes (Ward et al., 1999).
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2. Goals and Objectives
The goal of the studies presented in this thesis was to identify and clone schizont-
specific Plasmodium falciparum gene(s) involved in cytoadherence by expression in simian
COS 7 cells . A secondary goal was to bring forth a direct proof, that var gene-encoded
molecules can mediate binding to host cell receptors.
To this end, the project had the following developmental objectives:
A.) Objective 1: from the phenotype to the genotype  (Shotgun approaches 1 and 2)
1. Isolation of schizont-specific mRNA of synchronized Plasmodium falciparum
cultures after confirmation of adhesion of iRBCs to CD36 and huICAM-1 and
construction of a mammalian expression cDNA library into the pcDNA3.1-vector.
2. Establish an in vitro adhesion assay with CD36 and huICAM-1 expressing
screening cells on seeded, library-transfected COS 7 cells.
3. Identification of transfected, adhesion-mediating COS 7 cells, isolation of cDNA
clones, and identification of P. falciparum genes mediating adherence (Shotgun
approach 1).
4. Identification of COS 7 cells expressing iRBC-surface molecules with previously
generated monoclonal antibodies (PhD-thesis of K. Willimann, 1996) (Shotgun
approach 2).
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B.) Objective 2: from the genotype to the phenotype  (Direct approaches 1 and 2)
1. Design of degenerated primers to amplify semi-conserved domains from var genes
(DBL1-, CIDR- and ATS domains) from an adherent and a non a herent strain.
2. Screening of the cDNA library to identify full-length var genes.
3. Performing in vitro assays with var gene-transfected COS 7 cells to identify var
genes (or var gene domains) which mediate adhesion to host cell receptors (Direct
approach 1).
4. E. coli-expression of the conserved DBL1- and CIDR domains as 6xhis-tagged
proteins under native conditions.
5. Analysing the binding of these purified domains to host cell receptors, involved in
cytoadherence (Direct approach 2)
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3. Materials and Methods
3.1. Materials
3.1.1. Cell lines, Plasmodium falciparum- and Escherichia
coli-strains.
Most of the mammalian cell lines used in this work were obtained as a gift from other
research groups, three cell lines were purchased from the American Type culture collection
(ATCC, Table 3-I). All P. falciparum strains were obtained from the laboratory of H. Matile
at F. Hoffmann-La Roche Ltd (Table 3-II). The E. coli strains used in this work are listed in
Table 3-III
Table 3-I         Mammalian cell lines
Name Phenotype / expression of
receptors involved in sequestration
S urce (Reference)
Bosc23 cells Easily transfectable cell line derived
from human kidney cell line HEK
293.
B. Imhof, Centre Medical Uni-
versitaire, Genf, CH
(Pear et al., 1993)
Bosc-huICAM-1-
EGFP cells
stably transfected Bosc23 cells,
expressing huICAM-1 on the cell
surface and cytosolic GFP.
produced
C32 cells Human amelanotic melanoma cells,
expressing CD36 and CSA.
ATCC  Rockville, ML, USA
(Udeiyna et al., 1985 and
Pouvelle t al., 1998)
CHO cells Chinese hamster ovary cells,
expressing CSA.
H. Matile, Hoffmann-La Roche
Ltd, Basel, CH
CHO-huCD36 cellstably transfected CHO cells,
expressing CD36 and CSA.
ATCC, Rockville, ML, USA
(Scherf et al., 1998)
CHO-huICAM-1
cells
stably transfected CHO cells,
expressing ICAM-1 and CSA.
ATCC, Rockville, ML, USA
(Scherf et al., 1998)
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Name Phenotype / expression of
receptors involved in sequestration
S urce (Reference)
COS 7 cells Derived from the African green
monkey kidney cell line CV-1 by
transformation with an origin
defective SV40 virus.
B. Imhof, Centre Medical Uni-
versitaire, Genf, CH
(Gluzman, 1981)
L-cells Mouse fibroblast like cells. C. Figdor, the Netherlands Can-
cer Institute, Amsterdam, NL
L-huICAM-1 cells stably transfected L-cells, expressing
huICAM-1 on the surface.
C. Figdor
(Van Kooyk et al., 1993)
Table 3-II        Plasmodium strains
Name Phenotype Source (Reference)
ItG2.F6 knobby and adherent to C32-
and L-huICAM-1 cells.
H. Matile, Hoffmann-La Roche
Ltd, Basel (Magowan et al.,
1988)
K1 knobless and not adherentH. Matile
Table 3-III      E. coli strains
Name application Source
M15 protein expression (3.2.5.)Qiagen, Basel, CH
MOSblue competent
cells
T/A cloning ( 3.2.1.9.) Amersham,
Buckinghamshire, UK
Top10F' cDNA library Invitrogen, Leek, NL
Top10F' electrocompetent
cells
electroporation Invitrogen, Leek, NL
3. Materials and Methodes                                                                                                33
___________________________________________________________________________
3.1.2. Vectors
6 different vectors were used during this work. 5 of these vectors are commercially
available from Invitrogen (pcDNA3.1 and pcDNA3.1-EGFP), Amersham (pMOSblueT-
vector) and Qiagen (pQE30 and pREP4). See suppliers' catalogues for further information.
The plasmid pRE4 is a kind gift of Drs. Gary Cohen and Roselyn Eisenberg, University of
Pennsylvania, PA, USA (Cohen et al., 1988) and was already used earlier for expression of
plasmodial proteins in COS 7 cells (Chitnis and Miller, 1994). It contains a SV40 origin of
replication, a Rous sarcoma virus LTR as a promoter and the SV40 early polyadenylation
signal. The Herpes simplex virus glycoprotein D-gene (HSVgD-gene) was cloned in the
HindIII cloning site. The HSVgD-gene has a unique PvuII restriction site 81 bp downstream
the signal peptide cleavage site and a unique ApaI restriction site 213 bp upstream of the C-
terminal hydrophobic stretch, which we used to generate chimeric proteins, flanked by the
HSVgD leader sequence (5') and the HSVgD transmembrane and cytosolic domain (3').
The purposes of these vectors are summarized in Table 3-IV.
Table 3-IV     Vectors
Name Purpose Source
pcDNA3.1 cDNA-cloning and expression in
mammalian cells
Invitrogen, Leek, NL
pcDNA3.1-EGFP Expression of GFP in mam-
malian cells. Transfection- and
expression-control
B. Imhof, Centre Medical Uni-
versitaire, Genf, CH
pcDNA3.1-huICAM-
1-EGFP
Chimeric expression of hu-
ICAM-1 with GFP at COOH-end
produced
pMOSblueT-vectorT/A cloning of PCR-products Amersham, Buckinghamshire, UK
pQE30 E. coli-expression with a 6xhis-
tag at NH2-end
Qiagen AG, Basel
pREP4 Kanamycin-resistance and lac-
operon repressor
Qi gen AG, Basel
pRE4 Chimeric expression in mam-
malian cells with HSVgD
flanking regions
Drs. Gary Cohen and Roselyn
Eisenberg, University of Pennsyl-
vania, PA, USA
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3.1.3. Antibodies and secondary reagents
Antibodies and secondary reagents that have been applied in FACScan analysis,
western blots and in immunohistochemical assays are listed in Tables 3-V to 3-VII.
Table 3-V      Monoclonal Antibodies
Name Specificity Source (Reference)
MEM112 (CD54) human ICAM-1 Anawa AG, Wangen, CH
OKM*5 human CD36 Ortho Diagnostic System, Raritan
NJ, USA
Penta His 5xHis-tag Qiagen AG, Basel
anti-6x Histidine
Clone AD 1.1.10
6xHis-tag R&D Systems, Minneapolis, MN,
USA
aGFP (polyclonal)GFP Clonetech, Heidelberg, D
ID3 AA 11-19 of the mature HSVgD
protein
Drs. Gary Cohen and Roselyn
Eisenberg, University of Pennsyl-
vania, PA, USA
DL6 AA 272-279 of the mature
HSVgD protein
D s. G. Cohen and R. Eisenberg
Sup 9.22 GYGLFHKEKMIL motif of the
SPf66-peptide
Dr. G. Pluschke, STI, CH
SupI 202/7 iRBC (crossreacts with human
Lymphocytes)
All the following mAbs were
generated by K. Willimann (1996,
SupII 3c2/9 iRBC (crossreacts with human
lymphocytes)
PhD-thesis) and recognized iRBC
and intraerythrocytic P. falciparum
SupX 128 trophozoites stage proteins.
SupX 216 iRBC
SupX 304/3 late schizonts and merozoites
SupX 323/3 schizonts
SupX 331 merozoites and rings
SupX 435/3 surface of intracellular stages
SupX 509 schizonts
3. Materials and Methodes                                                                                                35
___________________________________________________________________________
Table 3-VI     Conjugated monoclonal Antibodies
Host Specificity Conjugate Source
goat mouse IgG F(ab')2 FITC Cappel, Durham, NC, USA
goat rabbit IgG (H+L) AP Jackson ImmunoResearch, West
Grove, PA, USA
goat mouse IgG AP Sigma, Buchs, CH
rabbit mouse total Ig HRP DAKO Corporation, Zug, CH
goat mouse IgA+G+M (H+L)
human serum adsorbed
HRP Kirkegaard & Perry Laboratories,
Gaithersburg, MD, USA
goat human IgG (g) HRP Kirkegaard & Perry
Table 3-VII     Polyclonal sera
Host Specificity Source
pooled
human sera
undefined, COS 7 cells
dsorbed prior to use.
Malaria exposed adults from PNG
3.1.4. Reagents
The majority of chemicals and reagents were purchased from Merck, Darmstadt, D.
Reagents supplied by others are listed in Table 3-VIII.
Table 3-VIII    List of chemicals and reagents
Name Supplier
30% Acrylamide/Bis solution (37.5:1)Gibco BRL Life Technologies, Basel, CH
AEC Tablets Sigma, Buchs, CH
Agar Difco Laboratories, Detroit, MG, USA
Agarose (electrophoresis grade) Gibco
Albumax II (low endotoxin) Gibco
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Name Supplier
Albumin, Bovine Fraction V (BSA) Sigma
Bacto tryptone Difco
Bacto yeast extract Difco
BSA, nuclease free New England Biolabs
CAPS, 99% pure Aldrich chemicals, Buchs, CH
Cellfectin Gibco
Chloroquine (Diphosphate salt) Sigma
CSA, sodium salt from bovine tracheaSigma
CSase ABC from Proteus vulgaris Sigma
DEAE-dextran (chloride form) Sigma
N,N-Dimethylformamide (DMF) Sigma
DMEM (high glucose) Gibco
DMRIE-5 Gibco
DMSO Fluka, Buchs, CH
dNTPs (100 mM each) Pharmacia, DŸbendorf, CH
Drymilk (Rapilait) Migros, Basel, CH
DTT Calbiochem, San Diego, CA, USA
FCS, ultra low IgG Gibco
Ethidium bromide 1% solution Boehringer Mannheim
G418 sulphate (Geneticin) Gibco
Gas mixture CO2 Carbagas, Basel, CH
Giemsa solution Fluka
Glycogen (1mg / ml) Boehringer Mannheim
HEPES BDH Laboratory Supplies, Poole, UK
HPS, sodium salt from bovine kidneyFluka
IMDM Gibco
IPTG Appligene Oncor, Basel, CH
L-Glutamine 200 mM Gibco
Lipofectin Gibco
LipofectAmine Gibco
LipoTaxi Stratagene, Heidelberg, D
Ni-NTA Agarose Qiagen AG, Basel, CH
RPMI 1640 Medium Gibco
Saponin (from Gypsophila) Sigma
SDS Serva, Heidelberg, D
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Name Supplier
SERVA Blue R Serva
Sodium pyruvate (100 mM) Gibco
SuperFect Qiagen, Basel, CH
Tris base (TRIZMA) Sigma
Triton X-100 Sigma
Trypanblue 0.4% solution in 0.85% salineICN Biomedicals Inc., Costa Mesa, CA, USA
Trypsin-EDTA solution (10 x concentrate)Gibco
Tween 20 Fluka
Urea, enzyme grade Gibco
Xylene cyanol Fluka
X-gal Appligene Oncor
3.1.5. Equipment and consumables
A list of items used in addition to the sandard laboratory equipment and consumables
is given in Table 3-IX.
Table 3-IX      List of equipment and consumables
Name Supplier
0.22, 0.44 µm syringe membrane filter Schleicher and Schuell, Dassel, D
0.22 µm bottle top filter (Steritop) Millipore, ZŸrich, CH
3 well glass slides Semadeni, Ostermundigen, CH
10 well glass slides BioMŽrieux, Lausanne, CH
12- 24- 48-well plates Costar at Integra Biosciences, Wallisellen, CH
ABI Prism 310 Genetic Analyzer Perkin Elmer, Foster City, CA, USA
Electroporator (EasyjecT) Equibio, Boughton, Montchetsea Kent, UK
Electroporation cuvette Equibio
Eppendorf Thermomixer 5436 Dr. Vaudaux AG, Schšnenbuch, CH
FACScan Becton Dickinson, San Jose, CA, USA
FACScan tubes (PS, Falcon 2052) Falcon Labware, Oxnard, CA, USA
Freezing vials Nunc Inc., Naperville, IL, USA
HyBond-C extra nitrocellulose membraneAmersham, Buckinghamshire, UK
HyBond-N+ Nylon membrane Amersham
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Name Supplier
Hybridizer 400HY Bachofer AG, Reutlingen, D
Hybridizer HB-2D Techne, Cambridge, UK
Inverted fluorescence microscope Zeiss, Basel, CH
Mini-PROTEAN II Electrophoresis cell Bio-Rad Laboratories AG, Glattbrugg, CH
Needle scalpel Moria-Dugast, Paris, F
PAP pen Anawa AG, Basel, CH
Petri dishes, tissue culture treated Falcon
Petri dishes, bacterial Greiner Labortechnik, KremsmŸnster, A
round bottom Tubes (PP, Falcon 2059)Falcon
Sonicator (Branson Sonifier) Skan AG, Basel, CH
Whatman 3MM filter paper Whatman, Maidstone, UK
X-ray films (Kodak X-Omat AR) Kodak
3.1.6. Media, Buffers, Solutions
Media, buffers and solutions for cell culture work were prepared with Millipore water,
sterilized by filtration through 0.22 µm bottle top filters. Uncompleted media was stored up
to 3 months at 4°C. If the media was older than 2 weeks, 2 mM L-Glutamine was added
when completed with FCS.
Buffers and solutions for mRNA isolation, which were not provided by the Fast Track kit,
were prepared with autoclaved and DEPC-treated Millipore water. A list of all prepared
media, buffers and solutions is given in Table 3-X to 3-XII.
Table 3-X       List of Media  
Name Composition Usage
DMEM (high
glucose)
1 litre
1 box
10 ml
3.70 g
ad to
Powder DMEM (high glucose)
sodium pyruvate 100 mM-stock
NaHCO3 (44 mM)
1 litre with water and adjust to
pH 7.0
Stock for Cell
culture.
Prior use, add 10%
FCS (L-Glutamine)
IMDM, 1 litre 1 box
3.02 g
ad to
Powder IMDM
NaHCO3 (36 mM)
1 litre with water.
Stock for Cell
culture.
Prior use, add 5%
FCS (L-Glutamine)
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Name Composition Usage
RPMI 1640 for CHO-
cell culture, 1 litre
1 box
2.10 g
ad to
Powder RPMI 1640
NaHCO3 (25 mM)
1 litre with water and adjust to
pH 7.0
Stock for Cell
culture.
Prior use, add 10%
FCS
RPMI 1640 for para-
site culture, 1 litre
1 box
2.10 g
2.38 g
50 µg / ml
50 µg / ml
0.5%
ad to
Powder RPMI 1640
NaHCO3 (25 mM)
HEPES (10 mM)
Hypoxanthine
Neomycin sulphate
Albumax II
1 litre with water
P. falciparum culture
RPMI 1640 storage
medium
1 box
5.95 g
ad to
Powder RPMI 1640
HEPES (25 mM)
1 litre with water and adjust to
pH 7.4
Storage of fixed cell-
slides (3.2.2.2.)
Binding medium 1 box
5.95 g
5.00 g
ad to
Powder RPMI 1640
HEPES (25 mM)
Albumax II (0.5%)
1 litre with water and adjust to
pH 7.0
Binding assays
(3.2.2.2. and 3.2.2.6.)
HBD, 1 litre 1 box
10 ml
5.95 g
ad to
Powder DMEM (high glucose)
sodium pyruvate 100 mM-stock
HEPES (25 mM)
1 litre with water and adjust to
pH 7.0
Transfection
(3.2.2.5.)
Cell-freezing medium20%
80%
DMSO
FCS
N2-Stabilates of cells
SOC medium, 1 litre20 g
5 g
0.5 g
10 ml
ad to
20 ml
Bacto tryptone
Bacto yeast extract
NaCl
250 mM KCl
1 litre with water and adjust to
pH 7.0, autoclave, allow to cool
down to 60°C before adding
1 M Glucose (0.22 µm filtered)
Culture medium for
E. coli cultures after
electroporation
LB medium 10 g
5 g
10 g
ad to
Bacto tryptone
Bacto yeast extract
NaCl
1 litre with water and autoclave
Culture medium for
liquid E. coli cultures
LB-Agar 1 litre
15 g
LB medium
Agar, then autoclave
Solid culture medium
for E. coli cultures
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Name Composition Usage
LB / 50% Glycerol 50%
50%
LB
Glycerol, anhydrous, extra pure
Freezing medium for
E. coli cultures
Super Broth medium25 g
15 g
5 g
ad to
Bacto tryptone
Bacto yeast extract
NaCl
1 litre with water and autoclave
Culture medium for
liquid E. coli cultures
used for protein ex-
pression
Table 3-XI      List of Buffers
Name Composition Usage
10 x PBS 1.37 M
27 mM
120 mM
15 mM
NaCl
KCl
Na2HPO4
KH2PO4
adjust to pH 7.0
Various
1 x DPBS 100 ml
800 ml
200 ml
10 x PBS
water
5 x CaCl2 / MgCl2 (add last)
Washing (3.2.2.2.)
1% formaldehyde in
1 x DPBS
540 ml
15 ml
1 x DPBS
37% formaldehyde
Fixation (3.2.2.2.)
1% glutaraldehyde
2% formaldehyde
in 1 x PBS
2 ml
2.7 ml
45.3 ml
25% glutaraldehyde
37% formaldehyde
1 x PBS
Fixation (3.2.2.6.)
FACS sheath fluid 0.05%
1x
NaN3
PBS
FACScan analysis
Phosphate buffer for
Giemsa stains
8 mM
18.8 mM
KH2PO4
Na2HPO4
adjust to pH 7.2
Giemsa stains
Tris-HCl (pH x) 10 mM Tris base
pH adjusted to x with HCl
various
Saponin-lysis buffer0.15 g
950 ml
50 ml
saponin (0.015%)
water
20 x SSC
Saponin lysis
(3.2.2.3.)
20 x SSC 3M
0.3 M
NaCl
Na3Citrate
adjust to pH 7.0
various
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Name Composition Usage
STET buffer 0.1 M
10 mM
1 mM
5%
NaCl
Tris-HCl pH 8.0
EDTA pH 8.0
Triton X-100
Rapid boiling protocol
(3.2.1.4.)
5 x TBE running
buffer
5 M
4 M
10 mM
Tris base
boric acid
EDTA, pH 8.0
Gel electrophoresis
(3.2.1.7.)
Gel loading buffer
(blue juice)
30%
10 mM
10 mM
a pinch
a pinch
glycerine
Tris-HCl, pH 8.5
EDTA, pH 8.0
bromphenol blue
xylene cyanol
Gel electrophoresis
(3.2.1.7.)
TE (storage buffer)10 mM
1 mM
Tris-HCl, pH 8.5
EDTA
Elution and storage of
DNA
10 x Taq PCR buffer0.5 M
0.1 M
15 mM
KCl
Tris-HCl, pH 8.8
MgCl2
PCR (3.2.1.8.)
10 x Pfu reaction
buffer
0.1 M
0.2 M
20 mM
60 mM
1%
100µg /ml
KCl
Tris-HCl, pH 8.8
MgCl2
(NH4)2SO4
Triton X-100
nuclease free BSA
PCR (3.2.1.8.)
1 M Phosphate
buffer =Na(P)
1 M
1 M
NaH2PO4 (pH 4.1) and
Na2HPO4 (pH 8.8) were mixed
to achieve pH 7.2 (approx. 1:5)
Southern blot (3.2.4.)
Prehybridisation
buffer
5.0 parts
3.5 parts
1.5 parts
1 M Na(P)
20% SDS stock in water
water
Southern blot (3.2.4.)
Southern buffer 100 mM
150 mM
Tris-HCl, pH 7.5
NaCl
Southern blot (3.2.4.)
Buffer 3 100 mM
100 mM
50 mM
Tris-HCl, pH 9.5
NaCl
MgCl2
Southern blot (3.2.4.)
Lysis buffer 50 mM
300 mM
NaH2PO4
NaCl
adjust to pH 8.0
Protein purification
(3.2.5.4.)
Buffer B 8 M
100 mM
10 mM
Urea
NaH2PO4
Tris-HCl, pH 8.0
adjust to pH 8.0
Protein purification
(3.2.5.4.)
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Name Composition Usage
2 x SDS-Page
sample buffer
2.5 ml
2.0 ml
0.4 g
0.31 g
1 mg
ad to
0.5 M Tris-HCl, pH 6.8
glycerol
SDS
DTT
bromphenol blue
10 ml with Millipore water
Protein separation
(3.2.1.11.)
5 x running buffer 15 g
72 g
5 g
ad to
Tris base
Glycine
SDS
1 litre with Millipore water
Protein separation
(3.2.1.11.)
1 x transfer buffer 5 ml
5 ml
40 ml
0.1 M CAPS, pH 11.0
MeOH
Millipore water
Western blot
(3.2.1.11.)
Buffer A 50 mM
5 mM
140 mM
0.05%
0.25%
Tris base
EDTA
NaCl
adjust pH to 7.4, then add
NP 40
gelatine, heat to dissolve
Western blot
(3.2.1.11.)
AP staining Buffer 100 mM
0.5 mM
Tris-HCl, pH 9.5
MgCl2
Western blot
(3.2.1.11.)
HRP staining buffer18.8 ml
1.2 ml
10 µl
1 x PBS
0.3% chloronaphtol in MeOH
30% H2O2   (Perhydrol)
Western blot
(3.2.1.11.)
Table 3-XII     List of Solutions
Name Composition Usage
5 x CaCl2 / MgCl2 5 mM
5 mM
CaCl2
MgCl2
Preparing of DPBS
Trypsin-EDTA
solution
1 part
9 parts
Trypsin/EDTA 10 x concentrate
1 x PBS
Detachment of cells
PBS-EDTA solution1 part
99 parts
50 mM EDTA, pH 8.0
1 x PBS
Trypsin-free detach-
ment of cells
Chloroquine stock 51.6 mg
10 ml
chloroquine
water
stock was 0.22 µm-filtered, ali-
quoted and wrapped in alumi-
nium foil (light sensitive)
Transfection (3.2.2.5.)
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Name Composition Usage
DEAE-dextran stock1g
10 ml
DEAE-dextran
water
stock was 0.22 µm-filtered and
aliquoted
Transfection (3.2.2.5.)
Hirt extract solution
with proteinase K.
10 mM
0.6%
100 µg/ml
EDTA pH 8.0
SDS
Proteinase K
Plasmid isolation
(3.2.2.8.)
Amp stock solution
Kan stock solution
Tet stock solution
50 mg
25 mg
15 mg
ampicillin / ml water
kanamycin / ml water
tetracycline / ml water
E. coli culture
(3.2.1.3.)
AEC / DMF Stock
solution
20 mg
5 ml
AEC (= 1 tablet)
N,N-Dimethylformamide
stock was aliquoted and
wrapped in aluminium foil (light
sensitive).
IFAs (3.2.3.3.)
Staining solution for
HRP-labelled mAbs
500 µl
10 ml
1.5 µl
AEC / DMF stock
0.1 M sodium acetate pH 4.8
(pH adjusted with glacial acid)
30% H2O2 (Perhydrol)
IFAs (3.2.3.3.)
Serva blue solution0.5 g
200 ml
1800 ml
Serva blue
acetic acid
Millipore water
Mix 1 hour and filter
Protein staining
(3.2.1.11.)
3.1.7. Commercially available kits
During this work, several kits were used. The buffers and solutions provided in these
kits were not listed separately in section 3.1.6. (See the supplier's notes and manuals for
further information). The kits are listed in Table 3-XIII
Table 3-XIII    List of Kit systems
Name Supplier
Fast Track 2.0 Kit Version D Invitrogen, Leek, NL
Qiagen mega plasmid purification kitQiagen, Basel, CH
Qiaprep Spin Plasmid Kit Qiagen, Basel, CH
Qiaquick Gel Extraction Kit Qiagen, Basel, CH
44                                                                                                  3. Materials and Methods
___________________________________________________________________________
Name Supplier
pMOSblue T-vector Kit Amersham, Buckinghamshire, UK
DNA Sequencing Dye Terminator KitPerkin Elmer, Rotkreuz, CH
BioPrime DNA labelling System Gibco BRL Life Technologies, Basel, CH
BLUEGENE Non radioactive Nucleic
Acid Detection System
G bco BRL Life Technologies, Basel, CH
QIAexpress Kit Type IV Qiagen, Basel, CH
3.1.8. Enzymes
3.1.8.1. Restriction enzymes
Most restriction enzymes and corresponding buffers used in this work were obtained
by Gibco BRL Life Technologies, Basel, CH, except ApaI and PvuII, which were obtained
by Promega, Wallisellen, CH. A list of all used enzymes is given in Table 3-XIV.
Table 3-XIV   List of restriction enzymes
Name Cutting site Name Cutting site
ApaI 5' GGGCC | C 3' KpnI 5' GGTAC | C 3'
BamHI 5' G | GATCC 3' NotI 5' GC | GGCCGC 3'
EcoRI 5' G | AATTC 3' PvuII 5' CAG | CTG 3'
HindIII 5' A | AGCTT 3' XbaI 5' T | CTAGA 3'
3.1.8.2. DNA polymerases and dNTPs
4 different DNA polymerases were used: Taq DNA polymerases (Gibco BRL Life
Technologies AG, Basel, CH and Qiagen, Basel, CH), Native Pfu DNA polymerase
(Stratagene, Heidelberg, D), Klenow polymerase (Boehringer Mannheim) and AmpliTaq
DNA polymerase (Perkin Elmer).
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Nucleotides were often included in Kit systems or were ordered: dNTPs, 100 mM
(Pharmacia, DŸbendorf, CH) and dNTPs, 500 mM (Boehringer Mannheim), as well as a-32P
labelled dCTP, 250 µCi (Amersham Life Science, Braunschweig, D) and Biotin-14-dCTP,
0.4 mM (Gibco BRL Life Technologies, Basel, CH).
3.1.8.3. Other enzymes
Name Supplier
Chondroitinase ABC Sigma, Buchs, CH
Lysozyme Appligene Oncor, Basel, CH
Proteinase K Appligene
T4 DNA Ligase Amersham, Buckinghamshire, UK
3.1.9. Primers
3.1.9.1. Custom-made primers
Primers were manufactured by Gibco BRL Life Technologies, Basel, CH, but *,
which were ordered at Mycrosynth, Balgach, CH and **, which were manufactured at the
Centre MŽdicale Universitaire (CMU), Geneva, CH. A complete list of the primers used is
given in Table 3-XV. Capital letters indicate the coding sequence of a gene and small letters
indicate internal restriction sites and/or ribosomal binding sites and/or additional bases,
necessary for in-frame ligation. All primers are given in 5' to 3' direction.
Table 3-XV     List of primers
Primer name Sequence Binding site      (Reference)
FW huICAM1** atataagcttccaccATGGCTCCCAGC
AGCCCCCGG
N-terminus of huICAM-1
                              (3.2.2.11.)
Rev huICAM totGFP**tataggatccggAGGCGTGGCTTGT
GTGTTCGG
C-terminus of huICAM-1
                              (3.2.2.11.)
FW MSP2 Hind atataagcttccaccATGAAGGTAATT
AAAACATTG
N-terminus of MSP2
                                (3.2.3.5.)
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Primer name Sequence Binding site      (Reference)
Rev MSP2 Bam tataggatccatGAATATGGCAAAA
GATAAAAC
C-terminus of MSP2
                                (3.2.3.5.)
FW MSP1 Eco atatgaattcccaccATGAAGATCATA
TTCTTTTTA
N-terminus of MSP1
                                (3.2.3.5.)
Rev MSP1 Bam tataggatcctcAGGGAGAGGATTT
GGTTTACT
AA 342-348 of MSP1
                                (3.2.3.5.)
FW MSP1 Kpn gggggtaccATGAAGATCATATTC
TTTTTA
N-terminus of MSP1
                                (3.2.3.5.)
Rev MSP1 Apa ggggggcccctcAGGGAGAGGATT
TGGTTTACT
AA 342-348 of MSP1
                                (3.2.3.5.)
SEQ HSV FW CATGGGGTCCGCGGCAAA AA 21-26 of HSVgD
                                (3.2.3.5.)
SEQ HSV Rev GGGGGTCTCGGACAGCTC AA 281-286 of HSVgD
                                (3.2.3.5.)
VARDBL5* GCACGAAGTTTTGCAGATAT
(A/T)GG
ARSFADIG-motif at the 5'
end of a DBL1 domain
                                (3.2.4.2.)
VARDBL3* AA(G/A)TCTTC(G/T)GCCCATT
CCTCGAACCA
WFEEWAED-motif at the 3'
end of a DBL1 domain
ATS5* CCTAAATATAAAACATT(G/A)
AT(A/T)GAAGT
PKYKTLIE-motif at the 5'
end of a ATS domain
ATS3.1* TCGTTGATTAGGTCGATACCA
CTATA
YSGIDLIN-motif at the 3'
end of a ATS domain
ATS3.2* TCATTAATTAAATCTATACCA
CTATA
YSGIDLIN-motif at the 3'
end of a ATS domain
DBL1 Fw Bam cgggatccGCACGAAGTTTTGCA
GATATTGG
ARSFADIG-motif with
restriction site         (3.2.5.2.)
DBL1 Rev Kpn ggggtaccTTCGGCCCATTCCTCG
AACCA
WFEEWAE-motif with
restriction site
CIDR Fw Bam cgggatccAAATGGAAATGTTAT
TATG
KWKCYY-motif at the 5'
end of a CIDR domain
CIDR Rev Kpn ggggtaccTTGTAGTAATTTATCA
ATT
IDKLLQ-motif at the 3' end
of a CIDR domain
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3.1.9.2. Commercially available primers
Name Purpose
T7 promoter primer (Gibco) forward sequencing pcDNA3.1 / pMOS
U19mer primer (Amersham) reverse sequencing pMOSblue T vector
pcDNA3.1/BGH reverse primer (Invitrogen)reverse sequencing pcDNA3.1
QIAexpress primer type III/IV (Qiagen) forward sequencing pQE30
QIAexpress primer reverse sequencing (Qiagen)reverse sequencing pQE30
3.1.10. Molecular weight markers
The following markers were used for DNA gel electrophoresis (3.2.1.7.) and for SDS-
Page gel electrophoresis (3.2.1.11.) to estimate the size and the amount of DNA fragments or
proteins. All markers were used according the supplier's instructions.
Name Supplier
1 kb Ladder Gibco BRL Life Technologies, Basel, CH
Low molecular weight marker Pharmacia Biotech, DŸbendorf, CH
Rainbow marker 756 Amersham, Buckinghamshire, UK
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3.2. Methods
The methods are arranged according to the four approaches used in this work (see:
Goals and Objectives). Methods which were not related exclusively to a single approach, are
described in the following first chapter of generally used methods:
3.2.1. Generally used methods
3.2.1.1. Cell culture
Maintenance and passaging
All cells were cultivated in a 37°C / 5% CO2 incubator. L-huICAM-1 cells were
cultivated in IMDM containing 5% FCS, supplemented with 1 mg / ml Geneticin as
described (Van Kooyk et al., 1993). Non-transfected L-cells were maintained without
Geneticin. Bosc23, C32 and COS 7 cells were cultivated without antibiotics in DMEM / 10%
FCS. Transfected and non-transfected CHO cells were cultivated in RPMI 1640 cultivation
medium / 10% FCS. For passages, all these adherent cells were first washed with PBS, then
covered with a minimum amount (800 µl / 75 cm2 and 400 µl / 25 cm2) of 1x Trypsin-EDTA
solution and placed in the incubator until the cells rounded up (2-5 minutes). Subsequently,
the cells were detached from the bottle by tapping or by rinsing harshly with a Pasteur pipette
and diluted to the desired cell concentration with fresh medium. Alternatively, all cell types,
but the C32 cells, could also be detached by analogous treatment with PBS / 0.5 mM EDTA
with a prolonged incubation at 37°C (up to 10 minutes). This treatment was used, if the cells
were used for assays, since some cell surface receptors were sensitive to trypsination.
Counting
Detached cells were suspended in complete medium and centrifuged at 300 g for 5
minutes. The supernatant was discarded and the cells were resuspended in the remaining
liquid. Depending on the size of the pellet, the suspension of cells was further diluted with 1-
3 ml of medium and 10 µl were diluted with an equal volume of Trypanblue solution and
transferred to a Neubaur chamber. The concentration of viable cells was calculated by
counting the white cells in 16 fields: number of cells x 2 x 10'000 per ml.
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Freezing and thawing
Cells were counted as described above. 50'000 cells were mixed with an equal volume
of cold, freshly prepared cell-freezing medium in a freezing vial. The vials were placed in a
styropor box and stored for 1 to 2 days a -70°C before they were transferred to liquid nitrogen
for long term storage. When a new batch of cells was needed, a stabilate was thawed as
quickly as possible (at 37°C or by hand) and immediately transferred to cold medium,
centrifuged for 5 minutes at 300 g and resuspended in complete medium for cultivation.
3.2.1.2. Parasite culture
Maintenance
Parasite cultures were kept in continuous motion with automated medium exchange
twice daily (Matile and Pink, 1990). The P. falciparum strains used in this work, were
cultured in RPMI 1640 supplemented with 0.5% Albumax II. Infected erythrocytes were
replaced by fresh human A+ erythrocytes when culture reached 5-10% parasitaemia.
Counting of P. falciparum-infected erythrocytes
Parasitaemia was measured by blood smears: thin films on glass slides were air dried,
fixed by covering with MeOH for 2 minutes, air dried, stained for 20 to 30 minutes in 5%
Giemsa solution diluted in phosphate buffer, washed under running tap water (chalk enhances
the staining) and air dried again. The blood films were analyzed by microscopy using a 1000-
fold magnification and oil immersion.
3.2.1.3. E. coli culture
E. coli cultures were used for a variety of purposes during this work. The liquid and
plate cultures were performed according to standard protocols (Sambrook, Fritsch and
Maniatis, 1989), as well as the preparation of glycerol stocks, but if many clones were to be
stored: then, the freezing medium was prepared in a 96 well plate, each colony from a LB /
agar plate was stripped into one well, the plate was sealed with Parafilm and immediately
stored at -70°C.
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3.2.1.4. Isolation of plasmids from E. coli cultures
The rapid boiling protocol
1.5 ml of an overnight or of an 8-hours culture were transferred to an Eppendorf tube
and pelleted with 14'000 g for 1 minute. The supernatant was discarded and the pellet was
resuspended in 350 µl of ice cold STET buffer and 25 µl of freshly prepared lysozyme stock
solution (10 mg / ml water) was added, mixed by inversion and incubated on ice for 10
minutes. After ten minutes the tube was transferred directly into boiling water for 40 seconds
and then briefly cooled down on ice. The tube was centrifuged at 15'000 g for 20 minutes at
room temperature. The resulting, sticky pellet was removed with a tooth pick and discarded.
The DNA was precipitated from the supernatant with isopropanol as described in 3.2.1.5. The
pellet was resuspended in 50 µl TE and stored at -20°C. The rapid boiling method was used if
the plasmids were not to be used for sensitive applications, such as ligation or transfection of
mammalian cells, or if a lot of colonies had to be screened.
Qiaprep Spin Plasmid Kit
This method was used when highly purified plasmids were needed for further working
steps. The kit was used according to the supplier's protocol. It is based on the following
principles: E. coli cultures are lysed under alkaline conditions (NaOH / SDS) in presence of
RNase A. The genomic DNA remains attached to the debris of the cell wall and is pelleted
with the SDS-precipitate prior to the application of the supernatant to a spin column
containing a silica gel membrane. The plasmid DNA binds to the membrane under the chosen
high salt conditions, is washed and is eluted under low salt conditions and a pH around 8.0.
The DNA of one culture was eluted in 50 µl TE and stored at -20°C.
3.2.1.5. Precipitation of DNA
DNA was precipitated either with isopropanol at room temperature or with ethanol for
1 hour on ice (precipitation of plasmids) or for 2 hours at -20°C when small particles of DNA
were to be precipitated (PCR fragments). Precipitation was performed according to standard
protocols (Sambrook et al., 1989). A special application of this method is the Hirt extraction
method (3.2.2.8.), where no salt was added for the precipitation, since 5 M NaCl was already
added to the DNA solution prior the precipitation of DNA. If small amounts of DNA were to
be precipitated, 20 µg of glycogen was added as a carrier.
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3.2.1.6. Restriction enzyme digests
If possible, all digests were performed as recommended by the supplier, using the
provided 10x reaction buffer. Whenever possible, double digests were performed
simultaneously in the appropriate buffer. However, if this was not possible and the enzymes
required different buffers, a simultaneous digest was performed, either in the buffer with the
lower salt concentration, or a two step digest was performed with a precipitation step in
between. In a typical digest, 0.5 to 2 units of enzyme(s) were used for up to 500 ng of
plasmid DNA in a reaction volume of 20 µl and the digest was usually performed for 1 hour
at 37°C. If the digested DNA was used for salt-sensitive applications such as ligation, the
digest was precipitated prior to further use.
3.2.1.7. DNA gel electrophoresis
Agarose gel electrophoresis
Horizontal gel electrophoresis was performed in 1 x TBE as running buffer. A
concentration of 0.75% up to 1.5% electrophoresis grade agarose was used to separate the
DNA with maximal 50 milliamp•res. The gels were stained for 15 minutes in 1 x TBE
containing 1 µg / ml EB. Gels were examined on an UV transilluminator connected to an
IBM PC equipped with the Grab-it 2.0 software.
RNase-free gels were poured similarly, with the exception, that all buffers were made with
DEPC-treated water and that the EB was already added to the gel before polymerising, in
order to keep the time between loading the samples and examination as short as possible.
Estimation of the size and concentration of DNA fragments
The size of DNA fragments was estimatd in relation to the fragments of the 1 kb
ladder (Gibco). The amount of DNA could be estimated by comparing the intensity of a band
with the 1.6 kb band of the 1 kb ladder (100 ng / µl), which represents 10% of the whole
marker applied (10 ng per µl marker applied).
Gel extraction
Agarose gel electrophoresis was also used to purify DNA fragments: PCR products or
restriction fragments were run on a agarose gel as described above and cut out with a scalpel
under UV light (302 nm). The QIAquick Gel Extraction Kit was used to elute DNA from gel
fragments.
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3.2.1.8. Polymerase chain reaction (PCR)
PCRs were part of several methods. The most commonly used polymerase was Taq
polymerase. The Pfu polymerase was used for amplification of templates bigger than 3 kb,
AmpliTaq polymerase was used with the sequencing reaction (see 3.2.1.10.), and Klenow
polymerase fragment was used for random priming and labelling reactions (3.2.4.3.).
PCR amplification with Taq polymerases
For a set of PCR amplifications, a master mix, containing buffer, dNTPs, primers, and
water was usually prepared. A negative control without DNA template and a positive control
with appropriate template w s always included. The template was added to the mix in a PCR
tube and overlaid with mineral oil. Each reaction contained the following components:
DNA template (0.1-1 µg)    x µl
10 x Taq PCR buffer 5.0 µl
10 x dNTPs (2 mM each) 5.0 µl
10 x forward primer (20 ng / µl) 5.0 µl
10 x reverse primer (20 ng / µl) 5.0 µl
Millipore water     29.8 - x µl
Taq DNA polymerase (5 u / ml) 0.2 µl
The Taq DNA polymerase was often added during the initial denaturing step (hot start) and
was not added to the mastermix. For most PCR reactions, the conditions were set as follows,
but if the reaction conditions differ from this set up it an experiment, the variation is given
with the description of that experiment.
  5:00 minutes denaturing at 95°C
  1:00 minute
  0:45 seconds
  2:00 minutes
denaturing at 95°C
primer annealing at
[2(A+T)+4(G+C)]-3°C
extension at 72°C  for 30 cycles
10:00 minutes 72°C
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PCR amplification with native Pfu polymerase
The PCR protocol is the same as with Taq polymerase, but the master mix contained a
higher concentration of primers:
DNA template (0.1 µg)    x µl
10 x Pfu reaction buffer 5.0 µl
10 x dNTPs (2 mM each) 5.0 µl
"10 x" forward primer (20 ng / µl)         12.5 µl
"10 x" reverse primer (20 ng / µl)         12.5 µl
Millipore water     13.0 - x µl
native Pfu DNA polymerase (2.5 u / ml)2.0 µl
The native Pfu DNA polymerase was added during the initial denaturing step. The conditions
were dependent from AT richness of the primers (annealing temperature) and also from the
length of the template (extension time), since native Pfu polymerase synthesizes 1 kb of DNA
per 2 minutes. The following profile was used:
  5:00 minutes denaturing at 95°C
  0:45 seconds
  0:45 seconds
  2:00 minutes
denaturing at 95°C
primer annealing at
[2(A+T)+4(G+C)]-3°C
extension at 72°C for
each kb of template
for 25 cycles
10:00 minutes 72°C
3.2.1.9. Subcloning
T/A cloning
This method was carried out with the pMOSblue T-vector kit (3.1.7.). The method
exploits the template-independent activity of Taq DNA polymerase to add a single adenosine
nucleotide to the 3' end of double stranded DNA. Such a PCR product can then be inserted
into a thymidine-tailed vector like pMOSblue T-vector and eliminates the requirement for
restriction sites being incorporated into PCR primers to produce sticky ends when cleaved.
The pMOSblue T-vector allows for blue/white screening.
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PCR products were purified by gel extraction and the concentration was estimated by
comparing to DNA standards (3.2.1.7.). The vector to insert ratio was adjusted to 1:9 up to
1:14. A master mix was usually prepared containing the following four components, provided
by the kit, for each PCR product to be cloned:
10x ligase buffer 1.0 µl
100 mM DTT 0.5 µl
10 mM ATP 0.5 µl
50 ng / ml vector 1.0 µl
For each PCR product to be cloned the following components were added to 3 µl mast r mix
insert    x µl
water         9.5-x µl
T4 DNA ligase (2 u / reaction)0.5 µl
3 reactions were prepared for each PCR product to be cloned. One reaction was incubated for
4 hours at room temperature, one reaction was incubated for 2 hours at 16°C before being
stored at 4°C overnight. The third reaction was immediately stored at 4°C overnight. The
next day the provided MOSblue competent cells were transformed according to the supplier's
manual and plated on X-gal / IPTG agar plates and incubated upside down overnight. White
clones were picked, DNA was isolated (3.2.1.4.) and the presence of an appropriate insert and
its orientation was determined by restriction digest (3.2.1.6) with EcoRI and HindIII and
sequencing with the according primers (3.1.9.2.).
Sticky end ligation
This method was the one, predominately used. It allowed cloning of PCR products in-
frame into different expression vectors by the use of primers with appropriate internal
restriction sites. Vector and insert were digested, whenever possible with two different
restriction enzymes to help reducing religation of vector, purified by gel extraction and
precipitated. The vector to insert ratio was adjusted to 1:3 up to 1:5. The final ligation mix
comprised of the following Amersham products:
2 µl 10 x T4 DNA Ligase buffer
(660 mM Tris-HCl pH 7.6, 66 mM MgCl2, 100 mM DTT, 66 µM
ATP)
1 µl T4 DNA Ligase 1:10 diluted with T4 DNA Ligase Dilution Buffer
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The ligation mix was kept on ice for up to 1 hour and then transferred to 16°C for 12 to 36
hours. For electroporation (3.2.2.9.), the mix was precipitated and resuspended in 5 µl of
water. A negative control without insert was always carried out in parallel to estimate the
amount of religated vector.
3.2.1.10. DNA sequence analysis
Sequencing was done using the DNA Sequencing Dye Terminator Kit based on the
dideoxy chain termination method (Sanger et l., 1977) with fluorescent dideoxy nucleotides
as terminators in a cycle sequencing PCR. This allowed to carry out the reaction in a single
tube and to fractionate it in a single 'lane'. Sequence analysis was carried out with an ABI
Prism 310 Genetic Analyzer (Perkin Elmer) and ABI Prism software was used to proof read
and translate the data into AA sequences.
The following alterations on the recommended protocol were found to improve the quality of
the sequence data:
1. ) The amount of recommended reaction mix (TRR) per PCR reaction was reduced to one
half (4 µl / 20 µl).
2. ) The tubes containing the PCR reaction were incubated for 1 minute at 95°C prior to the
step cycles of the PCR.
3. ) The amount of DNA template was increased from the recommended 100 to 500 ng up to
1 µg per reaction.
4. ) After the PCR, the DNA was precipitated in EtOH for 15 minutes on ice, washed and
dried and resuspended in 25 µl Template Suppression reagent for each sequence reaction.
The sample was mixed thoroughly, denaturated for 2 minutes at 95°C and could then be
stored for up to 1 week before being loaded into the sequencer.
3.2.1.11. SDS-Page gel electrophoresis and western blotting
Separation of proteins
The protein aliquots were mixed with 2 x SDS-Page sample buffer and denaturated
for 5 minutes at 95°C or, when the aliquots contained imidazole, by incubation at 37°C for 10
minutes. Proteins were separated in a Mini-PROTEAN II Electrophoresis cell (Bio-Rad)
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according to the supplier's manual by running a discontinuous polyacrylamide gel (Laemmli,
1970). The acrylamide concentration in the separating (lower) gel was 12.5% and in the
stacking (upper) gel 4%. The gels were run in 1 x running buffer with 200 volts. After the
run, gels could be stained in Serva blue solution (= Coomassie blue) to visualize the protein
bands, or the proteins were transferred to a HyBond-C extra nitrocellulose membrane by a
semi-dry western blot. The marker used in Coomassie blue stained gels was the low
molecular weight marker (Pharmacia Biotech) according to the supplier's instructions.
The semi-dry western blot protocol
Blotting was performed in a Trans-Blot SD Semidry Transfer Cell (Bio-Rad): the
stacking gel was cut off with a scalpel from the separating gel and discarded. The remaining
separating gel was measured and ten Whatman 3MM filter paper pieces and one HyBond-C
extra nitrocellulose membrane were cut to the same size; five filter paper pieces were
prewetted in freshly prepared 1 x transfer buffer and laid onto the Teflon plate of the blotter,
onto that stack of filters, the prewetted nitrocellulose, the prewetted gel, and finally the
remaining five prewetted filter paper pieces were laid. After air bubbles in this sandwich
were removed by rolling a plastic pipette over it, the upper Teflon plate was carefully put on
the sandwich and the lid was closed. Blotting was done for 30 minutes at 13 V.
Immunoassay on a western blot
The nitrocellulose was washed 2 x for 5 minutes with 10 ml buffer A in a 50 ml
Falcon tube rotating in a Hybridizer HB-2D, as described in 3.2.4.3. at room temperature.
The nitrocellulose was then blocked for 1 hour in buffer A / 3% BSA, before the first
antibody was applied in an appropriate dilution to the blocking buffer and incubated
overnight. The next day, the nitrocellulose was washed 6 x for 5 minutes with 10 ml buffer
A, before the second antibody was applied 1:1000 in buffer A / 3% BSA and incubated for 2
hours. Finally the nitrocellulose was washed 4 x for 5 minutes with PBS and was then ready
for the visualisation procedure:
If the second antibody was AP-conjugated, visualisation was performed using the
BLUEGENE Non radioactive Nucleic Acid Detection System. The nitrocellulose was
washed 2 x with AP staining buffer before NBT and BCIP were diluted 1:1000 in AP
staining buffer and this solution was applied directly to the nitrocellulose on a glass plate.
The reaction was allowed to develop in the dark.
If the second antibody was HRP-conjugated, the nitrocellulose was transferred on a
glass plate and the HRP staining solution was poured directly on to the nitrocellulose. Again,
the reaction was allowed to develop in the dark.
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3.2.2. Shotgun approach (1)
3.2.2.1. Overview
The aim of this approach was to identify P. falciparum-derived adhesion molecules by
expressing an ItG2.F6-cDNA library in COS 7 cells. The transfected cells were used in a cell-
cell adherence assay with screening cells expressing huICAM-1 on their surface, a receptor
known to be involved in sequestration of strain ItG2.F6. COS 7 cells, which accumulated
bound huICAM-1 expressing cells on their surface, were picked, the cDNA clones were
isolated, and used for a re-transfection of COS 7 cells to perform a second screen.
3.2.2.2. Testing for adhesion of P. falciparum-infected erythrocytes on
monolayers of L-huICAM-1-, L- and C32 cells
Preparation of adhesion assay slides
3-well glass slides were rinsed with 70% EtOH, dried and autoclaved prior to use. The
slides were placed in Petri dishes (5 slides per Æ 145 mm). 200 µl of cell-suspension
(500'000 L-cells, L-huICAM-1 cells or C32 cells / ml complete medium) were seeded on
each well, the Petri dishes containing the slides were put in a 37°C / 5% CO2-incubator and
the cells were allowed to attach and grow overnight. These slides were used directly the next
day (fresh cells) or were fixed and stored for further experiments (fixed cells).
Fixation and storing of adhesion assay slides
Slides with a confluent cell-layer were fixed and stored directly in the surrounding
Petri dish: each dish was washed twice with 40 ml DPBS (applying the buffer, swirling the
dish moderately 4-5 times and aspirating off the buffer) and then fixed for 1 hour at room
temperature in 40 ml of freshly prepared 1% formaldehyde in DPBS. The slides were then
transferred to a new dish, washed twice with DPBS and then overlaid with 50 ml RPMI 1640
storage medium. The dishes were then wrapped in Saran wrap and were stored at 4°C for up
to 3 months.
iRBC adhesion assay on slides
Fixed or fresh slides were transferred into a new Petri dish, the liquid was aspirated
off the black masks of the slides, but not from the wells, and one big circle was drawn around
all three wells with a water-repellent PAP-pen. Subsequently, the remaining liquid on the
cells was aspirated off and was replaced with 600 µl binding medium. The slides were put
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aside until the P. falciparum cultures were processed: the iRBC suspensions from parasite
cultures (5-10% parasitaemia) were centrifuged and resuspended in binding medium to 1%
haematocrit. 900 µl of iRBC suspension were applied on each slide and the cells were
allowed to adhere for 1 hour in the incubator (37°C / 5% CO2), with gentle agitation every 15
minutes. After 1 hour, the slides were washed 4 x with 40 ml of binding medium and then air
dried under a ventilator, fixed with MeOH, stained with 5% Giemsa solution and mounted in
Eukitt, as described above (3.2.1.2). Adherent iRBCs were counted by light microscopy in 4
mm2 areas on all three cell mono-layers, fixed and unfixed, with an uninfected RBC
suspension as a negative control.
3.2.2.3. mRNA-isolation from a schizont-enriched ItG2.F6 culture
Synchronisation of parasite cultures
Prior to the isolation of mRNA of the strain ItG2.F6, the culture was synchronized for
ring stage parasites according to the protocol of Matile and Pink (1990), splitted to 15 10mm
culture dishes and then cultivated for an additional 18 hours until most of the stages were late
trophozoites or early schizonts. Then, 5 culture dishes were pooled and after centrifugation
(four minutes, 350 g, no brake) resuspended to 50% haematocrit in culture medium to
perform a final iRBC-adhesion assay, with a small aliquot, as described in 3.2.2.2. After the
small aliquot was removed, the remaining parasites from each pool were isolated by saponin
lysis.
Saponin lysis (isolation of parasites from an iRBC-culture)
Parasite cultures were sedimented as described above. For the following, all buffers
were ice-cold and the centrifuge was cooled to at least 10°C. The pellets were washed twice
by resuspending each of them in 10 ml of parasite cultivation medium and centrifugation at
350 g for 5 minutes without break. The supernatant was discarded and the pellets were
resuspended in a small volume of medium. These suspensions were brought to the original
volume of the parasite cultures (5 cultures = app. 50 ml) with Saponin-lysis buffer and
incubated for 20 minutes on ice. Then, the parasites were pelleted with 600 g for 15 minutes
and washed twice in 1 x SSC buffer at the same conditions. Finally each pellet was
resuspended in 500 µl of PBS.
Such a suspension from 5 cultures was dropped directly into liquid nitrogen. The resulting 13
frozen pearls were stored at -80°C, whereas the suspension from the second and third pool
was used to isolate the mRNA.
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Isolation of mRNA from P. falciparum pellets
The mRNA was isolated from both, fresh and frozen P. alciparum pellets, within a
week. The fresh suspension on ice (10 synchronized, saponin-lysed cultures of ItG2.F6 in
1000 µl PBS) was processed immediately, the frozen pellets within 6 days. The mRNA
isolation was done with the Fast Track 2.0 Kit (Version D) according to the supplier's
manual, with the only difference, that the elution buffer was prewarmed to 65°C. Aft r
precipitation, the mRNA from both isolations was pooled and after the analysis of the amount
and size of the mRNA with a small aliquot on a RNase-free agarose gel (3.2.1.7.), the sample
was shipped on dry ice to Invitrogen.
3.2.2.4. Custom-made cDNA library (Invitrogen)
Upon arrival of the P. falciparum RNA, the cDNA library was constructed by
Invitrogen with the following specifications:
Starting material: mRNA of P. falciparum
Priming for first strand cDNA synthesis: Oligo dT (NotI)
Ligation with the following adapters: BstXI / EcoRI
Separation on an agarose gel and size fractionating at: 500 Bp
Unidirectional ligation into the vector: pcDNA3.1+
Transformation into the following host vector: Top10F'
6 tubes containing 2 ml each were shipped on dry ice to the STI, where they were stored at -
70°C. The titer of the library was estimated different dilutions of the cDNA library on
LB/Agar plates under ampicillin selection. For amplification, 2 ml of cDNA (1 tube) were
then diluted in 300 ml LB medium and incubated in a shaker for 3 hours at 37°C. A 12 ml-
aliquot of this culture was removed and pelleted, resuspended in 10 ml LB / 50% glycerol,
divided in 10 Eppendorf tubes and stored at -70°C (glycerol-stocks of 1 x amplified cDNA).
The remaining culture was pelleted and processed according to the Qiagen Mega Plasmid
Purification protocol. The DNA was finally eluted in 400 µl TE. The DNA-concentration was
measured photospectrometrically and adjusted with the appropriate amount of TE to 1 µg
DNA / µl TE. This 1 x amplified cDNA was then aliquoted and stored at -70°C and used for
all further experiments.
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3.2.2.5. Transient transfection of COS 7 cells
A) Transfections with chloroquine / DEAE-dextran for cell-cell adherence
assays
Preparation
Prior the transfection, COS 7 cells were grown to 75-90% confluency in 75 cm2 tissue
culture flasks. 4 x 105 COS 7 cells were necessary for one transfection. Aliquot(s) of
chloroquine stock solution (5.16 mg / ml) and DEAE-dextran stock solution (100 mg / ml)
were thawed on ice, whereas PBS, DMEM / 10% FCS, HBD and Trypsin / EDTA were
prewarmed to 37°C. For each transfection, a Falcon 2059-tube was prepared, since PP-tubes
are known not to interact with the transfection reagents.
Transfection
To the appropriate amount of HBD (3 ml / transfection) 1/100 volume of chloroquine
was added and, after mixing, it was divided into two equal aliquots (A) and (B). To (A) 1/200
volume of DEAE-dextran was added (final concentration of 500 µM) and mixed, whereas (B)
was divided into as many 1.5 ml aliquots as transfections were planned. To each aliquot of
(B) 3 µg of cDNA was added, then 1.5 ml of (A) was added, the tubes were gently mixed by
tapping and put aside until the COS 7 cells were harvested (3.2.1.1.), resuspended in HBD
and counted (3.2.1.1.). 4 x 105 COS 7 cells, resuspended in  HBD (not more than 200 µl)
were added to the DNA / DEAE-dextran mixes, then the tubes were vortexed and put into a
37°C water bath for exactly 2 hours. This incubation time is very critical: a shorter incubation
would decrease the transfection-rate, but a longer incubation would damage or kill the
majority of the COS 7 cells.
Seeding the cells
After 2 hours, the COS 7 cells of each transfection mix were pelleted at 300 g for 5
minutes, the supernatant was carefully aspirated off to 1 ml, the pellet was again resuspended
in 10 ml of HBD and the centrifugation step was repeated. Each pellet was finally
resuspended in 12 ml DMEM / 10% FCS and seeded in tissue culture-treated Petri dishes
(Æ 150 mm). These dishes were placed on a steel plate (to guarantee homogeneous heat
conduction) in the incubator for 48-60 hours, with an exchange of medium after the first
night, before they were used for a cell-cell adherence assay.
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B) Transfections with transfection lipids
Comparative transfection of COS 7 cells with 6 different lipids
4 lipids (Lipofectin, LipofectAmine, Cellfectin and DMRIE-5) were supplied in a
transfection reagent sample pack by Gibco BRL, SuperFect by Qiagen and LipoTaxi by
Stratagene.
In two 24 well tissue culture plates COS 7 cells were seeded at a density of 3 x 104 cells /
well in 1 ml of DMEM / 10% FCS one day prior to the transfection. Cells should be 60-80%
confluent at the time of transfection. The day of transfection, two fresh 24 well tissue culture
plates were taken, 6 rows were labelled from A-F and each column from 1-6. The plates
containing the cells were labelled identically. The labelled 36 wells were filled with 300 µl
DMEM without serum and 20 µl Lipofectin were added to well A1 as well as 10 µl
LipofectAmine (B1), 15 µl Cellfectin (C1), 10 µl DMRIE-5 (D1), 10 µl SuperFect (E1) and
10 µl LipoTaxi to well F1. The plates with the lipids were incubated for 30 minutes at room
temperature before 3.2 µg DNA / 300 µl DMEM were added to the wells of column 1 and the
plates were incubated again for 15 minutes at room temperature. Then, the lipid-DNA
complex was serially diluted by transferring 300 µl from column 1 to 2, mixing, transferring
300 µl from column 2 to 3 and so on, until the final 300 µl removed from well A6 were
discarded.
The COS 7 cells were washed once with 1 ml of PBS and the 300 µl lipid-DNA dilutions
were transferred from the wells without cells to the corresponding wells with cells. The cells
were incubated for 5 hours at 37°C / 5% CO2, then the lipid-DNA dilutions in each well were
replaced with 1 ml of DMEM / 10% FCS and the plates were incubated overnight at 37°C /
5% CO2. In parallel, a transfection with chloroquine / DEAE-dextran was carried out as
described above. These transfected COS 7 cells were seeded in a tissue culture treated Petri
dish (Æ 100 mm).
The DNA used in this comparative analysis was the vector pcDNA3.1-EGFP, which, upon
expression of GFP, can be easily used as a reporter system: cells expressing GFP will emit
bright green light (500 nm) when exposed to UV. Since LipoTaxi yielded the highest
transfection-rate (see results), it was further used for the transfection of mammalian cells.
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Transfection of COS 7 cells with LipoTaxi for cell-cell adherence assays
The cells were splitted 24 h prior transfection and seeded into tissue culture treated
Petri dishes (Æ 100 mm). They had to be 60-80% confluent at the time of transfection. For
each transfection 2.7 ml serum-free DMEM was transferred to a Falcon 2052 tube (PS) since
PS-tubes yield superior results to PE- or PP-tubes according to the supplier's information.
100 µl of LipoTaxi transfection reagent was added to a tube, the tube was tapped to mix and
5-10 µg of cDNA was added. After incubation for 20 minutes at room temperature, the
cultivation medium was removed from the cell culture dishes by aspiration, 5 ml of serum-
free DMEM was added to the transfection mix and, with a pipette, the entire mix (7.8 ml)
was transferred dropwise to the dish, while swirling the dish. The dish was then incubated for
5 hours at 37°C / 5% CO2 before adding 8 ml DMEM / 10% FCS, and was further incubated
overnight. The next morning, the medium was replaced with 15 ml of fresh, prewarmed
DMEM / 10% FCS. The cells were incubated for another 24-72 hours, before they were used
for a cell-cell adherence assay.
3.2.2.6. The cell-cell adherence assay
In a preliminary assay, L-huICAM-1 cells were seeded and allowed to grow to an
almost confluent cell-layer, before untransfected COS 7 cells were used as screening cells,
analogous to the iRBC adhesion assay (3.2.2.2.). Since the COS 7 cells did attach to the dish
during the incubation step, the background of screening cells was quite high. Therefore the
cell-cell adherence assay was altered as follows: chloroquine / DEAE-dextran transfected
COS 7 cells were seeded at a low density (4 x 105 COS 7 cells per tissue treated Petri dish,
(Æ 150 mm). During the incubation of 24-72 hours after transfection, these mostly singular
cells remained so or formed small patches of 4 to 8 cells, which simplified the screening
under the microscope.
The cell-cell adherence assay protocol
Prior to the assay, L-huICAM-1 cells were harvested, pelleted and resuspended in
binding medium (3.2.1.1.), then, the dishes with the adherent, cDNA-transfected COS 7 cells
were taken from the incubator and washed smoothly with 12 ml of binding medium. The
screening cells were applied in a 10-fold excess to each dish (4 x 106 L-huICAM-  cells /
dish) in 12 ml binding medium. The dishes were then placed on a gently agitated rocker or
shaker for 1 hour with a quarter-turn of the dishes by hand every 15 minutes. With a rocker,
the screening cells were dispersed more homogeneously than with an orbital shaker, where
areas with a high background resulted at the margin of the dishes. After 1 hour, the dishes
were washed 4 x with 12 ml of binding medium (applying gently, swirling the dish,
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aspirating off) and the cells were overlaid with 10 ml of screening / storing solution (10 mM
EDTA pH 8.0 in water). Like that, the assay was ready to be screened under the microscope,
but the assay could also be fixed and stored to be screened up to 3 days later.
Fixing and storing the cell-cell adherence assay
The fixing protocol was improved with ongoing numbers of assays. The fixation
method used for each specific assay is noted in the corresponding results section.
1st fixation method: after the 4th wash was aspirated off, the dish was washed once with 1 x
PBS, then 12 ml of 1% glutaraldehyde / 2% formaldehyde in PBS were applied. The dishes
were incubated for 1 hour at 37°C, washed twice with PBS and overlaid with 12 ml of 10
mM EDTA pH 8.0 in water. In that solution, the dishes could be stored at 4°C for up to 3
days or screened directly under the microscope.
The 2nd method was the same as above, but the incubation step was carried out for 1 hour at
4°C.
The best results were obtained using the following fixation method: The cells were fixed for
1 hour at 4°C with 1% glutaraldehyde / 2% formaldehyde in PBS, then the fixation solution
was aspirated off, followed by a second fixation step with 50% MeOH / 50% acetone for 15
minutes on ice. The second fixation solution had to be thoroughly mixed before applying it to
the dish, since the acetone attacks the plastic. With the 1st fixation step, the cell-cell
interaction was fixed, whereas the 2nd fixation step fixed the cells onto the dish. After these
two fixation steps, the dishes were treated as above.
Screening the cell-cell adherence assay
The dishes were screened under phase contrast with a microscope using a
magnification of 4 to 20-fold. A COS 7 cell was considered positive and marked, if at least 3
independent screening cells (L-huICAM-1 cells) were attached to the surface or at the margin
of a single COS 7 cell and only if the background around a positive cell was low, the cell was
selected to be picked.
From the second assay on, the screening method was simplified by staining the screening
cells with ethidium bromide (EB) prior to the adhesion assay, before the screening cells were
harvested. 1/200 volume of 1% EB stock solution was added to the screening cells and
incubated for 1 hour at 37°C. The dishes were then screened under dark field by a fluorescent
microscope with an UV-filter. If patches of screening cells were found, the light source was
switched to normal light, to examine possible adherence of the screening cells to a COS 7
cell.
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3.2.2.7. Picking positive COS 7 cells
Positive cells were picked either wit  a pipette or with a scalpel. A Drummond Pipette
with long, reusable, cut off Drummond gel loading tips was used or an Eppendorf Crystal
Pipette (1-10 µl), equipped with Milian multiplex gel loading tips: To pick, the screening /
storing solution was aspirated off from the cells and the dish was washed once with water, to
prevent crystallisation of remaining traces of PBS, and was allowed to dry. 2 µl of water was
applied on the area of the cell to be picked, and the cell was observed under the microscope.
As soon as the area started to dry out again, the cell could be scrapped of with the tip of the
pipette and was sucked in, often together with some neighbouring COS 7 and L-huICAM-1
cells. This small aliquot was immediately transferred into 200 µl of freshly prepared Hirt
extract solution containing proteinase K. This pick was either processed further as a "single
pick", or additionally picked cells were pooled together in one aliquot of Hirt extract solution
and were further processed as a "pooled pick".
In later experiments, positive cells were picked with a needle-scalpel: The dish was also
allowed to dry, and before it was completely dry, the cell was scraped off with the scalpel,
where the positive cell could actually be seen on the blade of the scalpel.
3.2.2.8. Isolation of cDNA clones using the Hirt extraction method
Immediately after the positive cell(s) were transferred into 200 µl of Hirt extraction
solution, the tube was incubated for 30 minutes in a 37°C water bath before adding 50 µl of 5
M NaCl and, after mixing, was stored 4°C overnight. The next day, the SDS / protein-
precipitate was spun at 14'000 g for 10 minutes at 4°C. The supernatant was transferred to a
fresh Eppendorf tube, 20 µg of glycogen was added as a carrier and 2.5 volumes of absolute
EtOH were added to precipitate the DNA; the tube was thoroughly mixed and stored at -20°C
for at least two hours. After centrifugation for 30 minutes at 14'000 g, the glycogen-DNA
pellet was washed once with 70% EtOH, centrifuged again for 10 minutes, air dried for ten
minutes, and redissolved in 2 to 5 µl of dH2O. The plasmids, isolated in such a manner form
a single- or pooled pick were then ready to use for the transformation of E. coli cells.
3.2.2.9. Transformation of E. coli cells by electroporation
Preparation of electrocompetent cells
Commercially available electrocompetent Top10F' cells were purchased from
Invitrogen (Table 3-III). With an aliquot of these cells, further electro-competent cells were
prepared: a 10 ml overnight culture of Top10F' electrocompetent cells was diluted with 990
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ml LB and was incubated in a shaker at 37°C until an OD 600 of 0.5 was reached. The
culture was chilled on ice for 30 minutes and centrifuged at 4000 g, 4°C for 15 minutes. The
supernatant was discarded, the pellet resuspended in 1 litre of ice-cold Millipore water and
centrifuged again. The resulting pellet was resuspended in 0.5 litre of ice-cold water and
incubated 30 minutes on ice, spun and the pellet was resuspended in 20 ml ice-cold water
containing 10% glycerol. This suspension was centrifuged again and resuspended in 2 ml of
water / 10% glycerol. This suspension was aliquoted (40 µl or 80 µl) in prechilled Eppendorf
tubes on dry ice and stored at -70°C.
The electroporation protocol
The E. coli cells were transformed with an Equibio electroporator according to the
following protocol: electrocompetent cells were thawed on ice, 40 µl transferred to a
precooled 2 mm electroporation cuvette and mixed with 2 µl DNA (3.2.2.8.) and incubated
for 1 minute on ice. The cuvette was then wiped dry with a Kleenex tissue, tapped to remove
air bubbles from the 2 mm gap, and placed into the EasyjecT electroporator to perform a
pulse with the following specifications:
voltage: 2.5 kV, capacity: 25 µF, shunt: 201 ½ and pulse time 5 msec.
Further treatment of transformed cells
After the pulse, 800 µl SOC medium without antibiotics were added as fast as
possible to the cuvette, mixed and transferred to a cultivation tube. The tube was incubated in
a shaker for 1 hour at 37°C. This culture was plated out in 180 µl aliquots on 5 ampicillin
plates. The glass spatula was not sterilized between each step, in order to prevent loss of
clones. The plates were then incubated upside down over night at 37°C.
3.2.2.10. Analysis of cDNA clones and second screens
Picking of cDNA clones
The colonies were counted and picked with an autoclaved tooth pick. The tooth pick
was then used to scratch a corresponding numbered field on an ampicillin plate, equipped
with a drawn grid on the back side of the dish. After that, the too  pick was placed in the
corresponding numbered culture tube containing 5 ml LB / ampicillin and was incubated for
8 hours in a shaker at 37°C.
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If a pick, from a single cell or from pooled cells, yielded more than 200 colonies, the cultures
were pooled after 8 hours in batches of 5-10 prior to the isolation of cDNA clones. Less than
200 colonies per pick were processed individually. The master plate, containing the clones
arranged in the grid, was stored at 4°C for up to 1 month and was used as a security back-up
for the clones of each pick.
Isolation of cDNA clones from E. coli cultures
This was done as described in 3.2.1.4: Isolation of plasmids from E. coli cultures and
in 3.2.1.5: Precipitation of DNA.
Analysis of the cDNA clones
First, the clones were analyzed for inserts (if any). Each cDNA clone was digested
with the restriction enzymes ApaI (Promega) and BamHI (Gibco) in reaction buffer A
(Promega) for 1 hour at 30°C and then loaded on a 0.8% agarose gel.
Second screens
Every cDNA clone with an insert was used for a second transfection of COS 7 cells.
Therefore, the clones of a single pick, that contained an insert, were pooled in equally
amounts. Sometimes, a pool of the clones bearing the biggest inserts, wa  additionally made.
Details are given in the results section. COS 7 cells were transfected with these pools and a
cell-cell adherence assay was performed as in the first screen, with one dish per cDNA-pool.
The dish was evaluated as the first screen, but with the expectation to see a 10-100 fold
increase of positive COS 7 cells.
3.2.2.11. Positive controls of the shotgun approach (1)
A positive control for transfection
The EGFP gene from a commercially available vector (pEGFP-1, Clonetech,
Heidelberg, D) was ligated into the pcDNA3.1 vector at the HindIII / NotI sites of the
polylinker (see: 3.2.1.9.). This control was used for every further transfection, in order to
estimate the transfection-rate in each experiment.
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A positive control for picking and Hirt extraction
COS 7 cells were transfected with a cDNA clone containing a DBL1 domain. Four
individual cells were picked and the cDNA clone was isolated as described (3.2.2.8.), but
instead of a transformation of E. c li cells by electroporation (3.2.2.9.), a PCR was performed
with the precipitated DNA in order to amplify the DBL1 domain.
Positive controls for expression in COS 7 cells (1)
The construct used to estimate the transfection-rate in each experiment (pcDNA3.1-
EGFP) was also an expression control. But EGFP was already optimized for mammalian
expression by adjusting the codon usage to a mammalian expression system. For a second
construct, the complete gene of huICAM-1 was amplified by PCR from the genomic DNA of
L-huICAM-1 cells and cloned in frame into the pcDNA3.1-EGFP vector at the HindIII /
BamHI sites of the polylinker. This construct was used as an expression control and as a
control for the recognition of leader sequences and the transport of proteins to the surface by
COS 7 cells.
Four further constructs, carrying plasmodial genes, will be dealt with in the shotgun approach
(2), section (3.2.3.5.).
3.2.3. Shotgun approach (2)
3.2.3.1. Overview
The aim of this approach was to identify P. falciparum-derived antigens, expressed
intra- or on the surface of COS 7 cells, by the use of mAbs, produced during the PhD-thesis
of K. Willimann (Willimann, 1996), which recognized iRBCs and intraerythrocytic
P. falciparum stage proteins.
3.2.3.2. Transfection of COS 7 cells in 6 well plates
COS 7 cells were seeded in 12 well plates (9x104 cells / well), allowed to settle down
and, after 2 hours, were transfected with the LipoTaxi transfection reagent. The transfection
protocol (3.2.2.5b.) was adapted to the size of the wells: for each transfection, 88 µl serum-
free DMEM were transferred to a Falcon 2052 tube (PS), then 8 µl of LipoTaxi transfection
reagent was added to each tube, the tubes were tapped to mix, and 3-4 µg of cDNA was
added to each tube. After 20 minutes, 200 µl of DMEM / 5% FCS was added. All further
steps followed the protocol given above. Medium was exchanged after 12 hours, and the
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plates were incubated for another 24-48 hours, before they were used for an IFA test. On
every plate, one well was transfected with the pcDNA3.1-huICAM-1-EGFP-construct to
estimate the transfection- and expression-rate of the transfected cells after 24 or 48 hours and
to control the assay conditions by detection of huICAM-1 with an appropriate mAb (see
Table 3-V).
3.2.3.3. The indirect immunofluorescence assay (IFA) on adherent cells
Performing the IFA
First, the transfection-rate of the transfected COS 7 cells was checked under the
fluorescence microscope, by determining the percentage of green fluorescent cells in the
positive control. If the percentage exceeded 50%, the IFA was performed. The cells were
washed once with PBS and then either fixed with a freshly prepared and thoroughly mixed
1:1-mixture of Methanol / Acetone for 15 minutes on ice (good mixing is very important
since pure acetone attacks the plastic), or not fixed at all, to detect antigens on the surface of
the cells only. If the cells were fixed, the fixative was aspirated off, the cells were washed
twice with PBS, and then incubated with 200 µl PBS / 5% FCS for 30 minutes at 37°C to
saturate and block unspecific binding. After removing the blocking buffer, 150 µl of PBS /
0.5% FCS, containing the first antibody in an appropriate concentration, was applied:
aICAM-1 (MEM112) was diluted 1:1000, whilst the supernatants of K. Willimann (Table 3-
V) were applied undiluted or diluted 1:20. The plates were wrapped with Saran wrap to
prevent evaporation of the antibody-containing solution, and were put on a rocker for 1 hour
at room temperature. After this incubation step, the first antibodies were aspirated off, the
cells were washed three times with PBS / 0.05% Tween 20, before the second antibody,
diluted 1:400 in PBS / 0.5% FCS, was applied. The second antibody was either HRP-labelled
rabbit / amouse total Ig or FITC-labelled goat / amouse IgG F(ab')2. The incubation step and
the further washing steps were the same as with the first antibody. Now the IFA could be
screened directly under the fluorescence microscope (FITC) or was ready for the staining
procedure (HRP).
The staining procedure for HRP-labelled antibodies
500 µl AEC / DMF stock was mixed in 10 ml of 0.1 M sodium acetate, pH 4.8 (Table
3-XII) and 1.5 µl of 30% H2O2 was added. 300 µl of this staining solution was applied to
each well, the plate was wrapped in aluminium foil (light sensitive reaction), and put on a
rocker for 20 to 40 minutes with a short check of the positive control every ten minutes.
When the well with the positive control appeared reddish by eye, the IFA was ready to be
screened by light microscopy.
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3.2.3.4. Further Steps in the shotgun approach (2)
Transfected COS 7 cells, which reacted with the mAbs of the supernatants, became
red (HRP) or were green fluorescent (FITC). These cells were picked as described in 3.2.2.7;
if more than one cell reacted per well, these cells were pooled, the cDNA-clones were
extracted according to the Hirt extraction protocol (3.2.2.8.), and the DNA was further
processed, as described in the shotgun approach (1), and was finally used to perform a second
screen. For a second screen, all isolated plasmids, derived from a first screen, were pooled,
and this pool was used to transfect COS 7 cells as in the first screen. The second screen was
evaluated like the first screen, with the expectation to see a 10- to 100-fold increase of
positive cells.
3.2.3.5. Positive controls of the shotgun approach (2)
Positive controls for expression in COS 7 cells (2)
The methods, described in the shotgun approach (2), were also used to establish
additional positive controls for the expression of plasmodial proteins in COS 7 cells (see
3.2.2.11.). The MSP2-gene was isolated from cDNA of strain ItG2.F6, using a pair of
primers, bearing a HindIII-site in the forward primer and a BamHI-site in the reverse primer
(Table 3-XV) and was cloned into the pcDNA3.1- and the pcDNA3.1-EGFP-vector
according to the sticky end ligation protocol (3.2.1.9.). A 1050 bp long N-terminal fragment
of the MSP1 gene from the strain Ro71, cloned into the pGEM-T vector, was amplified by
PCR with a pair of primers, bearing an EcoRI-site in the forward primer and a BamHI-site in
the reverse primer to clone it in the pcDNA3.1-vector. Another pair of primers, bearing a
KpnI-site in the forward primer and an ApaI-site in the reverse primer was used to clone it
into the pRE4 vector for expression of a chimeric protein with the HSVgD flanking regions.
The pRE4 vector has no KpnI site in the polylinker. Therefore the amplified MSP1 fragment
was only digested with ApaI, whereas the pRE4 vector was digested with ApaI (sticky end)
and PvuII (blunt end) and the insert was then ligated into the sticky/blunt digested vector
according to the sticky end protocol, with the only exception of using Pfu polymerase for the
PCR amplification to ensure a blunt end at the insert. The KpnI-site was introduced to be able
to digest the insert from the vector, since the PvuII-site was lost by ligation.
The 83.1 epitope of MSP1 that was used in the synthetic peptide malaria vaccine SPf66 was
present in the MSP1 fragment of strain Ro71 and can be detected with mAb 9.22 (Helg,
1997). The mAb 9.22 was used to detect expression of MSP1, whereas a serum pool of
malaria exposed adults from PNG was used to detect expression of MSP2
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3.2.4. Direct approach (1) (mammalian expression system)
3.2.4.1. Overview
The aim of this approach was to extract cDNA clones, containing full-length- or parts
of var genes, from the cDNA library and to use these clones to transfect COS 7 cells to
perform cell-cell adherence assays as described in the shotgun approach (1). Two methods
were used to identify var gene-clones: PCR with appropriate primers and the colony lift
protocol with DBL1- or ATS domains as a hybridisation probe.
3.2.4.2. PCR amplification of DBL1- and ATS domains
In a first step, DBL1- and ATS domains were amplified from genomic DNA of the
strain K1, in a second step, DBL1 domains were also amplified from the cDNA library. The
PCR reaction was performed with Taq polymerase as described in 3.2.1.8., either with
degenerated primers, or with a pool of defined primers (Table 3-XV). The reaction conditions
of the PCR were gradually optimized by increasing the temperature of the annealing step to
diminish the amount of unspecific PCR products. The optimal conditions are given below:
PCR amplification of the DBL1 domains
The primer pair used in this PCR consisted of the two degenerated primers
VARDBL5 (forward primer) and VARDBL3 (reverse primer). The conditions were as
follows:
  5:00 minutes denaturing at 95°C
  1:00 minute
  2:00 minutes
denaturing at 95°C
primer annealing and
extension at 72°C
(2-step PCR)  for 30 cycles
10:00 minutes 72°C
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PCR amplification of the ATS domains
The primers used in this PCR consisted of the degenerated primer ATS5 (forward
primer) and a 1:1 pool of ATS3.1 and ATS3.2 (reverse primers). The conditions were as
follows:
  5:00 minutes denaturing at 95°C
  1:00 minute
  0:45 seconds
  2:00 minutes
denaturing at 95°C
annealing at 62°C
extension at 72°C
 for 30 cycles
10:00 minutes 72°C
Cloning of DBL1- and ATS domains
The resulting PCR products (DBL1 domains of K1 and cDNA, ATS domains of K1)
were purified by gel extraction (3.2.1.7.) and ligated by the T/A cloning method into
pMOSblue T-vector (3.2.1.9.). The DNA was isolated from positive clones and the remainder
of the E. coli culture was used to prepare glycerol stocks (3.2.1.3.) Clones were digested with
EcoRI and HindIII to analyze the length of the insert. The DBL 1 domains were sequenced in
a later step, using the T7 promoter primer and the U19mer primer (3.1.9.2.)
3.2.4.3. Colony lift and southern blot hybridisation (non radioactive)
BioPrime-labelling of the hybridisation probes
All cloned DBL1 domains were amplified by a normal PCR with Taq polymerase as
above, but using the 10 x dNTP mixture of the BioPrime DNA labelling Kit. In this mixture,
for each dNTP, the concentration is 2 mM, but for dCTP and biotin-14-dCTP, for which the
concentration is 1 mM each. In this PCR reaction the annealing temperature was lowered to
65°C (instead of 72°C), since unspecific products were no longer a problem with the cloned
templates. The resulting PCR products were purified by gel extraction, eluted in TE and
stored at -20°C for further use.
To optimize the following colony lift / southern blot protocol, genomic DNA of strain K1
was used as a template to get random primed, biotinilated hybridisation probes. With these
probes, different membranes, buffers and incubation times were tested. The best protocol was
then used with the labelled DBL1 domains. The random primed probes were generated with
the BioPrime DNA labelling Kit according to the supplier's protocol.
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The colony lift protocol
5 agar plates containing ampicillin were used for each colony lift. 100 µl of 1:40'000
diluted 1x amplified cDNA (3.2.2.4.) was plated on each plate, yielding approximately 5000
colonies per plate after overnight incubation. The next day, a positively charged nylon
membrane (HyBond-N+) was laid on the colonies of a plate, asymmetrically stabbed 4 times
with a needle, carefully lifted from the plate, and placed, with the colonies on the upper side,
onto a fresh agar plate. This procedure was repeated with all plates, then all 10 agar plates,
the five bearing the nylon membranes and the five with the remainder of the lifted colonies,
were incubated upside down at 37°C for 4 to 5 hours. The plates with the regrown colonies
were wrapped with parafilm and were stored at 4°C up to 2 weeks. From the other plates the
membranes were carefully removed and s t, colonies on the upper side, onto Whatman 3MM
filter paper; the plates were discarded. Three sets of filter paper were prepared. The first filter
(now with the membranes on it) was soaked in 0.5 M NaOH and the membranes were
incubated for 5 minutes on it before being transferred by a forceps to the second filter, soaked
with 1 M Tris-HCl, pH 7.5. After 5 minutes, the membranes were transferred to the third
filter, soaked with 0.5 M Tris-HCl, pH 7.5 / 1.25 M NaCl and were incubated for 5 minutes,
before finally being transferred into a dish with 2 x SSC to be washed for 5 minutes. The
washed membranes were dried between filters for 2 hours. The DNA on the membranes was
then cross linked to the nylon in a UV Strata Linker 1800 (Stratagene) with 'auto link' setting.
The nylon membranes could now be stored for up to 3 days between filter papers or were
directly processed in a southern blot.
The southern blot protocol for colony lifts
The membranes were applied to glass tubes (Techne), put in a Hybridizer HB-2D
(Techne, Cambridge, UK), and were washed for 6 hours at room temperature in 20 ml
Prehybridisation buffer, with buffer exchange every 1 hour, and then prehybridized for 2
hours in 20 ml Prehybridisation buffer at 59°C. Hybridisation solution consisted of 20 ml
Prehybridisation buffer with 250 µl of the denaturated (10 minutes at 100°C and then snap
cooled) BioPrime-labelled pool of DBL1 domains. After 2 hours, the Prehybridisation buffer
was replaced by the prewarmed hybridisation solution and the membranes were incubated
overnight at 57°C. The next day, the membranes were washed with increasing stringency:
4 washes at 57°C with 50 ml 2 x SSC, 0.1% SDS for 10-15 minutes, followed by 1 wash at
57°C with 50 ml 0.2 x SSC, 0.1% SDS for 10 minutes sharp. Then the membranes were
rinsed with 2 x SSC at room temperature and washed once with Southern buffer at room
temperature. The membranes were then blocked for 1 hour at 57°C in Southern buffer with
3% BSA to reduce unspecific binding.
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Visualisation
Visualisation was done according to the BLUEGENE Non-radioactive Nucleic Acid
Detection System: after the membranes were blocked, streptavidine, conjugated to alkaline
phosphatase (SA-AP), was applied to the membranes, 1:1000 diluted in Southern buffer for
10 minutes at room temperature. The membranes were then washed 3 x with 100 ml Southern
buffer for 10 minutes and 2 x with Buffer 3 for 5 minutes at room temperature. After adding
the substrate for the alkaline phosphatase, the reaction was left in the dark to proceed until the
colour developed (10-20 minutes). The membranes were then demineralized with Millipore
water and were stored between filter papers. A dot blot with decreasing concentration of
cloned DBL1 domains in pMOSblue T-vector was used as a sensitivity control for the
visualisation step.
3.2.4.4. Colony lift and southern blot hybridisation (radioactive)
Radioactive labelling of the hybridisation probes
Two pools, containing either all cloned DBL1- or all ATS domains respect vely, were
prepared. Both pools were used as a template to get a-32P labelled hybridisation probes: 25
ng of DNA pool, diluted in 4.2 µl dH2O was denaturated for 10 minutes at 95°C and nap
cooled on ice. The following mix was added and incubated at 37°C for 30 minutes:
4.2 µl dH2O containing 25 ng of the denaturated DNA pool (DBL1 or ATS)
2.0 µl 10 x restriction digest buffer React 2 (Gibco BRL)
2.0 µl Fw Primer (200 ng)(VARDBL5 or ATS5)
2.0 µl Rev Primer (200 ng)(VARDBL3 or ATS3.1 + ATS3.2)
3.0 µl dNTPs without dCTP (25 µM each)
0.8 µl nuclease free BSA (10 mg/ml)
5.0 µl a-32P dCTP (10 µCi/µl)
1.0 µl Klenow polymerase fragment (2u/µl)
Radioactive hybridisation and visualisation
The colony lift protocol was exactly the same for radioactive and non-radioactive
hybridisation. The southern blot protocol follows the one given above with the following
alterations:
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  - radioactive hybridisation took place in a Bachofer 400HY Hybridizer (Reutlingen, D).
  - hybridisation was carried out overnight at 58°C.
  - hybridisation solution consisted of 10 ml Prehybridisation buffer mixed with 10 µl of
the denaturated (10 minutes at 100°C, snap cooled) a-32P-labelled pool of DBL1- or
ATS domains.
Visualisation was performed autoradiographically using x-ray films (Kodak X-Omat AR
Scientific Lightening Film) in a Quanta III cassette (Du Pont) containing a Cronex
intensifying screen at -70°C for 6 to 96 hours, depending on signal strength. Kodak GB-X
Developer and GB-X Fix were used to develop the x-ray films.
3.2.4.5. Isolation of var gene clones from the cDNA library
Identification and picking of positive clones
First, every membrane was matched to its plate by the aid of the 4 asymmetrically
pinned holes (mirror-oriented). Like that, the colonies, which were stained on the membrane
(non radioactive) or were visible on the x-ray films (radioactive), were identified on the plate
and a small region, containing the suspected colony, was picked with a pipette tip and applied
to 1 ml LB, stirred, and 50 µl of that suspension was taken and diluted 1: 40. 100 µl were
plated out on a new plate: such a plate was used for a second screen to verify the first screen.
Furthermore, a second screen made it possible to accurately pick a single colony, since the
colonies were much less dense than in the first screen.
The second screen was performed exactly as the first one. The remainder of the 1:40 diluted
suspension was grown overnight, the DNA was isolated and used as a template in a test PCR
with the DBL1 (ATS) primer pair. Single colonies, picked from a second screen, were
cultivated overnight, DNA was isolated, the size of the insert was determined by restriction
analysis and the insert was tested for a complete DBL1- (ATS) domain by PCR. Some
promising inserts were sequenced and used for transfection into COS 7 cells to perform a
cell-cell adherence assay, as described in the shotgun approach (1).
After a-32P-labelled clones, carrying a DBL1 domain, were identified, the labelled probes
were stripped from the membranes, and the washed membranes were incubated with a-32P-
labelled ATS probes to identify possible clones containing both domains and therefore a full
length var gene.
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Stripping radioactive probes from a nylon membrane
250 ml water / 1% SDS were heated to boiling point, removed from the heat source
and the membranes were incubated in the hot water for 5 minutes. The procedure was
repeated one more time, then the membranes were dried between filter papers and reused.
3.2.5. Direct approach (2) (bacterial expression system)
3.2.5.1. Overview
The aim of this approach was to express parts of var genes, namely the CIDR- and the
DBL1 domains, as 6 x histidine-tagged (6xhis-tagged) proteins. The domains were amplified
from the cDNA (strain ItG2.F6) and from gDNA of the strain K1. The 6xhis-tag was
introduced at the N-terminus by cloning the domains into the pQE30 vector. Proteins were
expressed in E. coli strain M15 and purified using Ni-NTA agarose columns. All these
components were part of the QIAexpress Kit Type IV. The binding properties of these
domains were evaluated by IFAs and FACScan analysis.
3.2.5.2. Cloning of CIDR- and DBL1 domains into pQE30
In a first step, both domains had to be amplified by a PCR with primers containing
convenient internal restriction sites to be able to introduce the insert in-frame into the pQE30
vector. The templates w re either cDNA, gDNA or already cloned DBL1 fragments (see
3.2.4.2.). The primer pair used for the amplification of CIDR domains was CIDR Fw Bam
and CIDR Rev Kpn, the primer pair for the amplification of DBL1 domains was DBL1 Fw
Bam and DBL1 Rev Kpn (see Table 3-XV). PCR and sticky end ligation into pQE30 vector
were done as described above (3.2.1.8. and 3.2.1.9.).
All CIDR- and the new DBL1 domains were sequenced, usi g the QIAexpress sequencing
primers (3.1.9.2.).
3.2.5.3. Expression of histidine tagged proteins
Small scale expression
M15 cells, containing a pQE30 plasmid and the pREP4 repressor plasmid, were
grown in Super Broth medium supplemented with 100 µg / ml ampicillin and 25 µg / ml
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kanamycin. 10 ml LB cultures were grown overnight at 37°C in  shaker. 2.5 ml of this
culture was used to inoculate 50 ml of prewarmed Super Broth medium with antibiotics and
allowed to grow until an OD600 of 0.5 was reached. The culture was left at 37°C or
transferred to room temperature, expression was induced by adding IPTG to a final
concentration of 1 mM and finished after 2 to 5 hours by harvesting the cells as described
above (3.2.2.9.). In order to get a non-induced control, a 1 ml sample was taken immediately
prior induction.
Culture growth for preparative purification
The ideal conditions, evaluated by the small scale expression protocol, were the
following: 50 ml overnight culture were used to inoculate 1 litre of Super Broth medium, the
suspension was allowed to reach an OD600 of 0.5 at room temperature before being induced
with IPTG and proteins were then expressed for 4 hours at room temperature. Cells were
spun down and the pellet was stored at -20°C overnight.
3.2.5.4. Solubilizing of histidine tagged proteins
The protocol is given for preparation under native conditions, whereas alterations for
denaturing conditions are given in brackets. For both preparations, the cell pellet was thawed
on ice for 15 minutes and then resuspended in lysis buffer (buffer B, containing 8 M Urea) at
5 ml per gram wet weight. For a preparation under native conditions, 1 mg / ml lysozyme was
added to the suspension, followed by an incubation on ice for 30 minutes. The suspension
was then sonicated on ice with 8 x 20 seconds bursts at 200-300 watt, with a 20 seconds
cooling period between each burst. After that, the lysate was drawn 5 times through a narrow
gauge syringe needle and distributed among an appropriate number of micro centrifuge tubes.
(For a preparation under denaturing conditions, the suspension was distributed among an
appropriate number of micro centrifuge tubes and mixed for 1 hour at room temperature in an
Eppendorf Thermomixer 5436). In order to pellet the cellular debris, both lysates were
centrifuged for 30 minutes at 10'000 g. The pellets were discarded and the proteins were then
purified from the cleared lysates according to the protocols given below (3.2.5.5.).
3.2.5.5. Purification of histidine tagged proteins
Principle of the purification using a Ni-NTA resin
The principle of this purification is as follows: Ni-NTA is a tetra dentate chelating
adsorbent, which occupies 4 of the 6 ligand binding sites in the co-ordination sphere of the
nickel ion, leaving two sites free to interact with the imidazole ring of histidine residues.
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Non-specific binding is prevented by adding increasing amounts of imidazole to the washing
buffers. Elution of the bound 6xhis-tag protein was achieved by adding 250 mM imidazole to
the Ni-NTA agarose columns.
Purification under native conditions
All but two proteins could be isolated and purified under native conditions. An empty
5 ml polypropylene column (Qiagen) was loaded with 1 ml of 50% Ni-NTA slurry per 4 ml
of cleared lysate and was equilibrated with 2 x 5 ml lysis buffer. The cleared lysate was
applied and resuspended in the resin according the supplier's manual. The resin was then
washed as follows: 2 x with 4 ml of lysis buffer (no imidazole), 2 x with 4 ml of lysis buffer /
20 mM imidazole and 1 x with 4 ml of lysis buffer / 35 mM imidazole. After these five
washing steps, the protein was eluted in 8 fractions with a total amount of 6.1 ml lysis buffer
/ 250 mM imidazole, with a first fraction of 500 µl and further fractions of 800 µl.
An aliquot of all eluted fractions, all washes, the flow-through, the cleared lysate, and of the
induced and non-induced cell pellets were analyzed by SDS-Page gel electrophoresis.
Purification under denaturing conditions
The two proteins, which could not be isolated and purified under native co itions
were purified as above, but instead of using lysis buffer with different concentrations of
imidazole, buffer B with decreasing pH was used. The column was washed 4 x with 4 ml of
buffer B, pH 6.3 and protein was eluted with 4 x 0.5 ml buffer B, pH 5.9 and later on with 4 x
0.5 ml buffer B, pH 4.5. As above, protein concentration was estimated by SDS-Page gel
electro-phoresis.
Dialysis of proteins
The eluted fractions with the highest concentration of purified CIDR- or DBL1
domains were pooled, diluted 1:1 in PBS to prevent precipitation, and then filled into dialysis
tubing (cut off 10 kDa, Chemie Brunschwig, CH), that had been boiled in sterile water for 5
minutes and then rinsed with sterile PBS. Dialysis was done overnight against 2 litres of PBS
at 4°C. The concentration of protein was determined photometrically. The protein solutions
were sterilized by filtration and aliquots were stored at -20°C.
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3.2.5.6. Binding assays with histidine tagged proteins on cells expressing
known ligands
Two different methods were tested: IFAs on adherent cells similar to the IFAs
described above (3.2.3.3.) and FACScan analysis with the cells in suspension.
Cell-protein IFAs on adherent cells
Cells expressing huICAM-1 (L-huICAM-1 cells) and cells expressing CD36 and CSA
(C32 cells), as well as cells, expressing no ligand involved in cytoadherence (L-cells), were
used to perform these assays. Cells were seeded and grown in tissue culture treated multi well
plates (12, 24 or 48 well plates). Cells were either fixed on ice with ice-cold Methanol for 1
minute prior to the application of proteins or thereafter, before the first antibody was applied.
The medium was removed from the wells, the cells were washed with PBS and, if desired,
fixed with MeOH and air dried (2-5 minutes). The cells were incubated for 1 hour in PBS /
5% FCS, pH 6.8 or in binding medium, pH 7.0 to saturate unspecific binding sites. Proteins
were applied in an appropriate dilution in binding medium for 1 hour at room temperature,
then the wells were washed 2 x with binding medium and the first antibody (ahis) was
applied 1:1000 in PBS / 0.5% FCS. After a 1 hour incubation step at room temperature, the
wells were washed twice with PBS / 0.05% Tween 20 and the second antibody (amouse) was
applied 1:1000 in PBS / 0.5% FCS for 1 hour at room temperature. After two washes as
above, the cells were ready to be screened (FITC-conjugated second antibody) or were
stained according the procedure given in 3.2.3.3. (HRP-conjugated second antibody).
Negative (no proteins or PBS instead of the first mAb) and positive controls (mAbs against
CD36 and huICAM-1) were always carried out in parallel.
Flow cytometric analysis
Cells were detached by trypsination or with PBS / 0.5 mM EDTA, counted, and a
defined number of cells (105-106) were applied to a Facs tube and incubated in 250 µl PBS /
5% Drymilk for 1 hour on ice, to saturate unspecific binding of the proteins. After 1 hour, the
cells were resuspended in 2 ml PBS / 1% BSA, pH defined (6.3 to 7.3, depending on the
proteins) and spun again with 300 g (1200 RPM in a cooled Beckman TJ6 centrifuge) for 3
minutes. The supernatant was discarded, the cells were resuspended in the remaining liquid
and 100 µl protein diluted in PBS / 1% BSA was added (1-2 µg / tube) and incubated on ice
for 1 hour. Cells were washed twice in PBS / 1% BSA as above, but after discarding the
supernatant, the tubes were inverted on a Kleenex tissue to drain remaining liquid. First
antibody was applied in 50 µl, diluted 1:100 (ahis) up to 1:1000 (ahu-ICAM-1 or aCD36) in
PBS / 1% BSA and incubated on ice for 1 hour. Washing steps were repeated, the second
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antibody was applied (50 µl amouse, FITC-conjugated, diluted 1:1000) and incubated as
above for 1 hour on ice. After two last washing steps, the cells were resuspended in PBS only
and were now ready for FACScan analysis. Negative (no proteins or PBS instead of the first
mAb) and positive controls (mAbs against CD36 and huICAM-1) were always carried out in
parallel.
FACScan analysis was also used to confirm expression of cell ligands like huICAM-1 or
CD36 on mammalian cells. This was done as described here for the protein binding assays,
but without proteins and the saturation step.
3.2.5.7. CSase treatment of CHO cells
CHO cells express the polysaccharide CSA on their surface. CSA could be digested
with chondroitinase ABC (CSase ABC). Cells, grown as mono-layers in tissue culture flasks,
were washed with PBS and incubated with 1 unit CSase ABC per 2 ml PBS for 1 hour at
37°C in the incubator. After this treatment, the cells were of round shape, but not completely
detached. PBS / CSase was aspirated off and the cells were detached using either PBS /
Trypsin or PBS / EDTA (see 3.2.1.1.).
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4. Results
4.1. Results of the shotgun approach (1)
The P. falciparum strain ItG2.F6 was tested for cytoadherence on L-ICAM-1- and
C32 cells, mRNA was isolated, a cDNA library was constructed by Invitrogen and the library
was used to transfect COS 7 cells in order to perform cell-cell adherence assays, as described
in 3.2.2.
4.1.1. Analysis of adhesion of iRBCs on L-ICAM-1- and C32
cells
The analysis of adhesion of strain ItG2.F6 was performed twice, as described in
3.2.2.2. The second assay was performed immediately prior to the saponin lysis, the first step
of the mRNA-isolation.
In the first assay, cultures of the strains ItG2.F6 and K1 (parasitaemia of 8% and 6%
respectively) were used to analyze binding properties on both fresh and fixed C32- and on
fixed L cells. A culture of uninfected red blood cells was used as control. In the second assay,
binding of strain ItG2.F6 (parasitaemia of 7%) was analyzed on fresh L-, L-ICAM-1- and
C32 cells. In the first assay, ItG2.F6 bound to both types of C32 cells, compared to L-cells,
strain K1 and uninfected RBCs (Table 4-I). In the second assay binding to C32 cells was
confirmed and binding to ICAM-1 was shown, compared to untransfected L-cells (Table 4-
II). This assured that the mRNA was isolated from a strain, which bound to huICAM-1 and
on C32 cells.
Table 4-I         Adherence of iRBCs to C32 cells compared to L cells
Strain Type of cells iRBCs / area (3 fields) uninfected RBCs / area
ItG2.F6 C32 cells fixed
C32 cells fresh
L-cells fixed
17, 10, 15
09, 11, 08
00, 01, 00
00, 01, 00
01, 01, 00
00, 00, 01
K1 C32 cells fixed
C32 cells fresh
L-cells fixed
00, 00, 00
00, 00, 00
00, 00, 00
00, 01, 01
00, 01, 01
00, 00, 00
none
culture of un-
infected RBCs
C32 cells fixed
C32 cells fresh
L-cells fixed
-, -, -
-, -, -
-, -, -
00, 00, 01
00, 00, 00
00, 01, 00
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Table 4-II        Adherence of strain ItG2.F6 to L-huICAM-1-cells
Strain Type of cells iRBCs/200 cells (4 fields)uninfected RBCs /200
cells
ItG2.F6 L-cells fresh
L-ICAM-1 cells
C32 cells fresh
00, 00, 00, 01
20, 08, 08, 41
10, 04, 03, 14
05, 20, 17, 11
12, 08, 02, 20
02, 04, 04, 05
4.1.2. Analysis of the custom-made cDNA
An aliquot of the isolated mRNA was analyzed on a RNase-free agarose gel. The
mRNA appeared as a faint, homogeneous smear, visible from 4000 to 500 bp, with no
distinct bands or degradation. The total amount was estimated to consist of 18 µg mRNA.
This amount was used by Invitrogen to construct the cDNA library (see: 3.2.2.4.). Invitrogen
did a quality control, which we repeated twice with the original and once with the 1 x
amplified cDNA library. The results of these controls are summarized in Table 4-III.
Table 4-III Analysis of the cDNA library
control 1 control 2 control 3 control 4
hours of cultivation prior analysis:- 17 7 8
Number of recombinants analyzed:10 10 10 12
Ratio containing an insert: 9 / 10 1 / 10 3 / 10 5 / 12
size range: 0.5 - 3.0 kb0.7 kb 0.7 - 2.7 kb0.8 - 4.4 kb
Average insert size: 1.68 kb 0.7 kb 1.33 kb 1.76 kb
ratio of mutated vector: 0 / 10 2 / 10 0 / 10 3 / 12
The original cDNA was used for control 1 (Invitrogen), control 2, and control 3, whereas the
1 x amplified cDNA was used for control 4.
During this thesis, more than 2000 cDNA clones were analyzed, in terms of presence of an
insert, insert size or if the insert was part of a var gene.
The largest insert found was 4.5 kb, the biggest insert containing a DBL1- or an ATS domain
was 3.1 kb and 2.5 kb respectively; however, no insert was found carrying both domains, i.e.
no full-length var genes were found in the cDNA library.
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4.1.3. Analysis of the different transfection methods
In the beginning of this thesis, the COS 7 cells were transfected using the chloroquine
/ DEAE-dextran technique (3.2.2.5a.), later on, this technique was replaced by using a
commercially available transfection lipid. The lipid was chosen by comparing 6 different
commercially available transfection lipids (3.2.2.5b.).
4.1.3.1. Transient transfection with chloroquine / DEAE-dextran
Transfection with the pcDNA3.1-EGFP vector (Transfection control, see 3.2.2.11.)
never yielded more than 10% of the cells expressing GFP. Furthermore, this method was
rather harsh to the cells to be transfected: After a two-hours incubation step, up to 50% of the
COS 7 cells died and failed to attach on the Petri dish and were removed by the medium
exchange after 12 hours. The remaining cells were visibly damaged and often showed non-
typical shapes. Also, they did not multiply as fast as non-transfected COS 7 cells.
4.1.3.2. Transfection with commercially available transfection lipids
The transfection-rates of 6 different transfection lipids were compared to each other
and to the transfection-rate, achieved by chloroquine / DEAE-dextran (3.2.2.5b.) with the
pcDNA3.1-EGFP construct. The transfection-rate was estimated by counting the percentage
of cells expressing GFP. The transfection-rates for each lipid are given in Table 4-IV.
Table 4-IV      Comparative transfection with 6 different transfection lipids
1:1 1:2 1:4 1:8 1:16 1:32
Row A 10 µl Lipofectin <1% 03% 05% 05% 10% 10%
Row B 10 µl LipofectAmine 25% 25% 10% 10% 05% 05%
Row C 15 µl Cellfectin 02% 05% 10% 05% 05% 02%
Row D 10 µl DMRIE-5 * 30% 30% 30% 30% 10% 10%
Row E 10 µl SuperFect 25% 20% 10% 05% <1% <1%
Row F 10 µl LipoTaxi 05% 10% 30% 20% <1% <1%
* The amount of lipid DMRIE-5 in the sample pack was 10 x less as indicated, therefore, the
concentration of lipid could have been 10 x higher than planned.
Two transfections with chloroquine / DEAE-dextran, carried out in parallel, yielded a 10%
transfection-rate each, while the LipoTaxi transfection lipid achieved the highest transfection-
rates ( 30% ) and showed no toxicity to the transfected cells.
In later applications, when LipoTaxi was used according the supplier's manual, the
transfection-rates with the pcDNA3.1-EGFP-control plasmid reached up to 70%.
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4.1.4. Results of the cell-cell adherence assays
4.1.4.1. Comparison of 8 first-screen cell-cell adherence assays
During this work, 8 first-screen cell-cell adherence assays were performed and
continually improved. The first assay could not to be screened due to the unfixed cells, which
started to lift off (see: 3.2.2.6.). From the 4th screen on, a transfection with the pcDNA3.1
vector only was always carried out as a negative control for the adherence assay. T  8th
assay was the only assay with LipoTaxi-transfected COS 7 cells and included the following
improvements: Transfections with the cDNA and with the pcDNA3.1-EGFP (positive control
for the transfection and negative control for the binding assay) were done, yielding a
transfection-rate of 60% as estimated by the expression of GFP, the screening cells used,
were EB-stained L-huICAM-1 cells, the double fixation method was used and positive cells
were picked with the scalpel.
Taken together, in all 8 cell-cell adherence assays, 54 COS 7 cells were positive in a
first screen and were picked, resulting in the isolation of 1202 cDNA clones, most of them
were used to perform a second screen.
All second screens were performed as the corresponding first screen. All clones,
isolated from a picked cell of the first screen were pooled to perform a second screen. From
the 3rd adherence assay on, a pool of all clones, carrying an insert, was also prepared to
transfect COS 7 cells for a second screen.
The cells of two second screens of the 4th adherence assay (inserts > 1 kb of Pool 3.1 and
pcDNA3.1-vector only, see: Table 4-V and 4-VI) were washed with PBS, scratched from the
dish, lysed and analysed by SDS-Page gel electrophoresis and western blot (3.2.1.11), with
the pooled human serum of malaria exposed adults of PNG (Table 3-VII) as first antibody.
The pattern of protein bands was compared to each other. A distinct, additional band in the
cells, transfected with the pool of inserts > 1 kb was visible in the blot at a size of
approximately 66 kDa. This was the first indirect evidence, that a P. falcip rum-protein,
which was encoded by the cDNA library, was expressed by COS 7 cells.
Nevertheless, all second screens were negative. After each failed second screen, the
assay was modified, with reference to fixation-, staining- or picking technique (see 3.2.2.6.),
or with reference to the used screening cells. A comparison of all eight first-screen cell-cell
adherence assays is given in Table 4-V.
84                                                                                                                             4. Results
___________________________________________________________________________
Table 4-V       Comparison of 8 first-screen cell-cell adherence assays
Nr. conditions
(see: 3.2.2.6.)
positive cells
(COS + screening)
pick clones
(inserts)
2nd screens
(composition)
1st fix:0, stain:0, screen:10 none - -
2nd fix: 1, stain: 0, 2     (1+18) Pick 1 2 (0) 1: 1 x pool of all
pick: 1, screen: 1        (1+5) Pick 2 17 (5) 19 clones
3rd fix: 2, stain: 1, 4     (1+4) Pick 3 0 2: 1x pool of all 45
pick: 1, screen: 1        (1+5) Pick 4 0 and 1x pool of 8
       (1+5) Pick 5 0 clones with insert
       (2+12) Pick 6 45 (8)
4th fix: 2, stain: 1+2, 18   6x (1+3 or 4)Pool 3.1194 (61) 3: 1x pool of 3.1 +
pick: 2, screen: 1+2       6x (1+3 or 4)Pool 3.2199 (n.d.)1x pool of 3.4 and
       (1+8) & (1+9)Pool 3.3307 (n.d.)1x with 22 clones
   3x(1+4) & (1+8)Pool 3.4  60 (12) with inserts > 1 kb
5th fix: 2, stain: 1, 6     (1+14) Pick 8.11     (0) 4: 1x with Pick 8.2
pick: 2, screen: 1+2       (1+6) Pick 8.2282 (232)and 1x Pick 8.4 and
       (1+4) & (1+4)Pick 8.30 1x with 17 clones +
       (1+4) & (1+3)Pick 8.430    (8) 1x with clone
84.18
6th fix:3, stain:1, screen:14      4x (1+5 to 7)none* - -
7th fix: 2+3, stain: 1, 6  2x(1+7)&(1+11)Pick 9 0** 2: 1x all 54 clones
pick: 3, screen: 1     2x(1+2)&(1+3)Pick 10 54 (10) +1x 10 with insert
8th fix: 2+3, stain: 1, 14   (1+6) LTP 1 2    (2) 9: 1 x with a pool
pick: 3, screen: 1        (1+10) LTP 2 3    (3) of 8 clones with an
       (1+4) LTP 3 3    (0) insert and 1x with
       (1+3) & (1+4)LTP 4 0 each of the eight
       6x (1+3 or 4)LTP  5 0 clones individually
       5x (1+3 or 4)LTP 6 3    (3)
Legend to Table 4-V
For each assay the modifications of the given method, the number of positive cells (bold
figures), the number of attached screening cells to 1 or 2 COS 7 cells, the resulting picks, the
number of isolated clones, and the composition of the second screen(s) are given. The
modifications were defined as follows:
fix: The assay was not fixed (0), fixed with 1% glutaraldehyde / 2% Formaldehyde in
PBS for 1 hour at RT (1) or at 4°C (2), fixed with 50% Methanol / 50% acetone for
15 minutes on ice (3), or fixed with (2) followed by (3).
stain: no cells were stained (0), the screening cells were stained with EB (1), the COS 7
cells were counterstained with Evans blue (2).
pick: positive cells were picked with a Drummond pipette (1), with an Eppendorf Crystal
pipette (2), or with a scalpel (3).
screen:The screening cells were L-huICAM-1 cells (1) or C32 cells (2).
*    the screening cells started to lift off and float before the positive cell was picked.
**  The 3 cells of Pick 9 were fibrous and wrinkled, indicating an artefact.
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4.1.4.2. Analysis of the isolated cDNA clones of picked COS 7 cells
During this work, 54 COS 7 cells were considered positive (i.e. to mediate adherence
to screening cells in a first screen cell-cell adherence assay) and picked, resulting in 22 picks
(11 single and 11 pooled picks, see: 3.2.2.7.), yielding in the isolation of 1202 cDNA clones.
The clones were pooled and/or used individually to retransfect COS 7 cells for a second
screen. The analysis of the clones is summarized in Table 4-VI.
Table 4-VI      Analysis of isolated cDNA clones of picked COS 7 cells
Assay Pick clones inserts size rangevar domains comments
2 Pick 1 2 0
Pick 2 17 5 0.6-1.8 kb no
3 Pick 3 0 COS cells of Pick 6 were
Pick 4 0 photographed
Pick 5 0
Pick 6 45 8 0.55-1.7 kbno
4 Pool 3.1194 61 0.2-3.0 kb no Transfection with 22 clones
Pool 3.2199 n.d. with insert > 1 kb (4.1.4.1.)
Pool 3.3307 n.d. Pool 3.2 and 3.3 stabilated as
Pool 3.460 12 0.5-2.0 no described (3.2.1.3.)
5 Pick 8.11 0 220/232 inserts were identical
Pick 8.2282 232 0.45-2.5 kbno (1.6 kb). Clone 84.18 (3.1 kb)
Pick 8.30 contained a DBL1 domain.
Pick 8.430 8 0.3-3.1 yes (DBL1)
Pool 8* 645 >400 < 3.1 kb n.d. no additional insert found
7 Pick 9 0 Picks 9 & 10 were photo-
Pick 10 54 10 0.5-2.1 no graphed
8 LTP 1 3 2 2.2 kb no Two clones (LTP 1.1 and 6.3)
LTP 2 3 3 0.8-1.6 kb no carried different fragments of
LTP 3 3 0 the soluble antigen gene which
LTP 4
LTP 5
0
0
makes up to 5% of total
mRNA in late blood stage pa-
LTP 6 3 3 2.1 kb no rasites (Nicholls et al. 1988)
Legend to Table 4-VI
The clones of each pick were analysed for an insert, the size, and if the insert contained a
DBL1- or an ATS domain.
* After the precipitation of the cDNA clones of Pick 8.1 to 8.4 only half of the amount was
used in the electroporation of E. colicells. When Pick 8.1 and 8.3 yielded no insert, the
remainder of Pick 8.1 to 8.4 was pooled (Pool 8) to perform an additional electroporation,
yielding in 645 clones. The inserts were not analyzed in detail, but only pool-wise, yielding
no insert bigger than 3.0 kb and a 1.6 kb-sized insert in every pool of ten clones, presumable
the same insert which was found in 78% of all clones of pick 8.2.
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4.1.5. Analysis of the different picking methods
4.1.5.1 Pipette versus needle-scalpel
Picking was either done with a pipette, equipped with a gel loading tip or with a
needle scalpel. The essential difference was the accuracy: picking with the pipette was always
a 'blind' process, insofar, as the selected cell could not be followed by eye, since it was
detached by scratching, often together with surrounding cells, and then sucked in, whereas
picking with the scalpel lead to the isolation of the selected cell only, which remained visible
on the 'blade' of the scalpel. This fact is reflected by the yield of clones per COS 7 cell: picks
with a pipette yielded a mean of 60.5 clones per selected cell, whereas picks with the scalpel
yielded a mean of 3.25 clones per selected cell.
4.1.5.2. Results of the positive control for picking and Hirt extraction
In parallel to the fourth cell-cell adherence assay, one transfection with a cDNA clone,
containing a DBL1 domain (var 5.4.1) was performed after the chloroquine / DEAE-dextran
protocol. After 72 hours, 4 single cells were randomly picked, with a pipette and processed
according the shotgun approach (1). A PCR was performed, resulting in an amplified DBL1
domain in 3 out of 4 picks.
Even though a transfection rate of 75% is most probably an overestimation due to the picking
method used, it was shown, that it is possible to extract cDNA clones out of relatively few
cells by the chosen method.
4.1.6. Analysis of the electroporation protocol
After the fourth cell-cell adherence assay was negative in the second screen, the
following hypothesis was tested: plasmids with big inserts, isolated from COS 7 cells,
containing attached screening cells in a first screen, were lost during electroporation, due to
the small pores generated by electroporation with the given specifications (3.2.2.9.), therefore
leading to negative second screens.
In order to test this hypothesis, a cDNA clone (var 5.4.1), was selected to transform E. coli
cells by using 4 different conditions. The selected plasmid carried an insert of 3.0 kb,
resulting in a total size of 8.4 kb. While the capacity, shunt and pulse time was kept constant
(25 µF, 201 ½ and 5 msec), the voltage was increased steadily from 2.0 to 3.5 kV. Each
transformation was plated, yielding no differences in the number of colonies between the four
conditions used.
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4.2. Results of the shotgun approach (2)
4 IFAs were performed using the mAbs of K. Willimann, which recognized iRBCs
and intraerythrocytic P. falciparum stages. The second antibodies used, were either FITC- or
HRP-conjugated; the sensitivity and specificity of both second antibodies was the same, yet
the latter IFAs were performed with HRP-conjugated antibodies, since picking of cells under
visible light was easier than picking under UV-light.
4.2.1. Analysis of the IFAs
The IFAs, performed with the supernatants of K. Willimann (Table 3-V), were
performed independently twice. One supernatant (SupI 202/7) could not be used, since it
recognized every COS 7 cell, while others never recognized any COS 7 cell. One supernatant
(SupX 128/3) repeatedly recognized single COS 7 cells in an assay. All positive cells of a
well were picked and pooled and plasmids were propagated in E. coli. Plasmid DNA was
subsequently isolated and pooled for second screens, but all second screens were negative.
The results of the four IFAs are summarized in Table 4-VII.
Table 4-VII     Comparison of 4 performed IFAs
mAb 1. & 2. IFA clones 3. & 4. IFA clones
SupI 202/7 all cells positive- all cells positive -
SupII 3c2/9 negative - negative -
SupX 128/3 4 cells picked 58 3 cells picked 0
SupX 216 negative - 2 cells picked 12
SupX 304/3 negative - 1 cell, not picked -
SupX 323/3 2 cells picked 23 negative -
SupX 331 negative - negative -
SupX 435/3 negative - negative -
SupX 509 negative - negative -
An additional IFA was performed:  As positive control for the shotgun approach (2) a
mAb (9.22) recognizing the 83.1 epitope (GYGLFHKEKMIL) of MSP1 (Helg, 1997). By
using the same primer pair, which was used to ligate the N-terminus of MSP1 into pRE4, a
specific MSP1 product was amplified from the cDNA. COS 7 cells were transfected with the
cDNA library and screened with mAb 9.22 in an IFA: Four individual cells were positive and
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picked. The pooled pick was used to transform E. coli and resulted in 48 clones. Clones were
analyzed for the presence and size of inserts:
Pick 9.22
Number of recombinants analyzed: 48
Ratio containing an insert: 17 / 48    (35%)
Size range: 2 x 0.6 / 5 x 0.8 / 1.3 / 2 x 1.6 / 1.7 / 6 x 3.0 kb
Average insert size of the clones analyzed:1.73 kb
Ratio of mutated vector: 2 / 48    (4%)
All clones were PCR-screened in pools of 6 with primers specific for MSP1. The
cDNA and the N-terminus of the MSP1 gene in the pGEM-T vector were used as a positive
control for the PCR. No MSP1 product was amplified from the eight pools. Nevertheless,
three second screens were performed, one with a pool of all clones carrying an insert, one
with a pool of all 48 clones, and one with a pool of the 6 clones, carrying an insert of 3.0 kb.
All second screens were negative.
Since it was not possible to detect cDNA clones, which carried an MSP1 gene or -fragment,
the feasibility of shotgun approach (2) remained questionable.
4.2.2. Analysis of the expression controls using P. falciparum
genes
4 expression controls were constructed to proof expression of P. falciparum genes in
COS 7 cells and to show the correct folding and transport of the corresponding proteins:
1.) MSP2 gene (ItG2.F6) cloned into pcDNA3.1 (HindIII / BamHI)
2.) MSP2 gene (ItG2.F6) cloned into pcDNA3.1-EGFP (HindIII / BamHI)
3.) N-terminus of MSP1 gene (Ro71) cloned into pcDNA3.1 (EcoRI / BamHI)
4.) N-terminus of MSP1 gene (Ro71) cloned into pRE4 (KpnI and PvuII / ApaI)
4.2.2.1. Constructs with the MSP2 gene
The MSP2 gene, which was isolated from the cDNA by PCR, was ligated correctly
into the pcDNA3.1- and the pcDNA3.1-EGFP-vector (confirmed by sequencing). Restriction
analysis was used to confirm, that the MSP2 gene belonged to the 3D7 family. COS 7 cells
were transfected with both constructs and expression of GFP was observed with the
pcDNA3.1-EGFP-MSP2-construct. However, in western blots, using a serum pool from
malaria exposed adults , no distinct (additional) MSP2 band could be detected. Many other
bands indicated, that the serum pool recognized COS 7 cell-specific proteins (see also
4.1.4.1.). A western blot with aGFP revealed a band, of the size of the GFP protein alone,
indicating a degradation of MSP2, a mutation or incorrect cloning in the second construct.
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4.2.2.2. Constructs with the N-terminus of the MSP1 gene
In order to generate an expression control, for which a mAb was available, the N-
terminus of MSP1 (AA 1 - 348), was amplified by PCR. The primers had an internal EcoRI
and a BamHI restriction site, respectively. The PCR product was ligated into pcDNA3.1.
A second control plasmid, containing the N-terminus of MSP1, was constructed by
amplifying the N-terminal part of MSP1. A pair of primers with internal ApaI and KpnI
restriction sites were used. Native Pfu DNA polymerase was used and pRE4 vector was
digested with ApaI (sticky end) and PvuII (blunt end), as described in 3.2.3.5. The KpnI site
was introduced to cut the insert from the vector, since the PvuII site was destroyed by
ligation. The insert replaced the central region of the Herpes simplex virus glycoprotein D-
gene (HSVgD-gene, AA 33-248), thereby generating a chimeric construct with the leader
sequence and the transmembrane and cytosolic domain of the original HSVgD protein.
Both constructs were used to transfect COS 7 cells, but neither in western blots nor in
IFAs, the N-terminus was detected by mAb 9.22, although both controls were confirmed by
sequencing to be in-frame. Also, neither the mAb ID3 nor DL6, which recognize AA 11-19
and AA 272-279 5' and 3' of the MSP2 insert respectively, recognized the construct, but
recognized the original HSVgD protein, indicating no expression of a chimaeric protein,
possibly by degradation of the MSP1 gene (see also: 5.1.2.2. and Figure 5.2).
4.2.3. Results of the control using the huICAM-1-EGFP
construct
The complete gene of huICAM-1 was amplified by PCR from the genomic DNA of
L-huICAM-1 cells and cloned in frame into the pcDNA3.1-EGFP vector at the HindIII /
BamHI sites of the polylinker. This construct was used to transfect Bosc23 cell according to
the LipoTaxi protocol for stable transfections. The transfected cells were sorted into a 96 well
plate by FACScan analysis with an integrated sorter. The plate yielded 5 clones which stably
expressed the GFP-huICAM-1 construct on the surface as shown in an IFA, using aICAM-1
mAb MEM112. Furthermore, the green fluorescence was persistent, even after fixation.
These cells were supposed to be used as screening cells for further cell-cell adherence assays,
since they did not need an additional staining and did not attach as fast to the plastic as L-
huICAM-1 cells, yet whether huICAM-1 is correctly presented on the surface of these cells
was not tested in an adherence assay.
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4.3. Results of the direct approach (1) (mammalian
expression system)
The DNA sequences, coding for DBL1- and ATS domains were amplified by PCR
from both, the cDNA library and genomic DNA of strain K1, cloned into pMOSblue-T
vector, sequenced and used as hybridisation probes in both, radioactive and non-radioactive
colony lifts, to identify cDNA clones, carrying a var gene insert, to perform cell-cell
adherence assays, as described in the shotgun approach (1).
4.3.1. Analysis of 2 var gene domains from K1 gDNA
Genomic DNA of strain K1 was used to amplify DBL1 and ATS domains (see:
3.2.4.2.).
4.3.1.1. DBL1 domains of strain K1
With the two-step PCR, as described in 3.2.4.2., three distinctive products of equal
intensity were amplified, representing products of 380, 420 and 460 bp. The PCR products
were extracted from the gel and ligated by T/A cloning into the pMOSblue-T vector (3.2.1.9.)
The ligation, which was transferred immediately to 4°C, resulted in the best ligation efficacy
(see: Table 4-VIII).
Table 4-VIII    Determination of ligation efficacy with DBL1 inserts
Ligation at Insert colonies: bluelight blue white Clones picked
4°C overnight DBL1 0 1 53 3:  DBL4.1 to DBL4.3
2 h 16°C / 4°C DBL1 2 2 42 3:  DBL16.1 to DBL16.3
4 h RT / 4°C DBL1 5 2 14 0
2 h 16°C / 4°C none 55 5 08 0
Legend to Table 4-VIII
Three clones were picked from the ligation, which was incubated for 2 hours at 16°C bef re
being stored at 4°C over night and from the ligation, which was immediately transferred to
4°C. All six picked clones carried an insert and were named DBL4.1 to DBL4.3 and
DBL16.1 to DBL16.3 respectively.
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Subsequent sequencing of the clones revealed, that 3 different DBL1 domains had
been cloned: clone DBL4.1 was identical to DBL16.1 (399 bp), clone DBL4.2 was the same
as DBL16.3 (417 bp) and DBL4.3 was identical to DBL16.2 (387 bp). The sequences of
these clones is given in chapter 4.4.1., together with sequences of DBL1 domains, isolated
from ItG2.F6 cDNA, and two additional DBL1 domains, lateron isolated from strain K1.
4.3.1.2. ATS domains of strain K1
6 distinctive products of different intensity were visible on a agarose gel after PCR
amplification of the ATS domain. The amplified products were: 480, 410, 500, 530, 450, and
590 bp long, sorted according their intensity. Extraction and ligation reactions were the same
as above and ligation efficacy was comparable to that above (Table 4-IX).
Table 4-IX      Determination of ligation efficacy with ATS inserts
Ligation at Insert colonies: blue light blue white Clones picked
4°C overnight ATS 4 17 45 ATS4.1 to ATS4.3
2 h 16°C / 4°C ATS 12 20 60 ATS16.1 to ATS16.3
4 h RT / 4°C ATS 31 23 28 none
2 h 16°C / 4°C none 73 21 19 none
Legend to Table 4-IX
Six clones were picked, only four clones carried an insert (ATS4.3 and ATS16.1 to
ATS16.3), all of different sizes: ATS4.3: 590 bp, ATS16.1: 480 bp, ATS16.2: 500 bp and
ATS16.3: 530 bp.
4.3.2. Analysis of DBL1 domains from ItG2.F6 cDNA
A two-step PCR was performed to amplify DBL1 domains from the cDNA, resulting
in a smear of bands, ranging from 480 to 550 bp, indicating that the DBL1 domains of strain
ItG2.F6 were generally larger than the DBL1 domains of strain K1. The ligation was
incubated overnight at 4°C, yielding 8 blue, 12 light blue and 29 white colonies. 20 white
colonies were picked and named DBLs 1 to DBLs 20. 6 clones had an insert, ranging from
500 to 550 bp and were subsequently sequenced, revealing 4 different DBLs sequences: The
sequences of clones DBLs 2 and DBLs 14 (414 bp) were identical, as well as the sequences
of clones DBLs 16 and DBLs 18 (429 bp). Unique sequences had clones DBLs 4 (471 bp)
and DBLs 9 (444 bp). The sequences are given in chapter 4.4.1.
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4.3.3. Results of the colony lifts and the corresponding
southern blots
All the DBL1 domains were used as hybridisation probes in the following non-
radioactive protocol. The isolated, cloned DBL1 domains were biotinilated and hybridized on
nylon membranes, carrying colony-lifted cDNA clones (3.2.4.3.). In the radioactive protocol,
the ATS domains of strain K1 were additionally used as hybridisation probes (3.2.4.4.).
4.3.3.1. Analysis of the non-radioactive protocol
The cDNA library was diluted 1:40'000 and plated on 4 plates, yielding approximately
5000 colonies per plate. On a fifth plate, the library was diluted 1:400'000, yielding 1000
colonies. After the visualisation procedure, all colonies were visible on the membranes as
light purple dots and some deep purple dots.
Four small regions, containing darker colonies, were picked from one plate with
approximately 5000 colonies, diluted and plated again. A second screen was performed with
these picks, together with a positive and a negative control (cloned DBL1 domain DBL4.2
and cloned ATS domain ATS16.2 respectively). The colonies on these plates were much less
dense (approximately 800 colonies) and the darker dots on the membranes of this second
screen could accurately be matched to the corresponding colonies. From each plate of the
second screen, 2 or 4 darker colonies were individually picked, cultivated and the plasmids
were isolated. The positive control resulted in clear, dark dots on the membrane, whereas the
negative control showed white dots on a weakly purple background.
Four dark, single colonies w re tried to be individually picked from the less dense plate with
1000 colonies, diluted and plated again. No second screen was performed but 3 colonies of
each plated pick were randomly picked, cultivated and the plasmids were isolated.
All 24 picks were tested by PCR for the presence of a complete DBL1 domain
yielding in 3 cDNA clones, which carried a complete DBL1 domain. Clone var 1.8.3 with an
insert of 1700 bp, var 5.3.4 (450 bp), and var 5.4.1 (3000 bp) were used to perform a cell-cell
adherence assay (see: 4.3.4.). Clone var 5.4.1. was additionally used in two positive controls
(see: 4.1.5.2. and 4.1.6.).
4.3.3.2. Analysis of the radioactive protocol
80 µl of 1:20'000 diluted cDNA library was plated on 5 plates, yielding approximately
800 clones per plate. Membranes of all 5 plates were hybridized in a first step with the P32-
labelled DBL1 probes. 30 black dots and no background were visible on the developed x-ray
film of membrane 4. From the corresponding plate, 17 small regions were picked and plated
for 17 second screens. In these second screens, 8 clones were identified to carry a complete
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DBL1 domain and were used to perform a cell-cell adherence assay (see: 4.3.4.). Clone
PD4.14.1 (insert 1600 bp) was lateron sequenced (see: 4.3.5).
The P32-labelled DBL1 probes were stripped from the membranes 1, 2, 3 and 5 and
the hybridisation was repeated with P32-labelled ATS domains. On the developed X-ray films
of membranes 1, 2 and 5, 5 dots were identified, which could represent the same clones on
both films. The 5 corresponding small areas were picked and plated for a second screens. The
colony lift from this second screen was performed twice, with a 6-hour incubation step in
between, to allow re-growth of the colonies. Like that, two membranes with an identical
colony-pattern were available; each of which was hybridized independently with P32-labelled
DBL1- and ATS probes. The developed x-ray films were then overlaid to identify single
colonies carrying both domains, but no such clones were identified.
The film of membrane 3 was used to identify 10 regions, carrying clones with an ATS
domain. The corresponding 10 small areas were picked from plate 3 and used for a second
screens. Two clones were identified to carry a complete ATS domain and clone PA3.4.1.
(insert 2500 bp) was sequenced (see: 4.3.5).
4.3.3.3. Comparison of the two colony lift protocols
The radioactive protocol produced more reliable results than the non-radioactive
protocol, since the background was minimal, compared to the very high background of the
non-radioactive protocol. Therefore, although the radioactive protocol is much more time
consuming, it should be given preference over the non-radioactive protocol.
4.3.4. Results of the cell-cell adherence assays
2 cell-cell adherence assays were performed with the clones, identified by the non-
radioactive protocol: In one assay the COS 7 cells were transfected with an equally mixed
pool of var 1.8.3, var 5.3.4, and var 5.4.1. In the other one, cells were transfected with clone
var 5.4.1 only. Transfection was performed with chloroquine / DEAE dextran (3.2.2.5a.) and
the assay conditions were the same as in the 4th cell-cell adherence assay (4.1.4.1.). Both
assays were negative, since only a few COS 7 cells were found with one or two attached
screening cells on it. The COS 7 cells which were transfected with var 5.4.1 only, were
further used in the positive controls for picking and Hirt extraction (see: 4.1.5.2.).
A third cell-cell adherence assay was performed with the 8 clones carrying a DBL1 domain,
as identified by the radioactive protocol: The cells were transfected (3.2.2.5a) with an equally
mixed pool of the 8 clones. The assay conditions were the same as in the 5th cell-cell
adherence assay (4.1.4.1.). The assay was negative.
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4.3.5. Sequence analysis of clones PD 4.14.1 and PA 3.4.1
Clone PD 4.14.1 was sequenced to answer the question, why an i sert, containing a
complete DBL1 domain, is only 1.6 kb long, which could not be a full-length var gen .
Sequencing revealed a stretch of 6 lysines, encoded by 17 consecutive adenosines (Figure
4.1), which presumably allowed priming of the Oligo dT (NotI) primer, used in first strand
cDNA synthesis. Furthermore it revealed a new DBL1 domain, which had not been cloned
before from the cDNA library (see: 4.4.1.).
Figure 4.1       Partial sequence of clone PD 4.14.1
1        10        20        30        40        50        60
|        |         |         |         |         |         |
PD4.14.1 GCACGAAGTTTTGCAGATATAGGT ATATCGTAAGAGGAAAAGATCTATATCTCGGTTATGATAAT
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  D  L  Y  L  G  Y  D  N
   70        80        90       100       110       120       130       140
   |         |         |         |         |         |         |         |
AAAGAAAAAGAACAAAGAAAAAAATTAGAACAGAAATTGTTTAACAAAAAATTTTTCAAGCAAATACATGATGAC
 K  E  K  E  Q  R  K  K  L  E  Q  K  L  F  N  K  K  F  F  K  Q  I  H  D  D
       150       160       170       180       190       200       210
        |         |         |         |         |         |         |
GTGACGTCGACGAGAGGGAGTAATGGGCAGGCTCTAAAAACACGCTACAAAGATGATCGCGAGAAAAATTATTTT
 V  T  S  T  R  G  S  N  G  Q  A  L  K  T  R  Y  K  D  D  R  E  K  N  Y  F
  220       230       240       250       260       270       280       290
   |         |         |         |         |         |         |         |
CAATTACGAGAAGATTGGTGGACGGCGAATCGAGAAACAGTATGGGAAGCCATGACATGCAGCAAGGAGCTTGAT
 Q  L  R  E  D  W  W  T  A  N  R  E  T  V  W  E  A  M  T  C  S  K  E  L  D
       300       310       320       330       340       350       360
        |         |         |         |         |         |         |
AATTCTTCATATTTTCGTGCAACGTGCAATGATACTGGACAAGGTCCATCACAAACCCACAACAAATGCCGGTGT
 N  S  S  Y  F  R  A  T  C  N  D  T  G  Q  G  P  S  Q  T  H  N  K  C  R  C
  370       380       390       400       410       420       430       440
   |         |         |         |         |         |         |         |
GATAAGGACAAGGGCGCAAATGCCGGCAAGCCAAAGGCTGGCGACGGAGATGTAACTATTGTCCCCACATATTTT
 D  K  D  K  G  A  N  A  G  K  P  K  A  G  D  G  D  V  T  I  V  P  T  Y  F
       450       460       470       480       490       500       510
        |         |         |         |         |         |         |
GACTACGTGCCGCAGTATCTTCGCT GTTCGAAGAATGGGCGGAAGATTTT G AGGAAAAAAAAAAAAAAAAAG
 D  Y  V  P  Q  Y  L  R  W  F  E  E  W  A  E  D  F  C  R  K  K  K  K  K  K
Legend to Figure 4.1
The sequence of clone PD4.14.1 is given from the binding site of the VARDBL5 primer
(nucleotides 1-23) to the polyA-stretch, 2 AA downstream the site of the VARDBL3 primer
(nucleotides 466-491). The remaining approximate 1000 bp of the insert of clone PD4.14.1
reach into the 5' UTR (sequence not shown).
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Clone PA 3.4.1 was sequenced, to check whether it contained an ATS domain and reverse
sequencing revealed more than 400 bp of a 3' UTR of a var gene, which showed 97%
homology to the sequence of a var gene, found in GenBankª (Accession number: L42636 /
PFAVAR 7: Su et al., 1995, see Figure 4.2).
Figure 4.2       Alignment of parts of clone PA 3.4.1 and L42636 3' UTR
PA 3.4.1  465 TATTTGTGGGTTATATTATAATTTTTATTTATGGGTTAAATATATATTTTTTT  413
     |||||||||||||||||||||||||||||||||||||| ||||||||||||||
L42636 7159 TATTTGTGGGTTATATTATAATTTTTATTTATGGGTTATATATATATTTTTTT 7211
PA 3.4.1  412 TTTTTGTGCATTTGTCTATTTTTTATTTGTGCTTTATATATATATATAGTTT  361
     |||| |||||||||||||||||||||||||||||||||||||||||||||||
L42636 7212 TTTT-GTGCATTTGTCTATTTTTTATTTGTGCTTTATATATATATATATTTT 7262
Finding a complete 3' UTR in clone PA 3.4.1 indicated a good quality of the isolated mRNA,
since deadenylation of the polyA-tail is often a first step in mRNA degradation in vivo.
Forward sequencing revealed, that the complete insert showed homologies to L42636 and
that the insert started more than 1000 bp upstream the ATS domain and extended into exon 1
(Figure 4.3). Therefore this sequence was indeed amplified by RT-PCR from mRNA and not
derived from a DNA contamination during mRNA isolation.
Figure 4.3       Alignment of parts of clone PA 3.4.1 and L42636 coding region
PA 3.4.1    1 AMLASV-EL--KLGTSSDPLVQCGGIHWVQNFLEDYNKIRHKISHCKENSEQTIC
            |   |  |    |       |   |||||| || ||  |      |
L42636 4816 KKIKNGQEGDKKYITMKELLKR-----WLEYFLEDYNRIRKKIKLC------T--
PA 3.4.1 KKDCKDKCKCVK----KWISTKKQEWQQIKTRLLEQYKGQDYYNVKTI-LEDLR
||   | ||| |    ||   |  ||| |    |||||  |  |  |  ||
L42636 KKE--DGCKCIKGCIEKWVQEKTKEWQKINDTYLEQYKN-DDGNTLTNFLEQFQ
PA 3.4.1 DRPVLNKAIKPCPSLNAFEKSCGLNGTDNSQNGNNNDLVLCMIKTL-KKIDNAK  432
 |     |||||  |  |  ||||| |||||||||||||||    | |||   |
L42636 YRTEFKNAIKPCDGLDQFKTSCGLNSTDNSQNGNNNDLVLCLLNKLQKKISECK 5259
4.3.6. Occurrence of full-length var genes in the cDNA library
In the direct approach (1), the cDNA library was screened for full-length var gen s to
transfect COS 7 cells. A first step to find full-length var genes was the search for clones in
the library, which carried both, a DBL1- and an ATS domain. However, no insert with these
specifications was found, neither by hybridisation with DBL1- and ATS domains (4.3.3.2.),
nor by PCR (3.2.1.8.).
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4.4. Results of the direct approach (2) (bacterial
expression system)
DBL1- and CIDR domains were amplified by PCR from both, the ItG2.F6 cDNA and
genomic DNA of K1, cloned into pQE30 vector, expressed as 6xhis-tagged protein in E. coli
strain M15, and purified using Ni-NTA agarose columns. The binding properties of these
domains were analyzed by IFAs and FACScan analysis (see 3.2.5.6.).
4.4.1. Analysis of all DBL1 domains used for bacterial
expression
All DBL1 domains cloned so far into pMOSblue-T vector (4.3.1.1. and 4.3.2) were
amplified by PCR with the primer pair DBL1 Fw Bam and DBL1 Rev Kpn, since direct re-
cloning into pQE30 was not possible. As a positive control, both, cDNA and gDNA of K1
were used as template in the PCR. Amplified PCR products of all cloned DBL1 domains
were gel-eluted, purified and ligated into the pQE30 vector, together with the PCR products
of the two control PCRs. All previously cloned DBL1 domains could be recloned in pQE30
as well as three additional new DBL1 domains, two from gDNA of strain K1 and one from
the cDNA, termed DBLK3, DBLK4 and DBLs20 respectively.
All 10 DBL1 domains were expressed as 6xhis-tagged protein and were solubilized
and purified under native conditions with the exception of DBLs4, which had to be
solubilized under denaturing conditions (8 M urea, see 3.2.5.4. and 3.2.5.5.).
The nucleotide and AA sequences of all 10 cloned DBL1 domains is given in Figure 4.4. The
AA alignment of these DBL1 domains with 6 DBL1 domains, retrieved from GenBankª and
the DBL1 domain of cDNA clone PD4.14.1 is shown in Figure 4.5.
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Figure 4.4      Sequences of 10 DBL1 domains, expressed as 6xhis-tagged proteins
1        10        20        30        40        50        60        70        80
|        |         |         |         |         |         |         |         |
DBL16.1 GCACGAAGTTTTGCAGATATAGGTGATATCGTACGCGGCAAAGATCTTTATCTTGGTAATAAGAAAGAACGAGCTAGATTA
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  D  L  Y  L  G  N  K  K  E  R  A  R  L
DBL16.2 GCACGAAGTTTTGCAGATATAGGTGATATCGTACGCGGCAAAGAACTGTATCTTGGTAATAATAAAGAAAAAAAGCAATTA
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  E  L  Y  L  G  N  N  K  E  K  K  Q  L
DBL16.3 GCACGAAGTTTTGCAGATATTGGAGACATTATACGAGGAAAAGATTTGTATCTCGGGTATGATGAAAAAGAAAAAAATCGA
 A  R  S  F  A  D  I  G  D  I  I  R  G  K  D  L  Y  L  G  Y  D  E  K  E  K  N  R
DBLK3 GCACGAAGTTTTGCAGATATTGGTGATATTGTAAGAGGAAAAGATCTTTATTTGGGTGATCAACAAGAAAAAGATAGATTA
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  D  L  Y  L  G  D  Q  Q  E  K  D  R  L
DBLK4 GCACGAAGTTTTGCAGATATTGGAGATATCGTACGCGGCAAAGATCTGTATCTAGGTAATCCACAAGAAAAAGAACAAAGA
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  D  L  Y  L  G  N  P  Q  E  K  E  Q  R
DBLs2 GCACGAAGTTTTGCAGATATTGGAGATATTGTCAGAGGAAAAGATCTATATAGAGGTAATAACAAAGAAAAAGAAAAAAGA
 A  R  S  F  A  D  I  G  D  I  V  R  G  K  D  L  Y  R  G  N  N  K  E  K  E  K  R
DBLs4 GCACGAAGTTTTGCAGATATTGGAGATATTGTCAGAGGAAGAGATTTATATCTTGGAAGGCACGCCAAGAGAGCCACCAAA
 A  R  S  F  A  D  I  G  D  I  V  R  G  R  D  L  Y  L  G  R  H  A  K  R  A  T  K
DBLs9 GCACGAAGTTTTGCAGATATTGGAGATATCGTACGCGCCAAAGATCTATATAGTGGTAATACCCAAGAAAAAAACCGAAGA
 A  R  S  F  A  D  I  G  D  I  V  R  A  K  D  L  Y  S  G  N  T  Q  E  K  N  R  R
DBLs16 GCACGAAGTTTTGCAGATATAGGAGACATTGTCAGAGGAAGAGATCCATTTTATGGTAATACACAAGAAAGTACACAAAGA
 A  R  S  F  A  D  I  G  D  I  V  R  G  R  D  P  F  Y  G  N  T  Q  E  S  T  Q  R
DBLs20 GCACGAAGTTTTGCAGATATTGGAGACATTATACGAGGAAAAGATCTATTTCGTGGTAATAAAAAAAAAAAATCAAACGAA
 A  R  S  F  A  D  I  G  D  I  I  R  G  K  D  L  F  R  G  N  K  K  K  K  S  N  E
        90       100       110       120       130       140       150       160
        |         |         |         |         |         |         |         |
DBL16.1 GAAGAAAATTTACAAAAAATTTTTAGGAATATATATGACAATTTGGTGGGTGCAGCAAAAAAACACTACGAAGGTGATAAA
 E  E  N  L  Q  K  I  F  R  N  I  Y  D  N  L  V  G  A  A  K  K  H  Y  E  G  D  K
DBL16.2 GAAGAGAATTTAAAAAAAATTTTCAAGCAAATACATGGTGGATTGAAGAATGGGGAGCTAAAAGCACTCTACCAAAAGGAC
 E  E  N  L  K  K  I  F  K  Q  I  H  G  G  L  K  N  G  E  L  K  A  L  Y  Q  K  D
DBL16.3 AGAAAACAATTAGAAAATAATTTGAAAGAAATTTTCACGCAAATACATGAGGGATTGTCGAAGAACGGCGCACAAAAACAC
 R  K  Q  L  E  N  N  L  K  E  I  F  T  Q  I  H  E  G  L  S  K  N  G  A  Q  K  H
DBLK3 GAAGAGAATTTAAGAAAGATTTTCAAGAAAATATATGAAGGATTGTCGAACAACGGCGCAGAAGAACGCTACAATGGTGAT
 E  E  N  L  R  K  I  F  K  K  I  Y  E  G  L  S  N  N  G  A  E  E  R  Y  N  G  D
DBLK4 GAAAAATTAGAAAATAAGTTGAAAGAGGTTTTTGGGAAAATACATAGTGGATTGACAGATAGTGGTGCAAAAGAACGCTAC
 E  K  L  E  N  K  L  K  E  V  F  G  K  I  H  S  G  L  T  D  S  G  A  K  E  R  Y
DBLs2 GAAAAATTAGAACAGAAATTGAAAGAAATTTTCAAGAAAATACATGGAAATTTGAGGAATGGTGTAAAAGACCACTACAAT
 E  K  L  E  Q  K  L  K  E  I  F  K  K  I  H  G  N  L  R  N  G  V  K  D  H  Y  N
DBLs4 ATAAATCTAAATGGAAAAGAAACAGAAAGAGGAAAATTAGAAAATAATTTGAAAGATATTTTCAAGAATATACATGATGAA
 I  N  L  N  G  K  E  T  E  R  G  K  L  E  N  N  L  K  D  I  F  K  N  I  H  D  E
DBLs9 GATCAATTAGAAAAGAATTTGAAAGAAATTTTCGGGGATATATATAATGACGTGACGTCTAGCGGCAATAATAAGGATGTG
 D  Q  L  E  K  N  L  K  E  I  F  G  D  I  Y  N  D  V  T  S  S  G  N  N  K  D  V
DBLs16 GAAAAATTAGAGAAGAATTTGAAAGAAATTTTCAAGGAAATACATAATGGATTGGATGGGGAAGCACAAGCTCGCTACAAT
 E  K  L  E  K  N  L  K  E  I  F  K  E  I  H  N  G  L  D  G  E  A  Q  A  R  Y  N
DBLs20 AGAGATAAATTAGAAGAGAATTTACCAAAAATTTTCAAGCAAATACATGATGACGTGACGTTCGACGAGAGGAGTAATGGG
 R  D  K  L  E  E  N  L  P  K  I  F  K  Q  I  H  D  D  V  T  F  D  E  R  S  N  G
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      170       180       190       200       210       220       230       240
       |         |         |         |         |         |         |         |
DBL16.1 GAAAATTTTTATCAATTACGAGAAGATTGGTGGAACGCTAATAGACAACAAGTATGGAACGCGATAACATGCGGCGCTGAG
 E  N  F  Y  Q  L  R  E  D  W  W  N  A  N  R   Q  Q  V  W  N  A  I  T  C  G  A  E
DBL16.2 GGTGATAATTATTTTCAATTACGAGAAGATTGGTGGGCACTTAATAGACAAGATGTATGGAAAGCTATCACATGTGGCGCT
 G  D  N  Y  F  Q  L  R  E  D  W  W  A  L  N  R   Q  D  V  W  K  A  I  T  C  G  A
DBL16.3 TACAATGGTGATACTAAAGATTATTTTCAATTACGAGAAGATTGGTGGGCTCTTAATAGAGACCAAGTATGGAAAGCTATT
 Y  N  G  D  T  K  D  Y  F  Q  L  R  E  D  W  W  A  L  N  R   D  Q  V  W  K  A  I
DBLK3 AAAGATCCAAATTATTATCAATTGCGAGAAGATTGGTGGGCACTTAATAGAGTACAAGTATGGAAAGCTATCACATGTGGT
 K  D  P  N  Y  Y  Q  L  R  E  D  W  W  A  L  N  R   V  Q  V  W  K  A  I  T  C  G
DBLK4 AAAGATGATGCCAAAAAAAATTTTTATCAATTACGAGAAGATTGGTGGACTGCGAATCGCGCCACAATCTGGGAAGCCATG
 K  D  D  A  K  K  N  F  Y  Q  L  R  E  D  W  W  T  A  N  R   A  T  I  W  E  A  M
DBLs2 GGTGACGGTGATAATTATTATCAATTAAGAGAAGATTGGTGGACTGCAAATCGTGAAACAGTATGGAAAGCTATCACATGC
 G  D  G  D  N  Y  Y  Q  L  R  E  D  W  W  T  A  N  R   E  T  V  W  K  A  I  T  C
DBLs4 GTGACGAAGGGAGGGAAGAATGGGGAGGCTCTAAAAACACGCTACGGAAGTGATAAAGAAAATTATTATCAATTACGAGAA
 V  T  K  G  G  K  N  G  E  A  L  K  T  R  Y  G  S  D  K  E  N  Y  Y  Q  L  R  E
DBLs9 CTAAAAGCACGCTACAATGGTGATACTGATAATTATTATAAACTAAGAGAAGATTGGTGGACTGCTAATAGAGAAACAGTA
 L  K  A  R  Y  N  G  D  T  D  N  Y  Y  K  L  R  E  D  W  W  T  A  N  R   E  T  V
DBLs16 GGTGATACTGATAATTATTATAAATTAAGGGAAGATTGGTGGACAGCGAATAGGCACACCGTGTGGGAAGCTATCACGTGC
 G  D  T  D  N  Y  Y  K  L  R  E  D  W  W  T  A  N  R   H  T  V  W  E  A  I  T  C
DBLs20 CAGGCTCTAAAAACACGCTACAAAGATGATCGCGAGAAAAATTATTTTCAATTACGAGAAGATTGGTGGACGGCGAATCGA
 Q  A  L  K  T  R  Y  K  D  D  R  E  K  N  Y  F  Q  L  R  E  D  W   W  T  A  N  R
     250       260       270       280       290       300       310       320
      |         |         |         |         |         |         |         |
DBL16.1 AATGATTCTCAATATTTTCGACGAACATGTGGTAGTGATGAAAAAACTGCAACTCGGACTCCTAGTCAATGCCGATGTACC
 N  D  S  Q  Y  F  R  R  T  C  G  S  D  E  K  T  A  T  R  T  P  S  Q  C  R  C  T
DBL16.2 GCGGGTGGTAAATATTTTAGAAATACATGTGTTGGGGGAAGTCCGACTCAAGATGACTGCCGATGCAGGACAAATGATGTA
 A  G  G  K  Y  F  R  N  T  C  V  G  G  S  P  T  Q  D  D  C  R  C  R  T  N  D  V
DBL16.3 ACATGTGATGCGCCACCTGATGCTCAATATTTTCGAGGAACATGTGTAGGTGATGGAAAACATTCAACTCTGGCTAAAGAC
 T  C  D  A  P  P  D  A  Q  Y  F  R  G  T  C  V  G  D  G  K  H  S  T  L  A  K  D
DBLK3 GCTACAATGAAAGATATATATTCAAAAACCACCGATAATGGTAAGCTGCTTCTTTGGAATTATAATTGCGGTCATCATGTG
 A  T  M  K  D  I  Y  S  K  T  T  D  N  G  K  L  L  L  W  N  Y  N  C  G  H  H  V
DBLK4 ACATGCGAAGCGAACGGTACATATTTTCGACCAACGTGCAGTATGAATGGAAGTGGAGCCCAAGCTAATAACAAATGCCGG
 T  C  E  A  N  G  T  Y  F  R  P  T  C  S  M  N  G  S  G  A  Q  A  N  N  K  C  R
DBLs2 AACGACAGGCTAGGGGGTAATGCATATTTTCGAAAAACTTGTAGTGATACAAAAGGTTCATCTGTAGCTAATCACAAATGC
 N  D  R  L  G  G  N  A  Y  F  R  K  T  C  S  D  T  K  G  S  S  V  A  N  H  K  C
DBLs4 GATTGGTGGACTGCGAATCGCGCCACAGTGTGGGAAGCATTAACATGTGAAGTTGGTAGTGGTACATATTTTCATGCAACG
 D  W  W  T  A  N  R   A  T  V  W  E  A  L  T  C  E  V  G  S  G  T  Y  F  H  A  T
DBLs9 TGGAAAGCCATCACGTGCGGTGCGCCAGAACATGCTTCATATTTTCGTGTAACATGCAGTGATGAACAAGGTGGAGCCGAA
 W  K  A  I  T  C  G  A  P  E  H  A  S  Y  F  R  V  T  C  S  D  E  Q  G  G  A  E
DBLs16 GAAGCTGGGAATGATTCTCAATATTTTCGACCAACATGTGGAGGTAATGAAAAAAATTCAACTCTGGCTAAAGACAAATGC
 E  A  G  N  D  S  Q  Y  F  R  P  T  C  G  G  N  E  K  N  S  T  L  A  K  D  K  C
DBLs20 GAAACAGTATGGGAAGCCATGACATGCAGCAAGGAGCTTGATAATTCTTCATATTTTCGTGCAACGTGCAATGATACTGGA
 E  T  V  W  E  A  M  T  C  S  K  E  L  D  N  S  S  Y  F  R  A  T  C  N  D  T  G
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    330       340       350       360       370       380       390       400
     |         |         |         |         |         |         |         |
DBL16.1 ACTCGTGTTGTTCCCACATATTTTGACTACGTGCCACAGTTTCTTCGCTGGTTCGAGGAATGGGCGGAAGGTACC
 T  R  V  V  P  T  Y  F  D  Y  V  P  Q  F  L  R  W  F  E  E  W  A  E  G  T
DBL16.2 CCTACATATTTCGATTATGTGCCACAGTATCTTCGCTGGTTCGAGGAATGGGCAGAAGGTACC
 P  T  Y  F  D  Y  V  P  Q  Y  L  R  W  F  E  E  W  A  E  G  T
DBL16.3 AAATGCCGCTGTGAAGGCGCAAATATTGTCCCCACATATTTCGACTATGTGCCGCAGTATCTTCGCTGGTTCGAGGAATGG
 K  C  R  C  E  G  A  N  I  V  P  T  Y  F  D  Y  V  P  Q  Y  L  R  W  F  E  E  W
DBLK3 AATAAAGATGTCCCAACAAACTTGGATTACGTGCCTCAATTTTTACGTTGGTTCGAGGAATGGGCCGAAGGTACC
 N  K  D  V  P  T  N  L  D  Y  V  P  Q  F  L  R  W  F  E  E  W  A  E  G  T
DBLK4 TGTGAGAACAAAACTGGCGCAAGTGGCAACGTAAGTATTGTCCCCACATATTTCGACTATGTGCCACAGTATCTTCGCTGG
 C  E  N  K  T  G  A  S  G  N  V  S  I  V  P  T  Y  F  D  Y  V  P  Q  Y  L  R  W
DBLs2 CGATGTCCCAATGGTAACGACCAGGTCCCCACATATTTCGATTATGTGCCGCAGTTTCTTCGCTGGTTCGAGGAATGGGCC
 R  C  P  N  G  N  D  Q  V  P  T  Y  F  D  Y  V  P  Q  F  L  R  W  F  E  E  W  A
DBLs4 TGCAGTATGAATGGAAGTGGAGCCCAAGCTAAAAATAACTGCCGCTGTAAGAAGGAAGACGGCAAAGATGACACCGACCAG
 C  S  M  N  G  S  G  A  Q  A  K  N  N  C  R  C  K  K  E  D  G  K  D  D  T  D  Q
DBLs9 GCTAATCACAAATGCCGCTGTCCCAAGTCAAGAGACAACAAGTCCAATGACCAAGTCCCCACATATTTCGATTATGTGCCT
 A  N  H  K  C  R  C  P  K  S  R  D  N  K  S  N  D  Q  V  P  T  Y  F  D  Y  V  P
DBLs16 CGCTGTAAGGACGAAAAATTCACAAAAGAGACCGACCAGGTTCCTACATATTTTGACTACGTGCCACAGTTTCTTCGCTGG
 R  C  K  D  E  K  F  T  K  E  T  D  Q  V  P  T  Y  F  D  Y  V  P  Q  F  L  R  W
DBLs20 CAAGGTCCATCACAAACCCACAACAAATGCCGGTGTGATAAGGACAAGGGCGCAAATGCCGGCAAGCCAAAGGCTGGCGAC
 Q  G  P  S  Q  T  H  N  K  C  R  C  D  K  D  K  G  A  N  A  G  K  P  K  A  G  D
   410       420       430       440       450       460       470       480
    |         |         |         |         |         |         |         |
DBL16.1 <<<
DBL16.2 <<<
DBL16.3 GCCGAAGGTACC
 A  E  G  T
DBLK3 <<<
DBLK4 TTCGAGGAATGGGCCGAAGGTACC
 F  E  E  W  A  E  G  T
DBLs2 GAAGGTACC
 E  G  T
DBLs4 GTTCCCACATATTTTGACTATGTTCCTCAATATTTGAGATGGTTCGAGGAATGGGCCGAAGGTACC
 V  P  T  Y  F  D  Y  V  P  Q  Y  L  R  W  F  E  E  W  A  E  G  T
DBLs9 CAATATTTGAGATGGTTCGAGGAATGGGCCGAAGGTACC
 Q  Y  L  R  W  F  E  E  W  A  E  G  T
DBLs16 TTCGAGGAATGGGCCGAAGGTACC
 F  E  E  W  A  E  G  T
DBLs20 GGAGATGTAACTATTGTCCCCACATATTTTGACTACGTGCCGCAGTATCTTCGCTGGTTCGAGGAATGGGCCGAAGGTACC
 G  D  V  T  I  V  P  T  Y  F  D  Y  V  P  Q  Y  L  R  W  F  E  E  W  A  E  G  T
Legend to Figure 4.4
The sequence of all ten DBL1 domains (K1, lane 1-5 and ItG2.F6, lane 6-10), expressed as
6xhis-tagged proteins, is given from the site of the DBL1 FW Bam primer (ARSFADIG-
motif) to the site of the DBL1 Rev Kpn primer (WFEEWAE-motif). All PCR products
showed homologies to DBL1 domains, since all domains contained a common motif
([Q/K]LREDWWX[A/L]NR) typical for DBL1 domains found in almost all published DBL1
domains. This motif is printed in bold.
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Figure 4.5      Aligned AA sequences of 17 DBL1 domains
1        10        20        30        40        50        60        70
|        |         |         |         |         |         |         |
L40608 ARSFADIGDIVRGRDLYLG---------NP-QEIKQRQQLENNL--KTIFGKIY-E------KLNGAEAR--YGNDPE
L40609.3 ARSFADIGDIVRGKDLYLG---------YDDEEKEKRKQLEKNL--KKFFQKIHDDVMKTSGRTNGKKSAEAQKRYND
L40609.2 ARSFADIGDIVRGRDLYRG---------ND-KE-KDR--LEENL--RKIFKKIY-D------NLNDAHVQEHYKDDDK
L42636 ARSFADIGDIVRGKDLYLG---------YDNKEKEQRKKLEQKL--KDIFKKIHKD------VMKTNGAQERYIDDAK
U27338 ARSFADIGDIVRGKDLYLG---------YDDKEKDERKKLENNL--IEIFKKIH-E------NLGTQDAKDHYKKDEE
U27339 ARSFADIGDIVRGKDLYLG---------YDDKEKDERKKLENNL--IEIFKKIH-E------NLGTQDAKDHYKKDEE
DBL16.1 ARSFADIGDIVRGKDLYLG---------NK-KE---RARLEENL--QKIFRNIY-D------NLVGA-AKKHYEGDKE
DBL16.2 ARSFADIGDIVRGKELYLG---------N-NKEK---KQLEENL--KKIFKQIHG-------GLKNGELKALYQKDGD
DBL16.3 ARSFADIGDIIRGKDLYLG---------YDEKEKNRRKQLENNL--KEIFTQIH-E------GLSKNGAQKHYNGDTK
DBLK3 ARSFADIGDIVRGKDLYLG----------DQQEK---DRLEENL--RKIFKKIYE-------GLSNNGAEERYNGDKD
DBLK4 ARSFADIGDIVRGKDLYLG---------NP-QEKEQREKLENKL--KEVFGKIHSGL--TDSGA-----KERYKDDAK
DBLs2 ARSFADIGDIVRGKDLYRG---------NN-KEKEKREKLEQKL--KEIFKKIH--------GNLRNGVKDHYNGDGD
DBLs4 ARSFADIGDIVRGRDLYLGRHAKRATKINLNGKETERGKLENNL--KDIFKNIHDEVTK--GGKNGEALKTRYGSDKE
DBLs9 ARSFADIGDIVRAKDLYSG---------NT-QEKNRRDQLEKNL--KEIFGDIYNDV--TSSGNNKDVLKARYNGDTD
DBLs16 ARSFADIGDIVRGRDPFYG---------NT-QESTQREKLEKNL--KEIFKEIH-N------GLDGE-AQARYNGDTD
DBLs20 ARSFADIGDIIRGKDLFRG---------NKKKKSNERDKLEENLP--KIFKQIHDDVTFDE-RSNGQALKTRYKDDRE
PD4.14.1 ARSFADIGDIVRGKDLYLG---------YDNKEKEQRKKLEQKLFNKKFFKQIHDDVTSTR-GSNGQALKTRYKDDRE
Consensus ARSFADIGDI*RG*DL* G         *   *   *  LE *L    *F  I*                  Y  D
 80        90       100       110       120       130       140       150
 |         |         |         |         |         |         |         |
L40608 ----FFKLREDWWTANRETVWKAITCNAW-GNT-YFHATC-NRG---ERTKGYCRCND---------------D-QVP
L40609.3 ATGNYYKLREDWWNANRDQVWKAITCDAADNDE-YFENSSDGLYVFSNGQ-----CGRNEGK--------------VP
L40609.2 GTKNYYKLRNAWWEANRQTVWKAITCGAA-GGT-YFRQTC-GTG---TWTNEKCRCPI---------------N-DVP
L42636 G-GDFFQLREDWWTSNRETVWKALICHAP-KEANYFIKTACNVG---KGTNGQCHCIG---------------G-DVP
U27338 ---NYYQLREDWWTANRSTVWKAITCHAG-ESDKYFRKTCCSGEWTDDK----CRCKDEEGKN--------ETN-EVP
U27339 ---NYYQLREDWWTANRSTVWKAITCHAG-ESDKYFRKTCCSGEWTD----DKCRCKDEEGKN--------ETN-EVP
DBL16.1 ---NFYQLREDWWNANRQQVWNAITCGAE-NDSQYFRRTCGSDEKTATRTPSQCRCT---------------TR-VVP
DBL16.2 ---NYFQLREDWWALNRQDVWKAITCGAAGG--KYFRNTCVG----GSPTQDDCRCRTN----------------DVP
DBL16.3 ---DYFQLREDWWALNRDQVWKAITCDAP-PDAQYFRGTCVGDGKHSTLAKDKCRCE--------------GAN-IVP
DBLK3 --PNYYQLREDWWALNRVQVWKAITCGATMK--DIYSKTTDN----GKLLLWNYNCGHHV-------------NKDVP
DBLK4 --KNFYQLREDWWTANRATIWEAMTCEAN-GT--YFRPTC-SMNGSGAQANNKCRCENKTGAS--------GNVSIVP
DBLs2 ---NYYQLREDWWTANRETVWKAITCNDRLGGNAYFRKTC-SDTKGSSVANHKCRCPNG--------------NDQVP
DBLs4 ---NYYQLREDWWTANRATVWEALTCEVGSGT--YFHATC-SMNGSGAQAKNNCRCKKEDGKD--------DT-DQVP
DBLs9 ---NYYKLREDWWTANRETVWKAITCGAP-EHASYFRVTC-SDEQGGAEANHKCRCP-KSRDN--------KSNDQVP
DBLs16 ---NYYKLREDWWTANRHTVWEAITCEAG-NDSQYFRPTCGGNEKNSTLAKDKCRCKDEKFTK--------ETD-QVP
DBLs20 --KNYFQLREDWWTANRETVWEAMTCSKELDNSSYFRATCNDTGQGPSQTHNKCRCDKDKGANAGKPKAGDGDVTIVP
PD4.14.1 --KNYFQLREDWWTANRETVWEAMTCSKELDNSSYFRATCNDTGQGPSQTHNKCRCDKDKGANAGKPKAGDGDVTIVP
Consensus    ****LREDWW  NR  VW A TC        YF  TC             CRC                    VP
L40608
L40609.3
L40609.2
L42636
U27338
U27339
DBL16.1
DBL16.2
DBL16.3
DBLK3
DBLK4
DBLs2
DBLs4
DBLs9
DBLs16
DBLs20
PD4.14.1
Consensus
  160       170
   |         |
TYFDYVPQYLRWFEEWAEDF
TNLDYVPQHLRWFDEWAEDF
TYFDYVPQYLRWFEEWAEDF
TYFDYVPQYLRWFEEWAEDF
TYFDYVPQYLRWFEEWAEDF
TYFDYVPQYLRWFEEWAEDF
TYFDYVPQFLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TNLDYVPQFLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TYFDYVPQFLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TYFDYVPQFLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEGT
TYFDYVPQYLRWFEEWAEDF
TYFDYVPQ LRWFEEWAE**
 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
Legend to Figure 4.5
The AA sequence of 17 DBL1 domains is given:
The published sequences 1 to 4 (Su et al., 1995) were
isolated from strain Dd2 (1 + 4) and FCR3 (2 + 3).
The published sequences 5 to 6 (Baruch et al., 1995)
were isolated from the Malayan Camp strain.
The consensus sequence is defined as follows:
bold letter: AA is the same in at least 16 of 17 DBL1
domains.
asterix (*): AA is the same in at least 14 of 17 DBL1
domains, or only 2 different AAs were found in the 17
sequences analyzed.
4. Results                                                                                                                              101
___________________________________________________________________________
4.4.2. Analysis of all CIDR domains used for bacterial
expression
3 distinctive products were amplified by the PCR amplification of the CIDR domain:
The PCR with the cDNA as a template resulted in two distinct bands of 520 and 550 bp,
whereas the PCR with the gDNA of K1 as template resulted in one band of 530 bp. The PCR
products were ligated as described (3.2.1.9.) and resulted in about 260 clones. In total, 42
clones were picked, 10 from K1 and 32 from ItG2 F6 cDNA. All clones were analyzed for
presence, size, and sequence of the insert. With mall scale expressions, it was checked, if the
CIDR domain was expressed as a 6xhis-tagged protein. An overview is given in Table 4-X.
Table 4-X       Comparison of 42 clones, tested for expression of a CIDR domain
Clone Insert ExpressionSequence Clone Insert Expression Sequence
C1 560 bp yes 1 (11xa) K22 520 bp yes =39
C2 560 bp yes =1 K23 520 bp degr. 100AA=39 (9xa)
C3 - - - K24 520 bp yes =39
C4 500 bp no n.d. C25 560 bp degr. 100AA=1 (12xa)
C5 500 bp no n.d. C26 560 bp yes =1
C6 500 bp no n.d. C27 520 bp yes =10
C7 500 bp no n.d. C28 500 bp no n.d.
C8 560 bp yes =1 C29 - - -
C9 520 bp yes 9 (11xa) C30 500 bp no n.d.
C10 520 bp yes 10 (9xa) C31 560 bp yes =1
C11 500 bp no =17 C32 560 bp yes 32 (11a)
C12 - - - C33 500 bp no n.d.
C13 560 bp yes =1 C34 - - -
C14 560 bp yes =1 C35 500 bp no n.d.
C15 500 bp no n.d. C36 560 bp yes =1
C16 500 bp no =17 C37 500 bp no =17
C17 500 bp no 17 (8xa) C38 500 bp no =17
C18 500 bp no n.d K39 520 bp yes 39 (10xa)
K19 520 bp yes =39 K40 520 bp yes =39
K20 520 bp yes =39 K41 - - -
K21 520 bp yes =39 K42 520 bp yes 42 (9xa)
Legend to Table 4-X
All 42 cloned CIDR domains were tested for expression and most were subsequently
sequenced. Each newly identified sequence was termed according to the clone (bold letters).
In all CIDR domains, a polyA-stretch between 9 to 11 adenosines was found (in brackets).
Two CIDR domains (CIDRK23 and CIDRC25) had an error in the polyA-stretch, resulting in
a frame shift and therefore resulted in degraded proteins (see also Figure 4.6 and 4.7).
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Together, 6 different CIDR domains were found and expressed as 6xhis-tagged
proteins, termed CIDR C1, CIDR C9, CIDR C10, CIDR C32 (all isolated from the cDNA),
CIDR K39 and CIDR K42 (both isolated from gDNA of strain K1).
An additional sequence (termed C17) was found five times in the cDNA, which could
never be expressed, since a single mutation at position 122 (see Figure 4.6) led to a stop
codon (TAG instead of TGG). All clones, derived from the ligation with the 520 bp PCR
product (see above), which were sequenced, carried this mutation, indicating that this error
had already been present in the template and was not an artefact of the PCR, since even an
error in the first PCR-step, would lead only to 50 % of the PCR product to have this error.
On the other hand, two clones (CIDRK23 and CIDRC25) had a mutation in a polyA-
stretch of their insert, which was possibly PCR-derived, since (internal) polyA stretches are
known to be possible 'slipping sites' for polymerases (Wagner t al., 1990). The polyA-
stretch, common for all isolated CIDR domains, is shown in bold letters in Figure 4.6.
- the clone CIDR K23 had the same sequence as CIDR K39, with the exception of an
adenosine missing in a 10xA-stretch, which lead to a frame shift and therefore to a degraded
protein of 101 AAs instead of 167 AAs.
- the clone CIDR C25 had the same sequence as CIDR C1, with the exception of an
additional adenosine in a 11xA-stretch, which lead to a frame shift and therefore lead to a
degraded protein of 100 AAs instead of 189 AAs.
A third clone, CIDR C32, which could be expressed as a complete 6xhis-tagged CIDR
domain had a sequence which was identical to the sequence of CIDR C10 for bp 1-211 and
then identical to the sequence of CIDR C1 for bp 194-567 (The region of recombination is
given in underlined letters in Figure 4.6). Whether this sequence was present in the cDNA or
was created during the PCR with the cDNA as a template, was not investigated further.
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Figure 4.6      Sequences of 7 CIDR domains, as ligated into the pQE30 vector
1        10        20        30        40        50        60
|        |         |         |         |         |         |
CIDR C1 GGATCCAGATGGAAATGTTATTATGATGAAAATGAAAAAAATAGTGAAAAAAATAATAATTGTGTA
 G  S  R  W  K  C  Y  Y  D  E  N  E  K  N  S  E  K  N  N  N  C  V
CIDR C32 GGATCCAAATGGAAATGTTATTATGATGAACATAAGCCTAGTAGTAAAAATAATAATAATTGTGTA
 G  S  K  W  K  C  Y  Y  D  E  H  K  P  S  S  K  N  N  N  N  C  V
CIDR C10 GGATCCAAATGGAAATGTTATTATGATGAACATAAGCCTAGTAGTAAAAATAATAATAATTGTGTA
 G  S  K  W  K  C  Y  Y  D  E  H  K  P  S  S  K  N  N  N  N  C  V
CIDR C9 GGATCCAAATGGAAATGTTATTATGATGAAAGTAAGGAAAGTGGACAAAATAATAATTGCATACTA
 G  S  K  W  K  C  Y  Y  D  E  S  K  E  S  G  Q  N  N  N  C  I  L
CIDR C17 GGATCCAAATGGAAATGTTATTATGATGATAGCGATAAAAGTAATAATTGTGTACAAGGAGAATGG
 G  S  K  W  K  C  Y  Y  D  D  S  D  K  S  N  N  C  V  Q  G  E  W
CIDR K39 GGATCCAAATGGAAATGTTATTATGAAAAAACCGATAAAAGTAATAATTGCATACTAGGAAAATGG
 G  S  K  W  K  C  Y  Y  E  K  T  D  K  S  N  N  C  I  L  G  K  W
CIDR K42 GGATCCAAATGGAAATGTTATTATGAAAAAAAAAATGAAAAGGATGGTGGCAAGGACATTAATTTT
 G  S  K  W  K  C  Y  Y  E  K  K  N  E  K  D  G  G  K  D  I  N  F
   70        80        90       100       110       120       130
   |         |         |         |         |         |         |
CIDR C1 GAAGGAACATGGGACACGTTTACACAGGGTAAAAAAGTTAAGCCCTATAATCCATTTTTTTGGGAT
 E  G  T  W  D  T  F  T  Q  G  K  K  V  K  P  Y  N  P  F  F  W  D
CIDR C32 GAAGGAACATGGGACAAGTTTACACAAGGTAAACAAACCGTTAAGTCCTATAATGTTTTTTTTTGG
 E  G  T  W  D  K  F  T  Q  G  K  Q  T  V  K  S  Y  N  V  F  F  W
CIDR C10 GAAGGAACATGGGACAAGTTTACACAAGGTAAACAAACCGTTAAGTCCTATAATGTTTTTTTTTGG
 E  G  T  W  D  K  F  T  Q  G  K  Q  T  V  K  S  Y  N  V  F  F  W
CIDR C9 GGAAAATGGGAGGACTTTACAGGGAACGAGGACGTTACATCTTATAATGTTTTTTTTTATAATTCA
 G  K  W  E  D  F  T  G  N  E  D  V  T  S  Y  N  V  F  F  Y  N  S
CIDR C17 AAAGATTTTCAAAAGGGTCAAAAGGTTACGTCTTATAATGCATTTTTTTGGAAGTA GTTCATGAT
 K  D  F  Q  K  G  Q  K  V  T  S  Y  N  A  F  F  W  K  *  V  H  D
CIDR K39 GAAAAGTTTCAAAAGGGACAAGAAGTTATGGTCTATCATCCTTTTTTTTGGAGTTGGGTTACTGAA
 E  K  F  Q  K  G  Q  E  V  M  V  Y  H  P  F  F  W  S  W  V  T  E
CIDR K42 TGTGTACTACAAGATGACAAAGCAAGGACATCAGAAGAAAAAAGTATGCACTATAATTCATTTTTT
 C  V  L  Q  D  D  K  A  R  T  S  E  E  K  S  M  H  Y  N  S  F  F
      140       150       160       170       180       190
       |         |         |         |         |         |
CIDR C1 TGGGTATATCATATGTTACACGATTCTTTAGATTGGAGAAACGAACTTGGGAGTTGTATAGATAAT
 W  V  Y  H  M  L  H  D  S  L  D  W  R  N  E  L  G  S  C  I  D  N
CIDR C32 GATTGGGTTCATGATATGTTACACGATTCTGTAGAGTGGAGAGAAAGACTTAATAGTTGTATAAA
 D  W  V  H  D  M  L  H  D  S  V  E  W  R  E  R  L  N  S  C  I  N
CIDR C10 GATTGGGTTCATGATATGTTACACGATTCTGTAGAGTGGAGAGAAAGACTTAATAGTTGTATAAAT
 D  W  V  H  D  M  L  H  D  S  V  E  W  R  E  R  L  N  S  C  I  N
CIDR C9 ATTATTGAAATGTTAAATGATTCTATAGAATGGAAAGACAAACTTGATATTTGTATAAATAATAAA
 I  I  E  M  L  N  D  S  I  E  W  K  D  K  L  D  I  C  I  N  N  K
CIDR C17 ATGTTAATCGACTCTATGCAATGGAGAGACGAACATGGTAAGTGTATAAATAAAGATAATGACAAC
 M  L  I  D  S  M  Q  W  R  D  E  H  G  K  C  I  N  K  D  N  D  N
CIDR K39 ATGTTGGACGATTCTATAAAATGGAGGAAAGAACTTGATAATTGCCTAAAAAATGAGAACAAACAA
 M  L  D  D  S  I  K  W  R  K  E  L  D  N  C  L  K  N  E  N  K  Q
CIDR K42 TGGGATTGGGTTTATCATATGTTACATGATTCTTTAAATTGGAGAAAACAACTTGGTAATTGTATA
 W  D  W  V  Y  H  M  L  H  D  S  L  N  W  R  K  Q  L  G  N  C  I
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200       210       220       230       240       250       260
 |         |         |         |         |         |         |
CIDR C1 GCCAAATCAGGACAATGTGAAAACAAATGTAATAGTAAATGTGAATGTTTTGAACGATGGGTTGA
 A  K  S  G  Q  C  E  N  K  C  N  S  K  C  E  C  F  E  R  W  V  E
CIDR C32 AATGCCAAATCAGGACAATGTGAAAACAAATGTAATAGTAAATGTGAATGTTTTGAACGATGGGTT
 N  A  K  S  G  Q  C  E  N  K  C  N  S  K  C  E  C  F  E  R  W  V
CIDR C10 AATGCCAAATCACAAAATTGTAAAAACAATAAATGTAATAGAGAATGTGGTTGTTTTGCAAAATGG
 N  A  K  S  Q  N  C  K  N  N  K  C  N  R  E  C  G  C  F  A  K  W
CIDR C9 ACGGGAAAATGTAGAAAAGTATGTAAAAATCCATGTGAATGTTATAAACGGTGGATTGAAAA AAA
 T  G  K  C  R  K  V  C  K  N  P  C  E  C  Y  K  R  W  I  E  K  K
CIDR C17 ACATGTATAAGAGGGTGTAAAAGTAAATGTGAATGTTTTCAAAAATGGGTAGATCAA A AAAGAA
 T  C  I  R  G  C  K  S  K  C  E  C  F  Q  K  W  V  D  Q  K  K  E
CIDR K39 TGTATAAGCAAATGTAATGGTAAATGTGATTGTTTCCAAAGATGGATTGATAAA AAAAACCGAA
 C  I  S  K  C  N  G  K  C  D  C  F  Q  R  W  I  D  K  K  K  T  E
CIDR K42 AATGACGCCAAATCAGGAAAATGTGAAAACAAATGTAATAGCAAATGTGATTGTTTTTTAAAATGG
 N  D  A  K  S  G  K  C  E  N  K  C  N  S  K  C  D  C  F  L  K  W
    270       280       290       300       310       320      330
     |         |         |         |         |         |         |
CIDR C1 AAAAAAAAAGAAGAATGGAAGGCAATAAAAGACCATTTTAAAAAGCAAAAAGATATTGAACAAGAG
 K  K  K  E  E  W  K  A  I  K  D  H  F  K  K  Q  K  D  I  E  Q  E
CIDR C32 GAAAAAAAAAAAGAAGAATGGAAGGCAATAAAAGACCATTTTAAAAAGCAAAAAGATATTGAACAA
 E  K  K  K  E  E  W  K  A  I  K  D  H  F  K  K  Q  K  D  I  E  Q
CIDR C10 GTTGTTAAAAAAAAAGACGAATGGGACAAAATAAAAGACCATTTTAACAAGCAAGAAAATATTGGG
 V  V  K  K  K  D  E  W  D  K  I  K  D  H  F  N  K  Q  E  N  I  G
CIDR C9 AAACCGAATTGGAAAAAATTAAAAGACCATTTTCGCAAGCAAAAAGATATTGGAGATGCAGCACAA
 K  P  N  W  K  K  L  K  D  H  F  R  K  Q  K  D  I  G  D  A  A  Q
CIDR C17 GAATGGAAAAATATCAAAATACATTTTCTGAAGCAAGACGATATTGGACAAGAAACACATTGTGAT
 E  W  K  N  I  K  I  H  F  L  K  Q  D  D  I  G  Q  E  T  H  C  D
CIDR K39 TGGGAAAATATCAAAATACATTTTGGCAAGCAAGAAGATAT GAGAACAAATTGGAGAGGATACA
 W  E  N  I  K  I  H  F  G  K  Q  E  D  M  R  E  Q  I  G  E  D  T
CIDR K42 GTTGTACAAAAAAAAACCGAATGGAAAAATATCAAAATACATTTTGGGAACCAATATTTTGTCAAG
 V  V  Q  K  K  T  E  W  K  N  I  K  I  H  F  G  N  Q  Y  F  V  K
        340       350       360       370       380       390
         |         |         |         |         |         |
CIDR C1 ACACATTGTGATCCTGGCGTAACTCTTGAATTACTTTTTATGAACGACGAACTTTTGAAAAATATT
 T  H  C  D  P  G  V  T  L  E  L  L  F  M  N  D  E  L  L  K  N  I
CIDR C32 GAAACACATTGTGATCCTGGCGTAACTCTTGAATTACTTTTTATGAACGACGAACTTTTGAAAAAT
 E  T  H  C  D  P  G  V  T  L  E  L  L  F  M  N  D  E  L  L  K  N
CIDR C10 CAAAACGTAGGTTTTATCGAATTTAATCACTATGGAGTTCTTGAAGGTGTTTTGGACAAAGATGAA
 Q  N  V  G  F  I  E  F  N  H  Y  G  V  L  E  G  V  L  D  K  D  E
CIDR C9 CGTGAAATGACCCTTAATATTACTTTAAATAATAATTTTTTGAATGATATTAAAGATGCTTATCCA
 R  E  M  T  L  N  I  T  L  N  N  N  F  L  N  D  I  K  D  A  Y  P
CIDR C17 CCTGGCGTAACTCTTGCAGCTGTTTTGGAGGAAGACAAACTTTTGAAAATTATTCAGGATACTTAT
 P  G  V  T  L  A  A  V  L  E  E  D  K  L  L  K  I  I  Q  D  T  Y
CIDR K39 GATCCTGGCATAATTCTTGAAGGTGTTTTGAATTTTGAGAATCTTTTCAAAAATATTAAAGATACT
 D  P  G  I  I  L  E  G  V  L  N  F  E  N  L  F  K  N  I  K  D  T
CIDR K42 CAAGACGGTTTCGACTTAGGAATGAATTCTCCTGATGTTGTTCTTGAATTACTTTTGGAGAAAAAT
 Q  D  G  F  D  L  G  M  N  S  P  D  V  V  L  E  L  L  L  E  K  N
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  400       410       420       430       440       450       460
   |         |         |         |         |         |         |
CIDR C1 AAAGATACTCATGCGAATGCAGATGACATAAAACACATTGAGGCACTGTTGCAAGAAACAGTTTTT
 K  D  T  H  A  N  A  D  D  I  K  H  I  E  A  L  L  Q  E  T  V  F
CIDR C32 ATTAAAGATACTCATGCGAATGCAGATGACATAAAACACATTGAGGCACTGTTGCAAGAAACAGTT
 I  K  D  T  H  A  N  A  D  D  I  K  H  I  E  A  L  L  Q  E  T  V
CIDR C10 CTTTTGAAAAATATTAAAGATACTCATGCGGATGCAAAGGACATAGAAAGAATTGATAAAATGTTG
 L  L  K  N  I  K  D  T  H  A  D  A  K  D  I  E  R  I  D  K  M  L
CIDR C9 GTCAAACAACAGCTGCAGAAAATTGAAGAACGTTTGAAAGATAAAATGCAGGAAGATTTTATTTTT
 V  K  Q  Q  L  Q  K  I  E  E  R  L  K  D  K  M  Q  E  D  F  I  F
CIDR C17 GGGAATACAGAGGAAACAAAACACCTTCGCCAAATGTTGCAACAAGCAGGCGTTGTTGGTGGTGTT
 G  N  T  E  E  T  K  H  L  R  Q  M  L  Q  Q  A  G  V  V  G  G  V
CIDR K39 TATGGGGACGTAAAAGAAATAGATCACATTAAGAAACTGTTGGAAGATGAAGAAAATGTTGGTGGC
 Y  G  D  V  K  E  I  D  H  I  K  K  L  L  E  D  E  E  N  V  G  G
CIDR K42 TTACTTTTGGAAATTATTAAAGATACTCATGCGAATGCAAAGGAAGATGAAATAAAAAACATTGAT
 L  L  L  E  I  I  K  D  T  H  A  N  A  K  E  D  E  I  K  N  I  D
      470       480       490       500       510       520
       |         |         |         |         |         |
CIDR C1 GATGGTGTTGCTGCTGGCGGTCCTGGTGGTGCTGGTAGTTATAAGTGTACTGAAGGTGCCAAGGGC
 D  G  V  A  A  G  G  P  G  G  A  G  S  Y  K  C  T  E  G  A  K  G
CIDR C32 TTTGATGGTGTTGCTGCTGGCGGTCCTGGTGGTGCTGGTAGTTATAAGTGTACTGAAGGTGCCAAG
 F  D  G  V  A  A  G  G  P  G  G  A  G  S  Y  K  C  T  E  G  A  K
CIDR C10 CAACAAGCAGGTGTTGTTGGTGGTGGTCGTGGTGGCGAAAATAATACCATAATTGATAAATTACTA
 Q  Q  A  G  V  V  G  G  G  R  G  G  E  N  N  T  I  I  D  K  L  L
CIDR C9 GAGAGAACGAAAACATCAATTGATAAATTACTACAAGGTACC
 E  R  T  K  T  S  I  D  K  L  L  Q  G  T
CIDR C17 GTTGGTAGTGGTGTTGGTGGTACC
 V  G  S  G  V  G  G  T
CIDR K39 GAACATAATACCACAATTGATAAATTACTACAAGGTACC
 E  H  N  T  T  I  D  K  L  L  Q  G  T
CIDR K42 AAAATGTTGCAAGAAACAAGTGGCAGTGGTGATAAATTACTACAAGGTACC
 K  M  L  Q  E  T  S  G  S  G  D  K  L  L  Q  G  T
530       540       550       560       570
 |         |         |         |         |
CIDR C1 AAACATAATACTAAAATTGATAAATTACTACAAGGTACC
 K  H  N  T  K  I  D  K  L  L  Q  G  T
CIDR C32 GGCAAACATAATACTAAAATTGATAAATTACTACAAGGTACC
 G  K  H  N  T  K  I  D  K  L  L  Q  G  T
CIDR C10 CAAGGTACC
 Q  G  T
Legend to Figure 4.6
The sequences of 7 CIDR domains (5x cDNA, 2x gDNA) are given.
polyA-stretches of all sequences are in bold letters (position 250 to 280), the stop codons at
position 305 in CIDR K39 and at position 303 in CIDR C1 are indicated in bold, the mutation
(Pos. 122) of CIDR C17, which led to a stop-codon is shown in bold letters, and the putative
site of recombination of CIDR C32 (position 197 to 210) is underlined.
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Figure 4.7      Aligned AA sequences of 12 CIDR domains
1        10        20        30        40        50        60        70
|        |         |         |         |         |         |         |
L40608 --EWKCYKGEDVVKVGHDEDDEEDYENVKNAGGLCILKNQKKNKEEGGNTSEKEPDEIQKTFNPFFYYWVAHMLKDSI
L40609.3 --KWKCY-------------------N-KNSDY--------NNCEMNISSYKDSTDANVMLSVECFHSWAKNLLIDTI
L40609.2 --QWKCYYGD------K-EYEVC-TLE---------------NRNKSEEDP----EEIQKTFHNFFYFWIRHLLNDSI
L42636 --KWQCYYD-------EHRPSSK-NNN---------------NCVEGTWDKFTQGKQTVKSYNVFFWDWVHDMLHDSV
U27338 --IWKCHYDD------NGTDDQTDDSN---------------DCVLGDWGNLTKED-KIMSYNAFFWMWVHDMLIDSI
CIDR C1 GSKWKCYYDE------NEKNSEK--NN---------------NCVEGTWDTFTQGK-KVKPYNPFFWDWVYHMLHDSL
CIDR C32 GSKWKCYYDE------HKPSS--KNNN---------------NCVEGTWDKFTQGKQTVKSYNVFFWDWVHDMLHDSV
CIDR C10 GSKWKCYYDE------HKPSS--KNNN---------------NCVEGTWDKFTQGKQTVKSYNVFFWDWVHDMLHDSV
CIDR C9 GSKWKCYYDE------SKESGQ---NN---------------NCILGKWEDFT-GNEDVTSYNVFFYNSIIEMLNDSI
CIDR C17 GSKWNCYYDD----------S--DNSN---------------NCVQREWKDFQKG-QKVTSYNAFFWK*VHDMLIDSM
CIDR K39 GSKWKCYYEK------------TDKSN---------------NCILGKWEKFQKG-QEVMVYHPFFWSWVTEMLDDSI
CIDR K42 GSKWKCYYEK------KNEKDGG-KDI---------------NFCVLQDDKARTSEEKSMHYNSFFWDWVYHMLHDSL
Consensus    W*CY*                  *               N*                  * FF  **  *L DS
 80        90       100       110       120       130       140       150
 |         |         |         |         |         |         |         |
L40608 HWKKKLQRCLQNGNRIK-CG-NNKCNNDCECFKRWITQKKDEWGKIVQHFKTQ-NIKGRGGSDNTAELIPFDHDYVLQ
L40609.3 KWEHQLKNCINNTNVTY-CES--KCIKNCECYEKWIKRKEHEWEKVKNVFGNNNRM-SYIYYNNLSRVFDSFLFQVMF
L40609.2 EWRDKINNCIEKAKEGK-CKN--ECKTDCGCFQRWIGKKKEEWGEIKKHFKTQ------DGFSIFGNNYDFVLENVLN
L42636 EWKTELSKCINNNTNGNTCRNNNKCKTDCGCFQKWVEKKQQEWMAIKDHFGKQTDI-VQQKGLIVFSPYG-VLDLVLK
U27338 KWRDEHGRCINKDKGK-TCIK--GCNKKCICFQKWVEQKKTEWGKIKDHFRKQKDI-PKDWTHDD---FLQTLL---M
CIDR C1 DWRNELGSCIDNAKSG-QCEN--KCNSKCECFERWVEKKKEEWKAIKDHFKKQKDI-EQE-THCD---PGVTLELLFM
CIDR C32 EWRERLNSCINNAKSG-QCEN--KCNSKCECFERWVEKKKEEWKAIKDHFKKQKDI-EQE-THCD---PGVTLELLFM
CIDR C10 EWRERLNSCINNAKSQN-CKNN-KCNRECGCFAKWVVKKKDEWDKIKDHFNKQENI-GQNVGFIEFNHYG-VLEGVLD
CIDR C9 EWKDKLDICINN--KTGKCRK--VCKNPCECYKRWIEKKKPNWKKLKDHFRKQKDI-G------DAAQREMTLNITLN
CIDR C17 QWRDEHGKCTNKDNDY-TCIR--RCKSKCECFQKWVDHLKEEWKNIKIHFLKQDDI-GQE-THCD---PGVTVAAVLE
CIDR K39 KWRKELDNCLKNENK--QCIS--KCNGKCDCFQRWIDKKKTEWENIKIHFGKQEDMREQIGEDTD---PGIILEGVLN
CIDR K42 NWRKQLGNCINDAKSG-KCEN--KCNSKCDCFLKWVVQKKTEWKNIKIHFGNQYFV-KQDGFDLGMNSPDVVLELLLE
Consensus  W   *  C*        C     C*  C C* *W*  K* EW  *K HF  Q                   *
  160       170       180       190       200       210       220
   |         |         |         |         |         |         |
L40608 YNLQEEFLKGDSEDASEEKSENSLDAEEAEELKHLREIIESEDNNQEASVGGGVTEQKNIMDKLLNYE         1
L40609.3 A--LDQDEKGKWDQFTEDLKKKFEPSK----------------------TNTPTGKSQDAIEFLLDHL         2
L40609.2 IDELFQDITEAYGNSQKI--QGIKDTLA------KKKAADDA------------TEQKNTIDLLFEYD         3
L42636 GGNLLQNIKDVHGDTDDI--KHIKKLLDEEDAVAV----------------VLGGKDNTTIDKLLQHE         4
U27338 KDLLLEIIQDTYGDANEI--KRIEALLEQAGVGGIDFAAL---AGLY--TKGFVAEKDTTIDKLLQHE         5
CIDR C1 NDELLKNIKDTHANADDI--KHIEALL-QETVFDGVAAGGPGGAGSYKCTEGAKGKHNTKIDKLLQGT         6
CIDR C32 NDELLKNIKDTHANADDI--KHIEALL-QETVFDGVAAGGPGGAGSYKCTEGAKGKHNTKIDKLLQGT         7
CIDR C10 KDELLKNIKDTHADAKDIER--IDKMLQQAGVVGG----------------GRGGENNTIIDKLLQGT         8
CIDR C9 NNFLND-IKDAYP-VKQQLQK-IEERLKDKMQEDFIFER-----------------TKTSIDKLLQGT         9
CIDR C17 EDKLLKIIQDSYGNTE--ETKHLRQMLQQ--------AGVVGGV------------VGSGGGKLLQGT        10
CIDR K39 FENLFKNIKDTYGDVK--EIDHIKKLLEDE--------------------ENVGGEHNTTIDKLLQGT        11
CIDR K42 KNLLLEIIKDTHANAKEDEIKNIDKMLQET-------------SGSG--------------DKLLQGT        12
Consensus    *   ***            *   *                                 ***LL*
Legend to Figure 4.7
The AA sequence of 12 CIDR domains is shown: The sequences 1 to 5 are the same as in
Figure 4.5 (see references noted there). These sequences were aligned with the 6 expressed
CIDR domains and with the sequence of the clone CIDR C17, a clone with an internal stop
codon. The cysteine-rich motif is underlined. The consensus sequence is defined as follows:
- bold letter: AA were identical in at least 11 of 12 CIDR domains.
- asterix (*): AA were identical in at least 9 of 12 CIDR domains, or only 2 different AAs
were found in the 12 sequences analyzed.
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4.4.3. Analysis of the expression of 6xhis-tagged var ene
domains
10 DBL1 domains (see Figure 4.4) and 6 CIDR domains (see Figure 4.6) were
expressed as 6xhis-tagged proteins. All but two domains could be isolated and purified under
native conditions (3.2.5.4. and 3.2.5.5.). DBLs 4 and CIDR C9 were isolated and purified
under denaturing conditions. All 16 domains were subsequently dialysed against PBS.
The size of all 16 purified domains ranged from 18 kDa (DBL16.2) to 28 kDa (CIDR C32).
In a preliminary experiment, the domains CIDR C1, CIDR C10, CIDR K39 and CIDR K42
were recognized on a western blot by an ahis-t g mAb (PentaHis, see Table 3-V), as well as
by pooled human serum from malaria exposed adults (Table 3-VII).
After storage at -20°C, some dialysed protein fractions precipitated, therefore the
protein concentration of all samples was evaluated photometrically and the samples were
diluted with PBS to a final concentration of 20 µg / ml and stored again at -20°C. In that
concentration no further precipitation was observed. All 16 expressed, purified and diluted
var gene domains were subsequently used in binding assays as described in 3.2.5.6.
4.4.4. Results of the IFAs, performed with 6xhis-tagged var
gene domains
The expressed and purified 6xhis-tagged var ene domains were tested in 13 IFAs for
binding to L-huICAM-1 cells, C32 cells, and L cells as a negative control (see 3.2.5.6.). Two
assays were additionally performed with CHO-huCD36 and CHO-huICAM-1 cells. All these
assays never gave clear reliable results, but some information, which is summarized below:
- The positive controls (OKM*5 on C32 cells and MEM112 on L-huICAM-1 cells) gave a
specific, clear signal, however, OKM*5 did not detect fixed C32 cells.
- The negative control using the aHis mAb without proteins resulted in a light back
ground on all cell types used, whereas OKM*5 (on L-huICAM-1 cells and L cells) or
MEM112 (on C32- and L cells) showed no background.
- From the 2nd IFA on, cells were always preincubated in PBS / 5% FCS, PBS / 5%
drymilk or in Binding medium, which decreased the background.
- No difference was found between applying the proteins in PBS / 0.5% FCS pH 6.3 or pH
7.3 and applying the proteins in Binding Medium pH 7.0.
- In three assays, C32 cells, incubated with CIDR domains and aHis mAb, showed
staining, compared to C32 cells with aHis mAb only, to C32 cells, incubated with DBL1
domains and aHis mAb, and to L-cells incubated with CIDR domains and aHis mAb,
indicating binding of CIDR domains to C32 cells.
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After these assays, it was concluded that:
1) the assays should be analyzed fluorcytometrically, since FACScan analysis uses unfixed
cells and can be evaluated quantitatively.
2) unlike L-huICAM-1- and C32 cells, the cells, used in the following protein-binding assays,
should only differ in the expression of a single, distinct surface molecule, therefore, only
three types of cells (CHO-huCD36, CHO-huICAM-1 and untransfected CHO cells) were
used for further assays.
4.4.5. Results of the FACScan analysis, performed with 6xhis-
tagged var gene domains
All expressed and purified 6xhis-tagged v r ne domains were tested for binding to
cells expressing both, huICAM-1 and CSA (CHO-huICAM-1 cells), and cells expressing
both, CD36 and CSA (CHO-huCD36 cells), as well as cells expressing CSA only (CHO
cells). In all assays, 10'000 cells were analyzed for each determination, except in one, where
5'000 cells were used (see Figure 4.10).
4.4.5.1. Binding of CIDR domains to CHO-huCD36-, CHO-huICAM-1-
and CHO cells
Initially, FACS analysis showed that all 6 recombinant CIDR-domains bound to
CHO-huCD36 cells in a dose-dependent manner (Table 4-XI, Figure 4.8). Binding affinity
varied, with CIDR C1 binding being the strongest (9x stronger than ahis-antibody without
protein) and CIDR K39 the weakest (2.5 x control). Subsequently, it was shown that all
CIDR domains also bound to non-transfected CHO cells (Table 4-XI) and CHO-huICAM-1
cells (data not shown), suggesting that binding was mediated through CSA.
At a concentration of 20 µg/ml, all CIDR-domains bound to CHO-huCD36 cells but at a
concentration of 2 µg/ml binding was only detectable by FACScan with CIDR C1 and CIDR
C32 (Table 4-XI).
In the following figures (Figure 4.8 to 4.11) the analysis of 10'000 (or 5'000) cells per
determination is visualized in histogram plots: The number of cells (Counts, Y-axis) is given
relative to the intensity of FITC-fluorescence (FL1-Height, X-axis)
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Figure 4.8      Binding of CIDR C1 domain to CHO-CD36 cells in a dose-dependent manner
Key Name
cd36/ah
cd36/2ugC1
cd36/1ugC1
cd36/0.2ugC1
Legend to Figure 4.8
Cytofluorogram of CHO-
CD36 cells, incubated with
decreasing concentrations of
CIDR C1 (20 µg/ml,
10 µg/ml, 2 µg/ml). Bound
protein was detected using an
ahis-tag mAb followed by
detection with FITC labelled
amouse IgG. As negative
control, ahis-tag mAb was
incubated without prior
incubation with protein.
Table 4-XI      Binding of all CIDR domains to CHO-CD36 and to CHO cells
amount of protein/
tested cells
ahis-tag
neg.
control
aCD36
pos.
control
CIDR
C1
CIDR
C9
CIDR
C10
CIDR
C32
CIDR
K39
CIDR
K42
20 µg/ml; CHO-CD36 4571 2684 1884 2609 1300 1712
10 µg/ml; CHO-CD36 4259 1482 1813 1838 826 1613
2 µg/ml; CHO-CD36 2128 724 829 1318 616 858
0 µg/ml; CHO-CD36 541 4215
7 µg/ml; CHO 1026 1563 806 995 842 911
0 µg/ml; CHO 394
Legend to Table 4-XI
Binding of different recombinant 6xhis-tagged CIDR-domains to CD36-transfected CHO
cells and non-transfected CHO cells was measured by cytofluorometry. Depicted is the
geometric mean fluorescence after staining with a  ahis-tag mAb followed by a FITC
labelled amouse IgG, as measured directly by the FACS analysis. As negative control ahis-
tag antibody was incubated in the absence of protein, as positive control CD36-transfected
CHO cells were incubated with OKM*5, a monoclonal antibody recognizing CD36. Both
controls were visualized using an amouse-IgG, labelled with FITC.
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4.4.5.2. Inhibition of protein binding by CSase ABC treatment of CHO
cells
To confirm binding to CSA, CHO and CHO-huCD36 cells were treated with CSase
ABC, and binding of 0.2 µg CIDR C1 to treated cells was compared to binding to untreated
cells (Figure 4.9). On both cell types binding was decreased after CSase ABC-treatment by at
least 90%. Increasing CSase ABC treatment (2 hours) and increasing the concentration of
CIDR-domains (0.5 µg CIDR C1, 1µg CIDR C10 or CIDR C32) resulted in a decrease of
binding up to 94% when compared to untreated cells (Table 4-XII).
There was no evidence of a difference in binding to CSase ABC treated CHO cells and CSase
treated CHO-huCD36 cells, indicating that CD36 was involved in the binding of CIDR C1
(Table 4-XII, Figure 4.9).
Figure 4.9       Binding of the CIDR C1 domain to CSase ABC treated cells
Key Name
cho/ah
cho/0.5ugC1
csase/0.5ugC1
Legend to Figure 4.9
Cytofluorogram of non-transfected
CHO cells, untreated and treated
with CSase ABC, and incubated
with 5 µg/ml CIDR C1.
Bound protein was detected using
an ahis-tag mAb followed by
detection with FITC labelled
amouse IgG. As negative control,
ahis-tag mAb was incubated
without prior incubation with
protein.
Note:
The negative control in Figure 4.9 (thin line) showed a typical, rather small additional peak,
which was often found with all CHO cell types used, but only when the anti 6xHis mAb was
involved. The peak was independent of CSA, since both, CSase ABC-treated and untreated
cells, showed the same peak. However, this peak was dependent on trypsination: the longer
the cells were incubated in presence of Trypsin-EDTA solution, the smaller was the peak.
Therefore it was concluded, that the anti 6xHis mAb interacts with a trypsin-sensitive protein,
present on the surface of all CHO cell types used.
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Table 4-XII     Binding of CIDR domains to CSase ABC treated and untreated CHO cells
tested cells treatment of cellsconcentration / proteinmean
fluorescence
percentage
of binding
CHO-CD36 none 0 µg/ml 661 0 %
CHO-CD36 none 2 µg/ml CIDR C1 983 100 %
CHO-CD36 CSase (1 hour) 2 µg/ml CIDR C1 616 -13 %
CHO none 0 µg/ml 467 0 %
CHO none 2 µg/ml CIDR C1 842 100 %
CHO CSase (1 hour) 2 µg/ml CIDR C1 500 8.8 %
CHO none 0 µg/ml 563 0 %*
CHO none 5 µg/ml CIDR C1 2768 100 %*
CHO CSase (2 hours) 5 µg/ml CIDR C1 687 5.6 %
CHO none 10 µg/ml CIDR C10 1952 100 %*
CHO CSase (2 hours) 10 µg/ml CIDR C10 732 12.2 %
CHO none 10 µg/ml CIDR C32 1691 100 %*
CHO CSase (2 hours) 10 µg/ml CIDR C32 765 17.9 %
Legend to Table 4-XII
Comparison of binding of three different CIDR-domains to CD36-transfected CHO cells and
non-transfected CHO cells, either with or without prior CSase ABC treatment. Binding is
measured by cytofluorometry using ahi -tag mAb followed by incubation with FITC-labelled
amouse-IgG. Depicted is the geometric mean fluorescence and remaining percentage of
binding after treatment. Percentage of binding was calculated using the value from untreated
cells as maximum (100%) and the value of the negative control (ahis-tag mAb only) as
minimum (0%). *Note that two independent experiments were carried out and the negative
controls were used accordingly.
4.4.5.3. Competition with soluble CSA and -HPS as a control
In parallel, 0.7 µg of each of the 6 CIDR-domains were tested against untreated CHO
cells, CSase-treated CHO cells (1 hour treatment), and untreated CHO cells with 200 µg
soluble CSA as competitor. Binding was inhibited up to 100% (CIDR C10) by 200 µg
soluble CSA, whereas CSase-treatment resulted in 67 to 89 % inhibition of binding. CIDR
C32 was also tested against untreated CHO cells and with 50 µg CSA or 200 µg HPS as
competitor. Competition with 50 µg CSA resulted in 62.4% inhibition of binding, whereas
binding of the same domain was only little affected (18.1 % inhibition) by 100 µg HPS
(Table 4-XIII, Figure 4.10).
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Figure 4.10     Binding of CIDR C32 domain to CHO cells in presence of free CSA
Key Name
cho/ahis
cho/C32
cho/C32/200csa
Legend to Figure 4.10
Cytofluorogram of non-
transfected CHO cells,
competitively incubated
with 7 µg/ml CIDR C32 and
200 µg soluble CSA.
Binding was compared
against incubation of protein
without addition of soluble
CSA. Bound protein was
detected using an ahis-tag
mAb followed by de-
tection with FITC labelled
amouse IgG. As negative control, ahis-tag mAb was incubated without prior incubation with
protein. In this assay, 5'000 cells were analyzed for each determination (see 4.4.5.)
Table 4-XIII    Competitive binding of CIDR domains and soluble CSA to CHO cells
assay
condition
ahis-tag
mAb
CIDR
C1
CIDR
C9
CIDR
C10
CIDR
C32
CIDR
K39
CIDR
K42
geometric mean of fluorescence (percentage of remaining binding)
none 3.94
(0)
10.26
(100)
15.63
(100)
8.06
(100)
9.95
(100)
8.42
(100)
9.11
(100)
CSase n.d. 5.98
(32.3)
5.22
(10.9)
5.20
(30.6)
4.90
(16.0)
5.10
(25.9)
4.64
(13.5)
+ 200 µg CSAn.d. 5.26
(20.9)
4.75
(6.8)
3.81
(-3.2)
5.16
(20.3)
5.23
(28.8)
5.29
(26.1)
+ 50 µg CSA 6.20
(37.6)
+ 100 µg HPS 8.86
(81.9)
Legend to Table 4-XIII
Competition was measured by cytofluorometry using ahis-tag mAb followed by incubation
with FITC-labelled amouse-IgG. Depicted is the geometric mean of fluorescence and
remaining percentage of binding. Percentage of binding was calculated using the value from
assays without CSase treatment or addition of soluble CSA as maximum (100%) and the
value of the negative control (ahis-tag mAb only) as minimum (0%). In all assays CIDR
domains were used at a concentration of 7 µg/ml.
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4.4.5.4. Binding of DBL1 domains to CHO-huCD36- and CHO-
huICAM-1 cells
In IFAs, using DBL1- and CIDR domains, CIDR domains bound to C32 cells,
whereas the DBL1 domains showed no binding. However, the binding of DBL1 domains to
CHO-huCD36 and CHO-huICAM-1 cells was also investigated in FACScan analysis assays.
In one assay, 1 µg of two DBL1 domains (DBL16.1 and DBL16.2) was found to bind
specifically to CHO-huICAM-1 cells, but not to CHO-huCD36 cells (Figure 4.11); 1 µg of all
other DBL1 domains did not bind neither cell type (data not shown). But this binding could
never be repeated in several subsequent assays, although different pHs in the binding and
washing steps were tried (pH 6.3, pH 6.8, pH 7.3 and pH 7.8), and different concentrations of
DBL1 domains were tested (1 µg, 2 µg and 5 µg per tube).
Figure 4.11     Binding of 2 DBL1 domains to CHO-huICAM-1 cells
Row 1 Row 2 Row 3 Row 4
Legend to Figure 4.11
The cytofluorograms in column 1 represent the negative controls (ahis-tag mAb only) on
CHO-huICAM-1 cells (upper row) and on CHO-huCD36 cells (lower row), whereas the
corresponding positive controls are shown in column 4. The DBL16.1- and DBL16.2 domain
bound specifically to CHO-huICAM-1 cells, but not to CHO-huCD36 cells (column 2 and 3).
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5. Discussion
The understanding of the molecular mechanisms leading to sequestration and thereby
to vital organ failure in human P. f lciparum infections is fundamental in the comprehension
of this disease. Precise knowledge of the parasite-derived ligands and the host cell receptors
involved, may firstly point out specific host and parasite factors, that indicate a risk for
development of severe disease and secondly may offer novel concepts in therapeutic
strategies by developing defined molecules that interfere with or reverse parasite
cytoadherence.
Although many receptors expressed on the surface of endothelium cells which line the
microvasculature have been identified, the parasite-derived adhesins, expressed on the
surface of iRBCs are still much less well studied. Many aspects are hampering the analysis of
these adhesins: limited parasite material, (possible) antigenic variation of these adhesins,
(possible) interaction of more than one parasite-derived protein in mediating adhesion, and
the additional influence of parasite-modified, but not parasite-derived proteins, like the
modified erythrocyte band 3 anion transporter, also termed Pfalhesin.
It was the aim of this thesis to identify parasite-derived ligands which are involved in
cytoadherence and to provide unequivocal evidence for the causality of their expression and
an adherent phenotype.
The following discussion is divided in two parts: the first part discusses the methodological
aspects of the approaches pursued during this thesis and discusses the results of the four
approaches, which will be compared to recently published results from similar studies. In the
second part, it will be discussed, whether and how these results fit into the already existing
knowledge of cytoadherence.
5.1. Methodology
The schizont-specific P. falciparum cDNA expression library
A good P. falciparum cDNA expression library was the fundamental basis of all four
approaches pursued during this thesis, especially of the two shotgun approaches. The
minimal condition this library had to satisfy, was to carry full-length plasmodial genes, since
this is the essential prerequisition for the expression, the correct transport, and introduction of
proteins into the COS 7 cell membrane. To guarantee superior quality of the library, it was
produced commercially.
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But, despite the fact that provided mRNA was of good quality as estimated by gel
electrophoresis (4.1.2.), 60% of the clones of the cDNA library did not contain an insert and
an additional 12% of the plasmids were recombinant or carried an insert which was not
correctly ligated into the polylinker. Since cultivation of cDNA clones never resulted in the
loss of a previously identified insert or in mutation of a plasmid, it can be assumed, that
cDNA clones, carrying an insert, were stable and that the high ratio of recombined or mutated
vector was possibly already present in the original cDNA.
Nevertheless, every gene or domain which was screened for in the cDNA library was
present (MSP1, MSP2, DBL1-, CIDR-, and ATS-domain). But no full-length var gene was
identified in the library by PCR or colony hybridization. No insert larger than 4.5 kb was
found in the library which might be explained by mRNA breakage, or premature termination
of cDNA synthesis. Since priming of the first strand cDNA synthesis started at the polyA-
tail, all inserts carrying a DBL1-domain, should also include the ATS domain, excluding
premature termination as sole explanation.
P. falciparum DNA exhibits an exceptionally high AT content of 69% in coding and 86% in
non-coding regions (Weber, 1987). This high AT content could lead to false or internal
priming of the oligo dT primer (18 T residues and a Not I restriction site). This was actually
confirmed by sequencing of clone PD 4.14.1 (see: 4.3.5, Figure 4.1), which contained a
DBL1 domain with a stretch of 6 Lysines, encoded by 17 consecutive adenosines. The size of
this insert was 1.6 kb, which indicated that the mRNA was intact into the 5' UTR of this var
gene.
At the beginning of this thesis and after the first description of the var gene family, it
was calculated, that the large repertoire of var genes accounts for 2-6% of the haploid
genome, and it was proposed, that the var gene family encodes for PfEMP-1 or a similar
variant surface molecule (Su t al. 1995). Since adhesion of iRBCs is manifested some 16-20
hours into the intraerythrocytic cycle, it was assumed that expression of var genes would
reach its maximum in the early trophozoite stage. Hence, for the preparation of cDNA
synchronized cultures at this stage were used. But recent studies (Chen et al. 1998b and
Scherf et al., 1998) indicate, that var gene mRNA is transcribed from many var gene loci
during ring stages, whilst probably only one var gene seems to be expressed in the late
trophozoite stage. In cultures, which were selected by panning for binding to a certain
receptor, mostly a single var gene transcript is found (Scherf et al., 1998). As a consequence,
a cDNA library of unsynchronized P. falciparum cultures might contain more different var
genes, than a library of synchronyzed cultures, but since the synchronized culture bound to
huICAM-1 and C32 cells prior the mRNA isolation (see 4.1.1.) adhesion mediating vargenes
were present in the mRNA. 6 different DBL1 and 4 different CIDR domains were found in
the library, indicating the presence of at least 6 different var g n  mRNAs in the
synchronized but not selected cultures.
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Picking the plasmids
Cell-cell adherence 
            assay
C32 cells L-ICAM-1 cells
-high copy number  
of plasmids 
 
-expression of plas- 
modial proteins 
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COS7 cell membrane
72 hours later:
electroporation
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¾
¾ ¾
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¾
¾
COS 7 cell cDNA library
positive COS 7 cell  
with 4 attached L- 
ICAM-1 cells
negative COS 7 cells 
and background of  
screening cells
Hirt extraction of  
cDNA clones
T
ransfection
 Figure 5.1  Schematic overview of the shotgun approach (1)
 Methodology of the shotgun approaches)
A  overview of a simplified shotgun approach (1) is given in Figure 5.1:
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Since none of the positive first screens could be confirmed in a second screen in this
approach, each step of it was extensively tested and improved:
Successful transfection was shown by the presenc  of plasmids in picked cells of first-
screen adherence assays and by the presence of plasmids in cells randomly picked as controls
later on (4.1.5.2.) and the GFP reporter system was introduced to estimate transfection
efficacy. Using this system, it was shown that LipoTaxi (Stratagene) was superior in both,
transient and stable transfection. Compared to the initially used chloroquine / DEAE dextran
method, efficacy was up to 100-fold higher and cells were healthier due to a limited toxicity.
Although transfection rates were lower than expected, its highly unlikely that failure in the
second screens was due to the transfection efficacy.
Picking and plasmid isolation methods were also improved by using a needle scalpel
blade and with the addition of glycogen as carrier in precipitation steps (Tracy, 1981).
Furthermore, plasmid size did not occur to be limited by electroporation since clone var 5.4.1
(8.4 kb) and huICAM-1-EGFP (7.6 kb) were frequently and successfully used to transform E.
coli cells.
Although COS 7 cells have been used to express plasmodial genes (Elliott et al.,
1990; Chitnis and Miller, 1994; Alano et al., 1995; Smith et al., and Kappe et al., both 1998)
and also generally is believed to be an easy and efficacious expression system, there are
doubts, whether it would fully allow such an approach as conducted.
Therefore, four control constructs were made to test expression:
-An MSP2 gene, amplified by PCR from the cDNA, was ligated correctly into the pcDNA3.1
and the pcDNA3.1-EGFP vector. Western blots with aGFP revealed a band, the size of the
GFP protein alone, indicating either degradation of the MSP2 gene or mutation of the second
construct.
- The N-terminus of MSP1 (strain Ro71) was ligated correctly into pcDNA3.1 and into
pRE4. Both constructs were used to transfect COS 7 cells, but neither in western blots nor in
IFAs, was the N-terminus of MSP1 detected by the supernatant 9.22. Similarly, both the mAb
ID3 and DL6, failed to recognize the native HSVgD protein. This also implied, that the
transfected plasmids were not correctly transcribed and expressed.
- COS 7 cells were transfected with a pool of 22 different clones from the cDNA, which
carried an insert bigger than 1 kb. On a western blot, an additional band of 66 kDa was
detected using the serum pool from malaria exposed adults, giving the first evidence of an
expressed P. falciparum-protein in COS 7 cells.
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Previous reports on expressed plasmodial proteins in COS 7 cells, in three cases also used
pRE4 (Chitnis and Miller, 1994; Smith et al., and Kappe t al., both 1998). Hence,
expression of plasmodial protein in COS 7 cells occurs to be possible and the question
remains, why all the four expression controls failed.
There is evidence that the AT-richness of P. falciparum ay disturb gene expression
in other eukaryotic systems: Pan and colleagues (1999) synthesized a gene encoding MSP1
from the FCB-1 strain adjusted for human codon preferences with a AT content of 55% AT
instead of 74% AT, since the high AT content has prevented stable cloning of the parasite
derived MSP1 gene. It has been speculated that mRNA-instability motifs (AUUUA) might be
responsible for the failure of expression.
Shyu and colleagues (1991) identified an AU-rich element (ARE) in the 3' UTR of the
c-fos mRNA. They showed by mutation of the ARE that this sequence controls two steps in
the process of mRNA degradation: removal of the polyA tail and subsequent degradation of
the transcribed portion of the message, which appears to be dependent on AUUUA
pentanucleotides, which are obviously abundant in PlasmodiumDNA.
AU-rich sequences are found in the 3' UTR of most immediate early mRNAs and are present
in labile mRNAs which encode cytokines. A large body of data links the AUUUA
pentanucleotide to the selective degradation of these mRNAs (Alberta et al., 1994 and
Peng et al., 1996).
However, other studies claim that AUUUA pentanucleotide are not sufficient to
promote mRNA decay, but showed, that UAUUUAU, when present in three copies, is
sufficient to destabilize mRNA (Lagnado et al., 1994), others identified the nonamer
UUAUUUAUU as the key AU-rich sequence motif that mediates mRNA degradation
(Zubiaga et al., 1995). Recently, the mammalian ELAV proteins (HuR and HuA) were
identified to be implicated in AUUUA-mediated mRNA decay (Myer et al., 1997 and Atasoy
et al., 1998).
Of the previously expressed plasmodial genes in COS 7 cells, the coding region of the
mRNA of the expressed Pf7 protein contained no AUUUA motif, whereas the coding region
of the expressed Pf12 protein contained two AUUUA motifs (Elliott et al., 1990), whereas
the six domains of the P. vivax protein (Chitnis and Miller, 1994) and the A4VAR CIDR
domain (Smith et al., 1998), which were ligated into pRE4 and expressed in COS 7 cells,
contained again no AUUUA motif. On the other hand, the mRNA of the N-terminus of MSP1
(strain Ro71), which was used here as an expression control contained 6 AUUUA motifs
(see: Figure 5. 2). Since the mRNA decay occurs to be dependent on the number of AUUUA
pentanucleotides in the mRNA (Lagnado et al., 1994), it might be possible, that Pf12 could
be expressed in COS 7 cells, whereas the N-terminus of MSP1, containing 6 degradation
motifs, could not be expressed in this system.
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Figure 5.2      ATTTA motifs in the N-terminus of MSP1
  PvuII  |  KpnI  |
ctggac cagGGG GTACCATGAAGATCATATTCTTTTTAGTTCATTTCTGTTTTTTATTATAAATACACAATGTGTA
 L  D  Q  G  G  T  M  K  I  I  F  F  L  C  S  F  L  F  F  I  I  N  T  Q  C  V
                             HindIII  |                          Binding-site
ACACATGAAAGTTATCAAGAACTTGTCAAAAAACTAGAAGCTTAGAAGATGCAGTATTGACAGGTTATGGTTTATTT
 T  H  E  S  Y  Q  E  L  V  K  K  L  E  A  L  E  D  A  V  L  T  G  Y  G  L  F
for supernatant 9.22
CATAAGGAAAAAATGATCTTAAATGAAGGAACAAGTGGAACAGCTGTTACAACTAGTACACCTGGTTCAGGTGGTTCA
 H  K  E  K  M  I  L   N  E  G  T  S  G  T  A  V  T  T  S  T  P  G  S  G  G  S
GTTACTTCAGGTGGTTCAGGTGGTTCAGTTGCTTCAGGTGGTTCAGGTGGCTCAGTTGCTTCAGGTGGTTCAGGTGGC
 V  T  S  G  G  S  G  G  S  V  A  S  G  G  S  G  G  S  V  A  S  G  G  S  G  G
TCAGTTGCTTCAGGTGGCTCAGTTGCTTCAGGTGGTTCAGGTAATTCAAGACGTACAAATCCTTCAGATAATTCAAGT
 S  V  A  S  G  G  S  V  A  S  G  G  S  G  N  S  R  R  T  N  P  S  D  N  S  S
                          1st
GATTCAGATGCTAAATCTTACGCTGA TTAAAACATAGAGTTCAAAATTACTTGTTCACTATTAAAGAACTCAAATAT
 D  S  D  A  K  S  Y  A  D  L  K  H  R  V  Q  N  Y  L  F  T  I  K  E  L  K  Y
              2nd                                                3rd
CCCGAACTCTTTGATTTAACCAATCATATGTTAACTTTGTGTGATAATATCCATGGTTTCAAATATTTAATTGATGGA
 P  E  L  F  D  L  T  N  H  M  L  T  L  C  D  N  I  H  G  F  K  Y  L  I  D  G
                                               4th
TATGAAGAAATTAATGAATTATTATATAAATTAAACTTTTATTTTGA TATTAAGAGCAAAATTAAATGATGTATGT
 Y  E  E  I  N  E  L  L  Y  K  L  N  F  Y  F  D  L  L  R  A  K  L  N  D  V  C
GCTAATGATTATTGTCAAATACCTTTCAATCTTAAAATTCGTGCAAATGAATTAGACGTACTTAAAAAACTTGTGTTC
 A  N  D  Y  C  Q  I  P  F  N  L  K  I  R  A  N  E  L  D  V  L  K  K  L  V  F
GGATATAGAAAACCATTAGACAATATTAAAGATAATGTAGGAAAAATGGAAGATTACATTAAAAAAAATAAAACAACC
 G  Y  R  K  P  L  D  N  I  K  D  N  V  G  K  M  E  D  Y  I  K  K  N  K  T  T
ATAGCAAATATAAATGAATTAATTGAAGGAAGTAAGAAAACAATTGATCAAAATAAGAATGCAGATAATGAAGAAGGA
 I  A  N  I  N  E  L  I  E  G  S  K  K  T  I  D  Q  N  K  N  A  D  N  E  E  G
                                     5th and 6th mRNA degradation motif
AAAAGAAAATTATACCAAGCTCAATATGATCTTTCTA T ACAATAAACAATTAGAAGAAGCACATAATTTAATAAGC
 K  R  K  L  Y  Q  A  Q  Y  D  L  S  I  Y  N  K  Q  L  E  E  A  H  N  L  I  S
GTTTTAGAAAAACGTATTGACACTTTAAAAAAAAATGAAAACATAAAGAAATTACTTGAAGATATAGATAAAATTAAA
 V  L  E  K  R  I  D  T  L  K  K  N  E  N  I  K  K  L  L  E  D  I  D  K  I  K
                                                   ApaI |
ACAGATGCCGAAAAACTCACTACTGGAAGT AACCAAATCCTCTCCCTGAGGGcccaaggccccatacacgagcacc
 T  D  A  E  K  L  T  T  G  S  K  P  N  P  L  P  E  G  P  K  A  P  Y  T  S  T
Legend to Figure 5.2:
The sequence of the N-terminus of MSP1 of RO71 (capital letters) and flanking regions of
the HSV gD gene (small letters) are given. The primer sites for FW MSP1 Kpn and REV
MSP1 Apa are underlined, restriction sites and AA 42-53, recognized by mAb 9.22, are in
bold, and the 6 ATTTA pentanucleotides are bold and underlined.
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The failure to detect COS 7 cells expressing plasmodial genes and to confirm
adhesion in all second screens may indeed reflect that positive cells in a first screen might
have been artefacts. The discussed AT-richness also adds to these problems and the assays
can only be validated by constructing positive controls, either for the cell-cell adherence
assay (shotgun approach 1) or the detection by a mAb (shotgun approach 2).
A recent publication, using almost the same cell-cell adherence assay may shed light
on that matter: Smith and colleagues (1998) transfected COS 7 cells with A4VAR constructs,
ligated into the pRE4 vector, and grew COS 7 cells on coverslips. During the assay, the cells
were overlaid with 2 x 106 CHO-huCD36 or CHO-huICAM-1 screening cells. Binding was
allowed for 5 to 15 minutes, then the coverslips were flipped onto a stand and centrifuged
with 8 g to remove unbound screening cells. Although this wash step was probably harsher
than swirling the dish, Smith and colleagues still found 1% of untransfected COS 7 cells
having bound five or more CHO-huCD36 cells. This background would have been
considered as positive in our assays.
Despite the problems faced in this study, the cell-cell adherence assay can be useful
and might be used in the identification of plasmodial adhesins. A mammalian expression
system has distinct advantages compared to a bacterial expression system, since proteins are
correctly folded and structural epitopes can be detected. However, this expression system
proved to be difficult in shotgun approaches, using P. falciparum cDNA, but could be used to
investigate protein interactions of defined genes or parts of genes.
Methodology of the direct approaches
Since the assays of the direct approaches do not rely on expression of genes mediating
cytoadherence, the direct approaches can lead more successfully to identification of defined
genes. These defined genes can then be further analyzed using an eukaryotic transfection
system as has been shown recently (Smith et al., 1998). However, such a system requires an
already known sequence or sequence fragment for screening and thus will not identify
different and yet unknown genes like the shotgun screening in COS 7 cells which uses
functional properties for the identification.
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5.2. Discussion of the results
The main result of this thesis was the finding, that certain CIDR domains of var genes
can bind to chondroitin sulphate A (CSA) in a dose dependent manner. Under the same
conditions, binding of these CIDR domains to CD36, as previously described (Baruch et al.,
1997), and binding of DBL1 domains to CD36, huICAM-1 or CSA could not be shown.
All CIDR- and DBL1 domains, which were analyzed for their binding to CSA, CD36
and huICAM-1 were amplified by PCR and expressed in E. coli. But whether the sequences
of CIDR K23 and CIDR C25 had a PCR-derived mistake in their nucleotide sequence (see
4.4.2.) or were translated pseudo genes, or whether the sequence of the CIDR C32 domain
(identical to CIDR C10 for bp 1-211 and then identical to CIDR C1 for bp 194-567, see:
Figure 4.6) was a PCR-artefact or an example for diversification by recombination in
Plasmodium falciparum, the proteins encoded by these sequences bound to CSA. Two
additional facts concerning the nucleotide sequence of the var g ne domains were interesting:
1.) theoretically, the polyA-stretch, in which the mistakes of domains CIDR K23 and
CIDR C25 were found (see: Figure 4.6) could represent a motif for the slipping of DNA
polymerase to induce a frame-shift in the subsequent translation, analogue to the 'ribosomal
slipping site' (Wagner et al., 1990). Such a stretch could lead to a frame-shift into another
ORF and thereby altering the adhesive properties from CD36-binding to CSA-binding.
Although tempting, this theory could not be applied to the polyA-stretch of the CIDR
domains, since in all 6 expressed CIDR domains, both 'alternative ORFs' led to the
termination of the protein within 6 to 31 AAs.
2.) Of all CIDR domains, only CIDR C10 contained a ATTTA motif (position 351 to
355, Figure 4.6). Five DBL1 domains contained no ATTTA motif, but DBL16.1, DBL16.2,
DBLK3, DBLs4, and DBLs20 each contained one ATTTA motif (position 89 to 93, 90 to 94,
90 to 94, 44 to 48, and 101 to 105). These CIDR- and DBL1 domains could be ligated into
pRE4 and expressed as chimeric proteins on the surface of COS 7 cells, to analyze the
binding properties of correctly folded domains to any given receptor.
The E. coli expressed 6x his-tagged var gene domains might not be folded correctly
and were surely not glycosilated. However, when Baruch and colleagues (1997) identified the
CIDR domain to mediate binding to CD36, they expressed the var gene domains as
glutathione-S-transferase (GST)-fusion proteins in E. coli with purification on glutathione-
sepharose. The CIDR domain, denoted rC1-2, was immobilized on plastic and promoted
binding of CHO-huCD36 cells but not to untransfected CHO cells or CHO-huICAM-1 cells.
Thus, in their assays, rC1-2 and additional CIDR domains bound CD36, but not CSA,
whereas all CIDR domains, tested in this project bound CSA, but not CD36.
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To date, E. coli expressed var gene domains have been shown to bind to CD36 via
CIDR domains (Baruch et al., 1997), to CSA via CIDR domains (this thesis), and it had been
shown that antibodies to the CIDR domain and to the DBL3 domain of a CSA-binding
PfEMP-1 variant inhibited iRBC binding to CSA (Reeder et al., 1999). This leads to an array
of questions:
> Why did the CIDR domains described by Baruch and colleagues (1997) bind to CD36 but
failed to bind to CSA. Similarly, why did the CIDR domains, presented here bind to CSA
but not to CD36?
> Is the limited sequence diversity of the CIDR domain sufficient to generate ligands for
two different host receptors?
> Are there CIDR domains, which can bind to CSA and to CD36 simultaneously, or is this
binding exclusively determined for each CIDR domain, hence are there two subgroups of
CIDR domains?
> Can a CIDR domain switch its binding preference? And if so, how?
One possible answer to these questions lies in sequence comparison of different CIDR
domains: The CIDR domain, which was first described to bind to CD36, denoted rC1-2
(Baruch et al., 1997) corresponded to AA 576 to 755 of the MC PfEMP 1 gene (Baruch t
al., 1995). The CIDR-domains introduced in this work show homologies to AA 527 to 755 of
the MC PfEMP 1 gene, therefore include the CD36-binding domain sequence of rC1-2.
However, the domains described here were expressed as 6xhis-tagged proteins and showed
no binding to CD36 on transfected CHO cells. For this, it is important to note that our
forward primer used for amplification recognized a sequence up-stream of the binding site
described by Baruch et al. (1997), and coded for the amino acid sequence KWKCYY
(AA 1-6 in Figure 5.3). Baruch and colleagues used a forward primer coding for
KEDKIMSY (AA 33-40 in Figure 5.3), a sequence which they found to be important for the
correct folding of the protein in E. coli. Due to the observed sequence diversity, amino acids
31 to 39 in our CIDR-domains (XGX(2-3)V(K/T/M)SY) were not identical to the described
ones in rC1-2 (KEDKIMSY).
In their work, Baruch and colleagues (1997) studied 13 further GST-fusion proteins
corresponding to rC1-2 from 8 different parasite isolates, which they tested for binding to
CD36. They found an additional 3 proteins (all from the Malayan Camp isolate, but differing
in rosetting behaviour or the expression of knobs: MCR+, MCR-, and MCK-) which bound
strongly to CD36, 7 proteins which bound weakly to CD36, and 3 CIDR domains which did
not bind at all to CD36 (from the Palo Alto strain and from Dd2). None of the CIDR-
domains, which weakly bound or failed to bind to CD36 were tested for binding to CSA.
These additional 13 sequences were amplified with the degenerated forward primer UNI
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179-5', which bound 3' adjacent to 179-5' to the sequence coding for FFWXWVXXML
(representing AA 43-52 in Figure 5.3). Therefore, the KEDKIMSY motif was not 'imprinted'
on these domains, which might be responsible for the lack of binding to CD36 in some of
these domains. Apart from the cysteine-rich motif, Baruch and colleagues (1997) identified 5
additional regions of homology, which they suspected to be involved in CD36 binding (see
Figure 5.3). Homology in region five again is probably due to its use as a primer binding site.
All other regions of homology also show some degree of homology to the CIDR domains
described here, except region 4 which was only found in CIDR K39.
By using primers corresponding to KEDKIMSY, Baruch et al. (1997) might have
selected for a certain group of var genes containing this motif and thus with CD36-binding
properties. Or it might have profound effects on the folding, which again might lead to
CD36-binding. In turn, lack of this motif, despite complete presence of cysteins, might allow
alternative folding leading to CSA-binding. The question, whether two subgroups of CIDR
domains exist, or whether two alternative foldings of one PfEMP-1 variant can lead to both
phenotypes could be answered by evaluation of the active domain of different CIDR
domains. Strong evidence for the existence of two different genotypes being involved in the
binding phenotypes of CIDR domains was found recently: Two var-genes have been
identified conferring binding to CSA (Scherf et al. 1998, Reeder t al. 1999). In both cases,
expressed var-genes were isolated after selection on CHO cells, and a single var-gene-
transcript was identified. The varcsa-gene (strain FCR3) was located on chromosome 10 and
had an unusual small transcript of 4.4 kb (Scherf et al. 1998), whereas the var-CS2 transcript
(strain ItG2) was 8.1 kb long (Reeder et al. 1999). In both cases the change to a new var-gene
variant was accompanied by the loss of the original binding phenotype (CD36 or CD36 and
ICAM1, respectively). Since the change of adhesive phenotype was reflected in a switch of
the var gene expressed, it excludes a refolding of the expressed PfEMP-1 variant to switch
the binding phenotype.
If the CIDR-domain is involved in both CD36 and CSA binding, then co-existence of
binding motifs is expected. The location of binding motifs might overlap and might be
completely exclusive, thereby leading to subgroups of va -genes binding either to CSA or to
CD36. Using recombinant gene-fragments, as in this study, might provide evidence for the
involvement of various regions in binding. However, such approach will not allow the
analysis of more complex molecular interactions, i.e. the concerted action of two or more
domains. Reeder and colleagues (1999) showed that the major inhibition of binding was
observed with antibodies against DBL3, however, they also showed inhibition of CSA-
binding with antibodies against the CIDR-domain. The published sequence from var-CS2
(GenBankª accession number AF 134154) also contains homologies identified in this study
(Figure 5.3) and might be responsible for the binding of the CIDR-domains to CSA.
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Figure 5.3      Comparison of rC1-2 and varCS2 to the CIDR domains of this thesis
1        10        20        30        40        50
|        |         |         |         |         |
CIDR C1 KWKCYYDE-NEKNSEKNNN-CVEGTWDTFTQGK--KVKPYNPFFWDWVYHMLHDSLDWRN
CIDR C32 KWKCYYDEH--KPSSKNNNNCVEGTWDKFTQGK-QTVKSYNVFFWDWVHDMLHDSVEWRE
CIDR C10 KWKCYYDEH--KPSSKNNNNCVEGTWDKFTQGK-QTVKSYNVFFWDWVHDMLHDSVEWRE
CIDR C9 KWKCYYDES--KESGQNNN-CILGKWEDFT-G-NEDVTSYNVFFYNSIIEMLNDSIEWKD
CIDR K39 KWKCYY------EKTDKSNNCILGKWEKFQKG--QEVMVYHPFFWSWVTEMLDDSIKWRK
CIDR K42 KWKCYYEKKNEKDGGKDINFCVLQD-DK-ARTSEEKSMHYNSFFWDWVYHMLHDSLNWRK
rC1-2                                 KEDKIMSYNAFFWMWVHDMLIDSIKWRD
var CS2                                         NDFFNFWVAHMLKDSIYWKK
Consensus KWKCYYDE   K S KNNN CV G WDKFT G    V  YN FFW WV  ML DS  WR
Regions                                           <    Region 1   >
60        70        80        90       100       110       120
|         |         |         |         |         |         |
ELGSCIDNAKSGQCEN-KCNSKCECFERWVEKKK-EEWKAIKDHFKKQKDI-EQETHC----DPGVTLELL
RLNSCINNAKSGQCEN-KCNSKCECFERWVEKKK-EEWKAIKDHFKKQKDI-EQETHC----DPGVTLELL
RLNSCINNAKSQNCKNNKCNRECGCFAKWVVKKKD-EWDKIKDHFNKQENI-GQNVGFIEFNHYGV-LEGV
KLDICINN-KTGKCRK-VCKNPCECYKRWIEKKKP-NWKKLKDHFRKQKDI-G-DAAQREM-----TLNIT
ELDNCLKNENK-QCIS-KCNGKCDCFQRWIDKKKT-EWENIKIHFGKQEDMREQIGEDT---DPGIILEGV
QLGNCINDAKSGKCEN-KCNSKCDCFLKWVVQKKT-EWKNIKIHFGNQYFV-KQDGFDLGMNSPDVVLELL
EHGRCINKDKGKTCIK-GCNKKCICFQKWVEQKKT-EWGKIKDHFRKQKDIP WTH-------DD FLQTL
KLERCLENGTK-KCGKN-CNNDCGCFEKWVKQKKEEEWDKIKEHFRKQTDL
 L  CI N K   C    CN  C CF  WV  KK  EW  IK HF KQ DI  Q         PG  LE
                  <           Region 2           >                <
130      140       150       160       170       180       190
|         |         |         |         |         |         |
FMNDELLKNIKDTHANADDI--KHIEALLQETVFDGVAAGGPGGAGSYKC-TEGAKGKHNTKIDKLLQGT
FMNDELLKNIKDTHANADDI--KHIEALLQETVFDGVAAGGPGGAGSYKC-TEGAKGKHNTKIDKLLQGT
LDKDELLKNIKDTHADAKDIER--IDKMLQQA---GVVGGGRGGE-------------NNTI IDKLLQGT
LNNNFLND-IKDAYP------VKQQLQKIEERLKDKMQEDFIFER-------------TKTS IDKLLQGT
LNFENLFKNIKDTYGDVK--EIDHIKKLLEDE--------------------ENVGGEHNTT IDKLLQGT
LEKNLLLEIIKDTHANAKEDEIKNIDKMLQET------------SGSG--------------- DKLLQGT
LMKDLLLEIIQDTY GDANEI--KRIEALLEQAG---V--GGIDFAALAGLYTKGFVAEKDTTIDKLLQHE
L    LL  IKDTH  A     K I   L
Reg. 3>       <    Region 4    >                            <Region 5>
Legend to Figure 5.3
Sequence alignment of 6 cloned and sequenced CIDR-domains, the rC1-2 CIDR-domain
described by Baruch et al. (1997), and the partial varCS2 CIDR-domain (amino acids 661-
729 in the original sequence) described by Reeder et al. (1999). Primer binding sites are
given in bold letters in rC1-2 and the tested sequences. The consensus sequence is given
when 2/3 of the sequences were identical for the respective amino acid.
Additionally, the first four regions of homology are given in italic letters in the rC1-2
sequence, the fifth region of homology is identical to the reverse primer binding site of rC1-2,
given in bold letters.
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The question remains open, why in our approach only CSA-binding and no CD36-
binding CIDR domain was identified. CD36-binding was found in one study with almost all
field isolates (Hasler et al., 1990), whereas prevalence of CSA-binding phenotypes have been
shown to be low in studies in Papua New Guinea (Rogerson et al., 1995) and Thailand
(Chaiyaroj et al., 1996). There are several possible answers to that question:
The prevalence of the CSA-binding phenotype is underestimated. A study on
cytoadhesion in human placentas (Fried and Duffy, 1996) revealed that iRBCs from all
placentas studied, cytoadhered to CSA, whereas no cytoadhesion was detected in iRBCs from
the peripheral blood of these pregnant women. This would imply that underestimation of
prevalence of CSA-binding phenotypes is likely.
Additionally, it is possible, that the primer design and identification of CIDR-domains
in this study selected a restricted var-gene repertoire with a CSA-binding phenotype and a
non-CD36-binding phenotype.
Furthermore, it can be speculated that the CSA-binding motif is rather short and
might be present in most, if not all PfEMP1 molecules, since Robert et al. (1995) showed that
mAb 1G11 and 4B2 against CSA could block adhesion of several different P. falciparum
strains to Saimiri brain epithelium. But iRBCs expressing this CSA-binding motif could also
bind to other receptors (e.g. CD36) with a higher avidity. Therefore, CSA-binding might be
observed in-vitro only, and might be less frequently observed in-vivo due to stronger binding
forces to other receptors.
5.3. Conclusions and perspectives
Due to the AT-rich genome of Plasmodium falciparum, ammalian expression
systems might not be useful for shotgun approaches. Nevertheless, they may help to further
elucidate products of defined genes or gene fragments. Domains of interest can be expressed
on the surface of COS 7 cells as chimeric proteins with Herpes simplex glycoprotein D
flanking regions by the use of the pRE4 vector. Furthermore, the binding properties of
proteins expressed in a mammalian system could be compared to binding properties of E. coli
expressed proteins.
Genes or gene fragments of interest can be identifed from a cDNA library, either by PCR or
by a colony lift. Proteins could then be expressed either as 6xhis-tagged proteins in E. coli or
on the surface of COS 7 cells using the pRE4 vector. As a control for expression and
transport to the surface, the mAbs ID3 or DL6 could be used. Using these approaches, the
following interesting questions could be investigated:
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- Will our CIDR domains, expressed on the surface of COS 7 cells (in pRE4), still mediate
binding to CSA?
- If the KEDKIMSY motif was imprinted on our CIDR domains (by PCR) and if these
altered CIDR domains were expressed as 6xhis-tagged proteins in E. coli, would these altered
CIDR proteins still bind to CSA in a FACScan analysis? Or would they even bind to CD36?
- If a common motif of the CSA-binding phenotype was identified, would it define a distinct
subspecies of var genes, which can not bind CD36? And will this common motif be similar to
the GAG-binding motif (WSPCSVTCG) of TRAP and the region 2 of CSP?
An answer to these questions would increase our knowledge of the adhesion of iRBCs to the
endothelium. The understanding of cell adhesion is rapidly gaining importance in the clinical
context, since cell adhesion molecules are becoming more and more legitimate targets for
therapeutic interventions. But to develop anti-adhesin therapies in malaria, it would be
necessary to know the exact binding sites of both, ligands and receptors, and their interaction
in iRBC sequestration. Therefore it would be necessary, to correlate the genotype of a given
PfEMP-1 variant to its receptor-binding phenotype and further, to correlate the expression of
a distinct PfEMP-1 variant with severity of the disease.
With this knowledge, anti-adhesive peptide therapy in cerebral malaria becomes feasible.
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